		1168 0 1 0 11 10 3 0 APR 2001				
FORM PTO-1390 U.S. DEPARTMENT OF COM- (REV_11-2000)	IMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER				
	TO THE UNITED STATES	GJE-65				
	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 15				
	IG UNDER 35 U.S.C. 371	09/83080/				
INTERNATIONAL APPLICATION NO. PCT/GB99/03721	INTERNATIONAL FILING DATE 09 Nov 1999	PRIORITY DATE CLAIMED 09 Nov 1998 (See #20 below)				
TITLE OF INVENTION Virulence Genes And Proteins, And Thei	r Use					
Jacqueline Elizabeth Shea and Robert Graham Fe		4.4 m VCC-460				
Applicant herewith submits to the United Sta	ates Designated/Elected Office (DO/EO/US)	the following items and other information:				
1. This is a FIRST submission of items	concerning a filing under 35 U.S.C. 371.					
2. This is a SECOND or SUBSEQUE	NT submission of items concerning a filing u	nder 35 U.S.C. 371.				
 This is an express request to begin n items (5), (6), (9) and (21) indicated 	ational examination procedures (35 U.S.C. 3' below.	71(f)). The submission must include				
 The US has been elected by the expi A copy of the International Applicat 	ration of 19 months from the priority date (A	rticle 31).				
	d only if not communicated by the Internation	nal Bureau)				
b. As been communicated by		in Bucau).				
c. is not required, as the appl	ication was filed in the United States Receivi	ng Office (RO/US).				
6. An English language translation of the	ne International Application as filed (35 U.S.	C. 371(c)(2)).				
 is attached hereto. 						
	itted under 35 U.S.C. 154(d)(4).					
	ernational Aplication under PCT Article 19 (
	ed only if not communicated by the Internation	onal Bureau).				
b. have been communicated I	by the International Bureau.					
c. have not been made; howe	ver, the time limit for making such amendme	ents has NOT expired.				
d. have not been made and w	ill not be made.					
8. An English language translation of the	he amendments to the claims under PCT Arti-	cle 19 (35 U.S.C. 371 (c)(3)).				
 An oath or declaration of the inventor 	or(s) (35 U.S.C. 371(c)(4)), unsigned.					
10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
Items 11 to 20 below concern documen	t(s) or information included:					
11. An Information Disclosure Statem	ent under 37 CFR 1.97 and 1.98.					
12. An assignment document for record	ding. A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is included.				
 A FIRST preliminary amendment. 						
14. A SECOND or SUBSEQUENT pt	reliminary amendment.					
15. A substitute specification.						
16. A change of power of attorney and	l/or address letter.					
 A computer-readable form of the s 	equence listing in accordance with PCT Rule	13ter.2 and 37 CFR 1.821 - 1.825.				
18. A second copy of the published int	ternational application under 35 U.S.C. 154(c	f)(4).				
19. A second copy of the English lang	uage translation of the international application	on under 35 U.S.C. 154(d)(4).				
20. Other items or information:		NUMBER OF THE PARTY OF THE PART				
Further priority dates: 17 December 1	998; 13 January 1999; and 28 January 1	999.				
Terescourse: 1 to 1 t	PRINCE LA LA PRINCE LA P					

US APPLICATION NO/(11 😽	30807		APPLICATION NO			ATTORNEY'S DOCS	
21. The followi	ng fees are submitted	:			CA	CULATIONS 1	PTO USE ONLY
BASIC NATIONAL	FEE (37 CFR 1.492	(a) (1) - (5)):					
Neither internation	al preliminary examin	ation fee (37	CFR 1.482)				
and International Se	arch fee (37 CFR 1.44 earch Report not prep	ared by the El	O or JPO	\$1000.	00		
International prelim	ninary examination fee ational Search Report	e (37 CFR 1.4	82) not paid to)			
International prelim	ninary examination fee arch fee (37 CFR 1.44	e (37 CFR 1.4	82) not paid to	USPTO			
out international sea	nen ice (37 CFR 1.44	(a)(2)) paid	w car i c	3/10.	"		
International prelim but all claims did no	ninary examination fee ot satisfy provisions o	e (37 CFR 1.4 of PCT Article	82) paid to US 33(1)-(4)	SPTO \$690 .	00		
International prelim	inary examination fee	(37 CFR 1.4	82) paid to US	PTO			
	fied provisions of PCT R APPROPRIAT				00	\$860.00	•
						\$860.00	
Surcharge of \$130.00 months from the earl	of for furnishing the oa iest claimed priority o	ith or declarat late (37 CFR	ion later than 1.492(e)).	20 3	0		!
CLAIMS	NUMBER FILED	NUMB	ER EXTRA	RATE	\$		
Total claims	22 - 20 =		2	x \$18.00		\$36.00	
ndependent claims	8 - 3 =		5	x \$80.00		\$400.00	
MULTIPLE DEPENI	DENT CLAIM(S) (if	* *		+ \$270.00		\$0.00	
— Ameliane daim				LATIONS =		\$1.296.00	
are reduced by	s small entity status. 1/2.	See 37 CFK I	.27. The tees	indicated above	+	\$0.00	
D 1 0 000				UBTOTAL =		\$1,296.00	
months from the earl	30.00 for furnishing the iest claimed priority of	late (37 CFR	1.492(f)).		30	\$0.00	
			AL NATIO			\$1,296.00	
Fee for recording the accompanied by an a	e enclosed assignment appropriate cover shee	: (37 CFR 1.2 at (37 CFR 3.2	(h)). The ass (8, 3.31). \$40	ignment must be 00 per property	+	\$0.00	1
		TOT	AL FEES E	NCLOSED =		\$1,296.00	
					Amo	ount to be refunded:	s
						charged:	S
b. Please char	the amount of \$ ge my Deposit Accou	nt No1		ne above fees is en		0 to cover the	above fees.
c. The Comm overpaymen	issioner is hereby autl nt to Deposit Account	horized to cha No. <u>19-00</u>	rge any additi 65 . A dupli	onal fees which m cate copy of this s	ay be requeet is end	iired, or credit as losed.	ny
	be charged to a credit n should not be inclu						
	appropriate time lin					petition to reviv	e (37 CFR
	IDENCE ADDRESS		vae applicati	on to pending sta	20	Dax	<i></i>
CONNECTOR	DEINGE ADDICESS	••		_	7 Sec	ur-Wac	Wis
CHSTO	MER NUMBE	R			ATURE		() -
	23,557		April 30		n P. Lac	lwig	
	20,001		DAT				
				46,8	53		
				REGI	STRATION	NUMBER	

JC08 Rec'd FCT/PTO 3 0 APR 2001

Patent Application Docket No. GJE-65

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants Helen Rachel Crooke, Enda Elizabeth Clarke, Paul Howard Everest.

Gordon Dougan, David William Holden, Jacqueline Elizabeth Shea,

Robert Graham Feldman

Docket No. GJE-241

For Hydroxamic And Carboxvlic Acid Derivatives having MMP and TNF

Inhibitory Activity

PRELIMINARY AMENDMENT

Please amend the above-identified patent application as follows:

In the Specification

After page 17: Please insert as new page 18 the attached Abstract of the Disclosure.

In the claims

The following amendments are made with respect to the claims in the international application PCT/GB99/03721 attached as Annexes to the International Preliminary Examination Report (IPER). Therefore, please replace existing page 17 of the international application with the amended claim sheet (replacement page 17) of the annex attached to the IPER, and make the following amendments to the pending claims so that they read as follows:

Claim 1 (amended):

An isolated peptide encoded by an operon, wherein said operon comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eckl, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 2 (amended):

The isolated peptide, according to claim 1, comprising an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.

Claim 3 (amended):

An isolated polynucleotide which comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eckl, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 4 (amended):

A host transformed to express a peptide encoded by an operon, wherein said operon comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E, coli K1, or a

homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 5 (amended):

A vaccine comprising a peptide, or the means for its expression, wherein said peptide is encoded by an operon, wherein said operon comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eckl, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 6 (amended):

A vaccine comprising a microorganism having a virulence gene mutation, wherein the gene is selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 7 (amended):

The vaccine, according to claim 6, wherein said virulence gene mutation comprises a virulence gene deletion in two genes, wherein one gene encodes *tatA* and the other encodes *tatE*.

Claim 8 (amended):

The vaccine, according to claim 6, wherein the gene lies within a pathogenicity island.

Claim 9 (amended):

A method for screening potential drugs, or for the detection of virulence, wherein said method utilizes a peptide encoded by an operon, wherein said operon comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eckl, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gramnegative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 10 (amended):

A method for treatment or prevention of a condition associated with infection by a Gramnegative bacterium, said method comprising administering a vaccine to a person or animal in
need thereof, wherein said vaccine comprises a peptide, or a host transformed to express said
peptide, wherein said peptide is encoded by an operon comprising a gene selected from the group
consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2, and
ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium,
wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a
functional fragment thereof.

Claim 11 (amended):

The method, according to claim 10, wherein the bacterium is E. coli.

Please add the following new claims:

- 12. The polynucleotide, according to claim 3, wherein said gene encodes a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.
- 13. The host, according to claim 4, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.
- 14. The vaccine, according to claim 5, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.
- 15. The vaccine, according to claim 6, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.
- 16. The vaccine, according to claim 15, wherein said virulence gene mutation comprises a virulence gene deletion in two genes, wherein one gene encodes tatA and the other encodes tatE.

- The vaccine, according to claim 15, wherein the gene lies within a pathogenicity island.
- 18. The method, according to claim 9, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.
- The method, according to claim 9, wherein said peptide comprises an amino acid sequence as set forth in SEO ID NO. 33.
- 20. The method, according to claim 10, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.
 - 21. The method, according to claim 20, wherein the bacterium is E. coli.
- 22. A method for treatment or prevention of a condition associated with infection by a Gram-negative bacterium, said method comprising administering a nucleotide to a person or animal in need thereof, wherein said nucleotide comprises an operon including a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eckl, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gramnegative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Remarks

Claims 1-11 have been amended and new claims 12-22 have been added.

No new matter has been added by these amendments.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully Submitted

Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Address: Saliwanchik, Lloyd & Saliwanchik

2421 N.W. 41st Street

Suite A-1 Gainesville, FL 32606

GPL/la

Marked-up Version of Amended Claims

Claim 1 (amended):

[A] An isolated peptide encoded by an operon, [including any of the genes identified herein as] wherein said operon comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2, and ms1 to [16] ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, [having] wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereoff, for therapeutic use].

Claim 2 (amended):

[A] The isolated peptide, according to claim 1, comprising [any of the amino acid sequences identified herein as] an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.

Claim 3 (amended):

[A] An isolated polynucleotide [encoding a peptide according to claim 1 or claim 2, for therapeutic use] which comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eckl, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 4 (amended):

A host transformed to express a peptide [according to claim 1 or claim 2] encoded by an operon, wherein said operon comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E, coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 5 (amended):

A vaccine comprising a peptide [according to claim 1 or claim 2], or the means for its expression, wherein said peptide is encoded by an operon, wherein said operon comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 6 (amended):

A vaccine comprising a microorganism having a virulence gene mutation, wherein the gene is selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof [according to claim 1 or claim 2].

Claim 7 (amended):

[A] The vaccine, according to claim 6, [having] wherein said virulence gene mutation comprises a virulence gene deletion in two genes, wherein one gene encodes tatA and the other encodes tatE.

Claim 8 (amended):

[A] The vaccine, according to claim 6, wherein the gene lies within a pathogenicity island, wherein the island comprises a gene identified herein].

Claim 9 (amended):

[Use of a product according to any of claims 1 to 4, or SEQ ID NO. 33,] A method for screening potential drugs, or for the detection of virulence, wherein said method utilizes a peptide encoded by an operon, wherein said operon comprises a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 10 (amended):

[Use of a product according to any of claims 1 to 4, for the manufacture of a medicament for use in the] A method for treatment or prevention of a condition associated with infection by a Gram-negative bacterium, said method comprising administering a vaccine to a person or animal in need thereof, wherein said vaccine comprises a peptide, or a host transformed to express said

peptide, wherein said peptide is encoded by an operon comprising a gene selected from the group consisting of tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eckI, iroD, iroC, iroE, mtd2, and ms1 to ms16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, wherein said homologue has at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof.

Claim 11 (amended):

[Use] The method, according to claim 10, wherein the bacterium is E. coli.

10

15

20

25

30

WO 00/28038

1 VIRULENCE GENES AND PROTEINS, AND THEIR USE

Field of the Invention

This invention relates to the identification of virulence genes and proteins, and their use. More particularly, it relates to their use in therapy and in screening for drugs.

Background to the Invention

E. coli is a member of the Enterobacteriaceae, or enteric bacteria, which are Gram-negative microorganisms that populate the intestinal tracts of animals. Other members of this bacterial family include Enterobacter, Klebsiella, Salmonella, Shigella and Yersinia. Although E. coli is found normally in the human gastrointestinal tract, it has been implicated in human disease, including septicaemia, meningitis, urinary tract infection, wound infection, abscess formation, peritonitis and cholangitis.

The disease states caused by *E. coli* are dependent upon certain virulence determinants. For example, *E. coli* has been implicated in neonatal meningitis and a major determinant of virulence has been identified as the K1 antigen, which is a homopolymer of sialic acid. The K1 antigen may have a role in avoiding the host's immunological system and preventing phagocytosis. Summary of the Invention

The present invention is based on the identification of a series of virulence genes in *E. coli* K1, and also related organisms the products of which may be implicated in the pathogenicity of the organism.

According to one aspect of the present invention, a peptide is encoded by an operon including any of the genes identified herein as mdoG, creC, recG, yggN, tatA, tatB, tatC, tatE, eck1, iroD, iroC, iroE, mtd2 and ms1 to 16, from E. coli K1, or a homologue thereof in a Gram-negative bacterium, or a functional fragment thereof. Such a peptide is suitable for therapeutic use, e.g. when isolated.

The term "functional fragments" is used herein to define a part of the gene or peptide which retains similar therapeutic utility as the whole gene or peptide. For example, a functional fragment of the peptide may be used as an antigenic determinant, useful in a vaccine or in the production of antibodies.

10

15

20

25

30

A gene fragment may be used to encode the active peptide. Alternatively, the gene fragment may have utility in gene therapy, targetting the wild-type gene *in vivo* to exert a therapeutic effect.

A peptide according to the present invention may comprise any of the amino acid sequences identified herein as SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 23, 24, 25, 26, 28, 31, 29, 32 and 35-48.

The identification of these peptides as virulence determinants allows them to be used in a number of ways in the treatment of infection. For example, a host may be transformed to express a peptide according to the invention or modified to disrupt expression of the gene encoding the peptide. A vaccine may also comprise a peptide according to the invention, or the means for its expression, for the treatment of infection. In addition, a vaccine may comprise a microorganism having a virulence gene deletion, wherein the gene encodes a peptide according to the invention.

According to another aspect of the invention, the peptides or genes may be used for screening potential antimicrobial drugs or for the detection of virulence.

A further aspect of this invention is the use of any of the products identified herein, for the treatment or prevention of a condition associated with infection by a Gram-negative bacterium, in particular by *E. coli.*

Description of the Invention

The present invention has made use of signature-tagged mutagenesis (STM) (Hensel et al, Science, 1995;269:400-403) to screen E. coli K1 strain RS228 (Pluschke et al, Infection and Immunity 39:599-608) mini-Tn5 mutant bank for attenuated mutants, to identify virulence genes (and virulence determinants) of E. coli.

Although *E. coli* K1 was used as the microorganism to identify the virulence genes, corresponding genes in other enteric bacteria are considered to be within the scope of the present invention. For example, corresponding genes or encoded proteins may be found, based on sequence homology, in *Enterobacter, Klebsiella* and other genera implicated in human intestinal disease, including *Salmonella*, *Shigella* and *Yersinia*.

10

15

20

25

30

3

The term "virulence determinant" is used herein to define a product, e.g. a peptide or protein that may have a role in the maintenance of pathogenic bacteria. In particular, a virulence determinant is a bacterial protein or peptide that is implicated in the pathogenicity of the infectious or disease-causing microordanism.

A gene that encodes a virulence determinant may be termed a "virulence gene". Disruption of a virulence gene by way of mutation, deletion or insertion, will result in a reduced level of survival of the bacteria in a host, or a general reduction in the pathogenicity of the microorganism.

Signature-tagged mutagenesis has proved a very useful technique for identifying virulence genes, and their products. The technique relies on the ability of transposons to insert randomly into the genome of a microorganism, under permissive conditions. The transposons are individually marked for easy identification, and then introduced separately into a microorganism, resulting in disruption of the genome. Mutated microorganisms with reduced virulence are then detected by negative selection and the genes where insertional inactivation has occurred are identified and characterised.

A first stage in the STM process is the preparation of suitable transposons or transposon-like elements. A library of different transposons are prepared, each being incorporated into a vector or plasmid to facilitate transfer into the microorganism. The preparation of vectors with suitable transposons will be apparent to a skilled person in the art and is further disclosed in WO-A-96/17951. For the Gram-negative bacteria, e.g. *E. coli*, suitable transposons include Tn5 and Tn10. Having prepared the transposons, mutagenesis of a bacterial strain is then carried out to create a library of individually mutated bacteria.

Pools of the mutated microorganisms are then introduced into a suitable host. After a suitable length of time, the microorganisms are recovered from the host and those microorganisms that have survived in the host are identified, thereby also identifying the mutated strains that failed to survive, i.e. avirulent strains. Corresponding avirulent strains in a stored library are then used to identify the genes where insertional inactivation occurred. Usually, the site of

10

15

20

25

30

transposon insertion is identified by isolating the DNA flanking the transposons insertion site, and this permits characterisation of the genes implicated in virulence

Once an avirulent microorganism has been identified, it is possible to determine more fully the potential role of the mutated gene in virulence, by infecting a suitable host animal with a lethal dose of the mutant. The survival time of the infected animal is compared with that of a control infected with the wild-type strain, and those animals surviving for longer periods than the control may be said to be infected with microorganisms having mutated virulence genes.

Alternatively, the potential role in virulence can be investigated by infecting an animal host with a mixture of the wild-type and mutant bacteria. After a suitable period of time, bacteria are harvested from organs of the host animal and the ratio of wild-type and mutant bacteria determined. This ratio is divided by the ratio of mutant to wild-type bacteria in the inoculum, to determine the competitive index (CI). Mutants which have a competitive index of less than 1 may be said to be avirulent.

It is possible that the gene which is inactivated by the insertion of the transposon may not be a true virulence gene, but may be having a polar effect on a downstream (virulence) gene. This can be determined by further experimentation, placing non-polar mutations in more defined regions of the gene, or mutating other adjacent genes, and establishing whether or not the mutant is avirulent.

Having characterised a virulence gene in *E. coli*, it is possible to use the gene sequence to establish homologies in other microorganisms. In this way it is possible to determine whether other microorganisms have similar virulence determinants. Sequence homologies may be established by searching in existing databases, e.g. EMBL or Genbank.

Virulence genes are often clustered together in distinct chromosomal regions called pathogenicity islands. Pathogenicity islands can be recognised as they are usually flanked by repeat sequences, insertion elements or tRNA genes. Also the G+C content is normally different from the remainder of the

10

15

20

25

30

chromosome, suggesting that they were acquired by horizontal transmission from another organism. For example the G+C content of the *E. coli* K12 genome is 52%. Any pathogenicity islands found in *E. coli* strains are likely to have a G+C content that varies from this average.

The identified virulence genes are likely to be useful both in generating attenuated vaccine strains and as a target for antimicrobials. The same may be true for homologues in Gram-negative bacteria in general.

For the purpose of this invention, the appropriate degree of homology is typically at least 30%, preferably at least 50%, 60% or 70%, and more preferably at least 80% or 90% (at the amino acid or nucleotide level).

Proteins according to the invention may be purified and isolated by methods known in the art. In particular, having identified the gene sequence, it will be possible to use recombinant techniques to express the genes in a suitable host. Active fragments and homologues can be identified and may be useful in therapy. For example, the proteins or their active fragments may be used as antigenic determinants in a vaccine, to elicit an immune response. They may also be used in the preparation of antibodies, for passive immunisation, or diagnostic applications. Suitable antibodies include monoclonal antibodies, or fragments thereof, including single chain for fragments. Methods for the preparation of antibodies will be apparent to those skilled in the art.

The preparation of vaccines based on attenuated microorganisms is known to those skilled in the art. Vaccine compositions can be formulated with suitable carriers or adjuvants, e.g. alum, as necessary or desired, and used in therapy, to provide effective immunisation against *E. coli* or other Gramnegative bacteria. The preparation of vaccine formulations will be apparent to the skilled person.

More generally, and as is well known to those skilled in the art, a suitable amount of an active component of the invention can be selected, for therapeutic use, as can suitable carriers or excipients, and routes of administration. These factors will be chosen or determined according to known criteria such as the

10

15

20

25

30

nature/severity of the condition to be treated, the type or health of the subject etc.

The following Examples illustrate the invention. For the Examples, STM was used to screen an *E. coli* K1 mini-Tn5 mutant bank for attenuated mutants, using a mouse model of systemic infection. The basic procedure followed that disclosed in Hensel *et al.*, *supra*. *E. coli* K1 containing a mini-Tn5 insertion within a virulence gene was not recovered from mice inoculated with a mixed population of mutants, and is therefore likely to be attenuated.

The DNA region flanking either side of the mini-Tn5 insertion was cloned by inverse PCR or by rescue of a kanamycin-resistance marker. In the latter case, chromosomal DNA from the STM-derived mutant was digested with restriction enzymes, ligated into the plasmid pUC19, and kanamycin-resistant clones selected after transformation into competent *E. coli* K12 cells. Subsequent cloning and sequencing was then performed and the gene sequences compared using sequences in publicly available sequence databases (EMBL) to help characterise the putative gene products.

Example 1

In a first mutant, two fragments of cloned DNA were sequenced. The nucleotide sequences are shown as SEQ ID NO. 1 and SEQ ID NO. 3 and a translated region of the DNA from SEQ ID NO. 1 is shown as SEQ ID NO. 2. SEQ ID NO. 1 shows 99.8% identity to the *mdoGH* region from *E. coli* K12 (EMBL database accession number AE000206) from nucleotides 2577 to 6908. This DNA fragment encodes the 5'-part of the *ymdD* gene, the entire *mdoG* gene and the 5'-part of the *mdoH* gene. The product of the *mdoG* gene is of unknown function, but is believed to be involved in the biosynthesis of membrane-derived oligosaccharides.

SEQ ID NO. 3 shows 98.3% identity to the 3'-part of the *mdoH* gene and downstream gene sequences from *E. coli* K12 (nucleotides 7187 to 7760). SEQ ID NO. 2 shows 99.6% identity to the *mdoG* protein from *E. coli* K12 (Swiss Prot accession number P33136) at amino acid 1 to 511.

The novel gene was tested for attenuation of virulence, using mixed infections, in a murine model of systemic infection (Achtman et al., Infection and

10

15

20

25

30

Immunity, 1983; Vol. 39:315-335), and shown to be attenuated with a competitive index (CI) of 0.38. This confirms that the attenuation of the original transposon mutant is likely to be due to the disruption of the *mdoG* gene.

Polar and a non-polar deletion mutants of *mdoG* were constructed. The *mdoG* gene and flanking regions were amplified by PCR with oligonucleotides 5'-TGCTCTAGAGCCATTACTCAGAATGGG-3' (SEQ ID NO. 49) and 5'-CGCGAGCTCGACGACTGAATGATCCC-3' (SEQ ID NO. 50). The product was cloned into pUC19. A PCR product containing 5'- and 3'-terminal fragments of *mdoG* and the entire pUC19 sequence was then amplified by inverse PCR with the oligonucleotides 5'-TCCCCCGGGTACTGCAGCACTCAACC-3' (SEQ ID NO. 51) and 5'-GATCCCGGGACCACTGAAATGCGTGC-3' (SEQ ID NO. 52). A non-polar kanamycin resistance cassette (*aphT*) was inserted in both orientations between the *mdoG* sequences to give a polar and a non-polar construct. The *mdoG::aphT* fusions were then transferred to the suicide vector pCDV442. The chromosomal copy of the *mdoG* was mutated by allelic transfer after conjugation of the pCDV442 constructs into wild type *E. coli* K1.

The contructed mutants were tested for attenuation of virulence in a murine model of systemic infection (Achtman et al., *supra*). Both the polar and the non-polar constructs were attenuated in virulence, with competitive indices of 0.37 and 0.35, respectively (mean CI from three mice each). This confirms that the attenuation of the original transposon mutant is likely to be due to the disruption of the *mdoG* gene.

Example 2

A second mutant was identified with a virulence gene having the nucleotide sequence shown in SEQ ID NO. 4 and the translated amino acid sequence shown as SEQ ID NO. 5. The mini-Tn5 transposon inserted at nucleotide 581 (SEQ ID NO. 4) and at amino acid 187 (SEQ ID NO. 5).

These sequences show 97.9% identity to the creC gene of E. coli K12 (EMBL and Genbank accession numbers M13608, AE000510 and U14003).

The creC protein from E. coli K12 belongs to the protein family of histidine kinases as well as to a protein family consisting of proteins containing a signal domain.

The novel gene was tested for attenuation of virulence (Achtman *et al*, *supra*.), and shown to be attenuated with a competitive index of 0.09.

As the *E. coli* K12 *creC* gene is transcribed as part of an operon with the *creD* gene, it is possible that this attenuation is due to a polar effect on a presumed *E. coli* K1 *creD* gene.

Example 3

5

10

15

20

25

30

A third mutant had a nucleotide sequence shown as SEQ ID NO. 6 immediately following the mini-Tn5. A translation of this sequence is shown as SEQ ID NO. 7.

The nucleotide sequence shows 93.7% identity to the recG gene of E. coli K12, at nucleotides 5-146 (EMBL and Genbank accession numbers P24230 and M64367). This demonstrates that the disrupted gene is at least partially identical to the recG gene of E. coli K12. The recG gene of E. coli K12 encodes a 76.4kD protein which functions as ATP-dependent DNA helicase, and plays a critical role in DNA repair.

In tests for attenuation, the competitive index was shown to be 0.48. The recG gene is transcribed as the terminal gene of an operon, and it is therefore unlikely that this attenuation is due to a polar effect on another $E.\ coli$ K1 gene. Example 4

A fourth mutant had a transposon inserted within the nucleotide sequence shown as SEQ ID NO. 8, with a translation product shown as SEQ ID NO. 9.

The mini-Tn5 transposon inserted at nucleotide 359 and amino acid 80.

These sequences show 98.5% sequence identity to the yggN gene of E. coli K12 (EMBL accession number AE000378) at nucleotides 339-1054, and 99.6% identity at the amino acid level.

Although the sequence of the yggN gene is known, the function of its encoded protein has not yet been determined.

The novel gene was tested for attenuation of virulence, and shown to be attenuated with a competitive index of 0.43.

Example 5

10

15

20

25

30

Several mutants were also found with a transposon insertion within the same region. Cloning and sequencing the region revealed a nucleotide sequence shown as SEQ ID NO. 10. This sequence has homology with the *tatABCD* operon of *E. coli* K12 (EMBL and Genbank accession numbers AJ005830, AE000459 and AE000167). This operon encodes proteins of predicted mass 9.6 kD, 18.4 kD, 28.9 kD and 29.5 kD, which function as components of a Sec-independent protein export pathway. The pathway permits translocation of fully folded proteins to the periplasm through a gated pore, after the attachment of co-factors in the cytoplasm.

Translation of the nucleotide sequence revealed a protein corresponding to *tatA* (SEQ ID NO. 11), a sequence corresponding to *tatB* (SEQ ID NO. 12), a sequence corresponding to *tatC* (SEQ ID NO. 13) and a sequence corresponding to *tatD* (SEQ ID NO. 14).

The mini-Tn5 transposons in the mutants identified by STM are located at nucleotides 1429 and 2226 of SEQ ID NO. 10. These transposon insertions disrupt the *tatB* protein sequence at amino acid 50 and the *tatC* protein sequence at amino acid 143.

The tatB and tatC genes were tested for attenuation of virulence and were shown to be attenuated with competitive indices of 0.0012 and 0.0039, respectively. These genes were also attenuated in virulence when tested in single infections in the same model of systemic infection.

Example 6

A further mutant was insertionally inactivated within a region corresponding to the *tatE* gene of *E. coli* K12, shown as SEQ ID NO. 15. A translation of the sequence as shown as SEQ ID NO. 16. The *tatE* gene shows 98% identity to that of the *E. coli* K12 gene (accession number AE000167) at nucleotides 6719-7306.

To establish whether the *tatA*, *tatD* and *tatE* genes are required for virulence, non-polar deletion mutations were constructed in each. The regions of DNA flanking either side of the *tatA*, *tatD* and *tatE* genes were amplified with the following primers:

tatA

5'-TCG TCT AGA GAT GAT GGT GAT GGA GCG-3' (SEQ ID NO. 53)

5 5'-GAA CTG CAG CCA AAT ACT GAT ACC ACC C-3' (SEQ ID NO. 54)
5'-GAA CTG CAG GCT AAA ACA GAA GAC GCG-3' (SEQ ID NO. 55)

CI OAT OOA TOO AOT OOA TAT OAO AAO OOO CI (OTO ID NO CO

5'-CAT GCA TGC ACT CCA TAT GAC AAC CGC-3' (SEQ ID NO. 56)

Primers SEQ ID NO. 53 and SEQ ID NO. 54 were used to amplify DNA sequences upstream of *tatA*, Primers SEQ ID NO. 55 and SEQ ID NO. 56 were used to amplify DNA sequences downstream of *tatA*.

15 tatD

20

10

5'-TCG TCT AGA ATG AAG CTG CGC ATG AGG-3' (SEQ ID NO. 57)

5'-CAA CTG CAG TCG CAA ATT GCG AAC TGG-3' (SEQ ID NO. 58)

5'-CAA CTG CAG ACC GCA ACT TTT CGA CGC-3' (SEQ ID NO. 59)

5'-CAT GCA TGC CAG TGA GCC ATT GTT CCC-3' (SEQ ID NO. 60)

25 Primers SEQ ID NO. 57 and SEQ ID NO. 58 were used to amplify DNA sequences upstream of tatD, Primers SEQ ID NO. 59 and SEQ ID NO. 60 were used to amplify DNA sequences downstream of tatD.

tatE

30 5'-TGC TCT AGA TAC GAC TCT GAC AGG AGG-3' (SEQ ID NO. 61)

5'-TCA GAT ATC AAC TAC CAG CAG TTT GG-3' (SEQ ID NO. 62)

35 5'-TCA GAT ATC CAT AAA GAG TGA CGT GGC-3' (SEQ ID NO. 63)

5'-TGC TCT AGA AAA CGT GGC AAC AGA GCG-3' (SEQ ID NO. 64)

40 Primers SEQ ID NO. 61 and SEQ ID NO. 62 were used to amplify DNA sequences upstream of tatE, Primers SEQ ID NO. 63 and SEQ ID NO. 64 were used to amplify DNA sequences downstream of tatE.

10

15

20

25

30

After cloning these flanking DNA fragments into pUC19, a non-polar aphT kanamycin resistance cassette (Galan et al, J.Bacteriol, 1992;174:4338-4349) was inserted between the flanking DNA fragments to replace the tatA, tatD and tatE genes. These DNA fragments were then transferred to the suicide vector pCVD442 (Blomfield et. al, Mol. Micro., 1991;5:1447-1457). The chromosomal copies of the E. coli K1 tatA, tatD and tatE genes were then mutated by allelic transfer after conjugation of the pCVD442 constructs into wild type E. coli K1.

Disruptions of the tatA, tatD and tatE genes have been tested for attenuation of virulence (Achtman et al., supra).

None of the genes was attenuated when deleted in isolation. The genes may still play a role in virulence, and to test this, mutants were prepared with deletions in both *tatA* and *tatE* genes. The double mutant was tested for attenuation in virulence using mixed infections with the wild-type strain and shown to be attenuated with a competitive index of 0.0017. It seems therefore that the *tatA*, *tatD* and *tatE* genes may be used in combination to create avirulent microorganisms.

Given the similarity of the *E. coli* K1 tatABCD genes to predicted tatABCD genes present in the *S. typhimurium* genome and *Neisseria meningitidis* genome it seemed likely that the tat system may also be required for virulence in these, and other, organisms. A deletion in the *S. typhimurium tatC* gene (SEQ ID NO. 17) was constructed by amplifying the DNA flanking either side of the tatC gene with the following primers:

5'-TGC TCT AGA AGG CGT TGT CGA TCC TG-3' (SEQ ID NO. 65)

5'-GAA CTG CAG GAA AAG GCC GAG CAG ACT G-3' (SEQ ID NO. 66)

5'-GAA CTG CAG TAC AGC CAT GTT TAC GGT-3' (SEQ ID NO. 67)

5'-CAT GCA TGC GGT GTA CGA CAG TTT GCG-3' (SEQ ID NO. 68)

10

15

20

25

30

Primers SEQ ID NO. 65 and SEQ ID NO. 66 were used to amplify DNA sequences downstream of the *S. typhimurium tatC* gene, Primers SEQ ID NO. 67 and SEQ ID NO. 68 were used to amplify DNA sequences upstream of the *S. typhimurium tatC* gene.

The encoded amino acid sequences for two regions of the tatC gene are shown as SEQ ID NO. 18 and SEQ ID NO. 19.

After cloning these flanking DNA fragments into pUC19, a non-polar kanamycin resistance cassette (aphT) was inserted between the flanking DNA fragments to replace the *S. typhimurium tatC* gene. This DNA fragment was then transferred to the suicide vector pCVD442. The chromosomal copy of the *S. typhimurium tatC* gene was then mutated by allelic transfer after conjugation of the pCVD442 construct into wild type *S. typhimurium* strains TML and SI 1344.

The disrupted *S. typhimurium tatC* gene was tested for attenuation of virulence, using mixed and single infections in a murine model of systemic infection. For mixed infections, 6-7 week old *balbC* mice were inoculated intraperitoneally with 10⁴ bacterial cells. Competitive indices were calculated after comparing the numbers of mutant and wild-type bacteria present in spleens after 3 days. For single infections, mice were inoculated either intraperitoneally or orally with varying doses and mouse survival monitored for 17 days. The strains were attenuated in virulence, the competitive indices of the SL1344 *tatC* and TML *tatC* deletion strains being 0.078 and 0.098, respectively.

In single infections, mouse survival was extended compared to the wildtype controls.

Sequence homology was also demonstrated with the tat sequence from Neisseria meningitidis. The gene sequence from N. meningitidis is shown as SEQ ID NO. 20 and the encoded amino acid sequence for tatC is shown as SEQ ID NO. 21.

To test for virulence, a deletion mutant was created using the following primers:

10

15

20

25

30

5'-TGCTCTAGACACATCATGGGCACACC-3'	(SEQ ID NO. 69)
5'-GAACTGCAGAACCGTCCACATCAGGCG-3'	(SEQ ID NO. 70)
5'-GAACTGCAGACCCTGCTTGCCATTCCG-3'	(SEQ ID NO. 71)
5'-GAACTGCAGACCCTGCTTGCCATTCCG-3'	(SEQ ID NO. 72)

Cloning of the DNA fragments and the aphT kanamycin resistance cassette into pUC19 followed the procedure outlined above for *S. typhimurium*. The chromosomal copy of the *N. meningitidis tatC* gene was mutated by transformation of the pUC19-based constructs into wild-type *N. meningitidis* cells.

Southern analysis of the resulting transformants indicated that all the transformants were merodiploids and contained both the wild-type and mutated copies of the *tatC* gene. This indicates that there is some selection against the isolation of mutants in which the *tatC* gene has been deleted.

Further studies on polar and non-polar constructs showed that transformants did not grow on selective media. This suggests that the *N. meningitidis tatC* gene is essential for the *in vitro* growth of this organism. Example 7

A further mutant was identified with a transposon insertion within a nucleotide sequence identified herein as SEQ ID NO. 22, at nucleotide 3981. The sequence defined herein as eck1, shows sequence homology to several Group 1 glycosyltransferases from a number of bacteria. Sequence homology was also shown to the gnd gene of E. coli K12 (at nucleotides 4197-4604 of SEQ ID NO. 22).

The translation of the *E. coli eck1* gene is shown as SEQ ID NO. 26. The gene has been tested for attenuation of virulence, as described above, and is shown to be attenuated with a competitive index of 0.025.

Several open reading frames (ORF) were also identified from the DNA sequence (SEQ ID NO. 22). The first of these is defined herein as MS1 and a translation product shown as SEQ ID NO. 25. The amino acid sequence is shown to have 50.3% identity to a putative glycosyl transferase from E. coli

10

15

20

25

30

serotype 0111 (TrEMBL database accession number AAD46732). The amino acid sequence also shows homology with the eck1 protein from *E. coli* K1 and also the TrsE protein from *Yersinia entercolitica* (TrEMBL database accession number Q56917).

A second open reading frame identified herein as MS2 had the gene sequence shown as SEQ ID NO. 24. This shows sequence homology to the putative glycosyl transferase TrsC from Yersinia entercolitica (TrRMBL database accession number Q56915), and also the glycosyl transferase WbnA from E. coli serotype 0113 (TrEMBL database accession number AAD50485).

A third open reading frame encodes a product identified herein as MS3 (SEQ ID NO. 23). The amino acid sequence shows 30.2% identity to a rhamnosyltransferase from Streptoccus mutans.

The gene sequence shown as SEQ ID NO. 22 may be at least part of a pathogenicity island, with multiple virulence genes being positioned in a cluster on the microorganism's genome.

Example 8

A further mutant was identified having a transposon insertion within the *iroCDE* operon. The nucleotide sequences flanking either side of the mini-Tn5 insertion are shown as SEQ ID NO. 27 and SEQ ID NO. 30.

The mini-Tn5 transposon is inserted at nucleotide 1272 of SEQ ID NO. 27 and at nucleotide 1 of SEQ ID NO. 30, and interrupts the *iroD* gene. The N-terminal region of *iroD* is shown as SEQ ID NO. 29, and the C-terminal region is shown as SEQ ID NO. 31.

In addition to *iroD*, the gene shown as SEQ ID NO. 27 encodes a partial peptide with the amino acid sequence shown as SEQ ID NO. 28. This amino acid sequence shows 70.9% identity to the putative ATP binding cassette transporter *iroC* from Salmonella typhi.

The gene sequence shown as SEQ ID NO. 30 includes an open reading frame that encodes a peptide with the amino acid sequence shown as SEQ ID NO. 32 and this has sequence homology to the *iroE* protein from *Salmonella typhi*.

15

20

25

30

Testing the genes in a model for attenuation of virulence, as described above, showed that the *iroD* gene was attenuated with a competitive index of 0.107. The mini-Tn5 mutation in the iroD gene has been reintroduced into the wild-type *E. coli* K1 strain by P1 transduction. The resulting transductant is also attenuated in virulence with a competitive index of 0.1. This indicates that the attenuated phenotype is linked to the insertion within *iroD*. However, it is possible that the attenuation is due to a polar effect on the *E. coli* K1 *iroE* gene. Example 9

A further mutant was identified with a transposon insertion within the nucleotide sequence shown as SEQ ID NO. 33. The transposon is inserted at nucleotide 2264 of SEQ ID NO. 33. The nucleotide sequence shows sequence homology to the aslA / hemY region of E. coli K12 (EMBL accession number AE000456). The aslA encodes an arylsulfatase homologue whereas hemY is involved in the biosynthesis of protoheme IX. This demonstrates that the disrupted region is at least partially identical to the aslA / hemY region of E. coli K12.

The transposon is inserted at nucleotide 2264 of SEQ ID NO. 33. This insertion site is 216 nucleotides downstream from the stop codon of the hemY gene and 472 nucleotides upstream from the start codon of the asiA gene.

The novel region has been tested for attenuation of virulence, as described above, and shown to be attenuated with a competitive index of 0.033. The mini-Tn5 mutation in this region has been reintroduced into the wild-type *E. coli* K1 strain by P1 transduction. The resulting transductant is also attenuated in virulence with a competitive index of 0.008. This indicates that the attenuated phenotype is linked to the transposon insertion in this region. However, polar and non-polar deletion mutants of *asIA* were constructed and tested for attenuation of virulence as described above.

Neither the polar nor the non-polar mutants were attenuated in virulence and this demonstrates that the attenuation of the original transposon mutant is not due to a polar effect on the asiA gene. This indicates that the transposon is disrupting some other function encoded within the intergenic region between asiA and hemY. For example there could be some untranslated RNA molecule,

such as a regulatory RNA similar to oxyS (Altuvia et al., Cell, 1997;90:43-53), encoded within this region. Alternatively the transposon could be disrupting some DNA structure that may, for example, be involved in DNA replication. This DNA region is also present in the pathogen Salmonella typhimurium suggesting that it may be important for pathogenicity in other organisms. This region (SEQ ID NO. 33) may be used as a target, to identify anti-microbial drugs.

Example 10

5

10

15

20

25

A further mutant was identified and the DNA region flanking either side of the mini-Tn5 insertion was cloned and had the nucleotide sequence shown as SEQ ID NO. 34. This nucleotide sequence has homology with the *mtd2* gene of *Herpetosiphon aurantiacus* (EMBL accession number P25265), with the *mtd2* gene product functioning as a cytosine-specific methyltransferase. The *mtd2* gene is not found in the *E. coli* K12 genome and may represent a pathogenicity island.

The mini-Tn5 transposon insertions were located at nucleotides 4773 and 3764 of SEQ ID NO. 34 and were shown to interrupt the *mtd2* gene.

The amino acid sequence of the mtd2 gene is shown as SEQ ID NO. 43.

The *E. coli* K1 *mtd2* gene was tested for attenuation of virulence, as described above, and shown to be attenuated with a competitive index of 0.073.

In addition to the *mtd2* gene, a series of open reading frames were also identified with translation products identified herein as MS4 to MS16, SEQ ID NOS. 48-44 and 42-35, respectively. As the open reading frames are located in a potential pathogenicity island, mutations in these genes may also result in attenuation in virulence. Further, since it is known that *E. coli* and other bacteria may encode peptides in different forms in the nucleotide sequence, the coding regions of some of these proteins may overlap. In addition, any aminoacid sequence shown starting with Val may in fact start with Met.

25

17

CLAIMS

- 1. A peptide encoded by an operon including any of the genes identified herein as tatA, tatB, tatC, tatE, mdoG, creC, recG, yggN, eck1, iroD, iroC, iroE, mtd2 and ms1 to 16, obtainable from E. coli K1, or a homologue thereof in a Gram-negative bacterium, having at least 30% homology at the amino acid or nucleotide level, or a functional fragment thereof, for therapeutic use.
- A peptide according to claim 1, comprising any of the amino acid sequences identified herein as SEQ ID NOS. 2, 5, 7, 9, 11, 12, 13, 14, 16, 18, 19, 21, 23, 24, 25, 26, 28, 29, 31, 32 and 35-48.
- A polynucleotide encoding a peptide according to claim 1 or claim 2, for therapeutic use.
 - A host transformed to express a peptide according to claim 1 or claim 2.
 - A vaccine comprising a peptide according to claim 1 or claim 2, or the means for its expression.
- 15 6. A vaccine comprising a microorganism having a virulence gene mutation, wherein the gene encodes a peptide according to claim 1 or claim 2.
 - A vaccine according to claim 6, having a virulence gene deletion in two genes, wherein one gene encodes tatA and the other encodes tatE.
 - A vaccine according to claim 6, wherein the gene lies within a pathogenicity island, wherein the island comprises a gene identified herein.
 - Use of a product according to any of claims 1 to 4, or SEQ ID NO. 33, for screening potential drugs or for the detection of virulence.
 - 10. Use of a product according to any of claims 1 to 4, for the manufacture of a medicament for use in the treatment or prevention of a condition associated with infection by a Gram-negative bacterium.
 - 11. Use according to claim 10, wherein the bacterium is E. coli.

Abstract of the Disclosure

The present invention is based on the identification of a series of virulence genes in *E. coli* K1, the products of which may be implicated in the pathogenicity of the organisms. The identification of the genes allows them, or their expressed products, to be used in a number of ways to treat infection.

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of subject matter which is claimed and for which a patent is sought on an invention entitled VIRULENCE GENES AND PROTEINS, AND THEIR USE

the specification of which $\ \ \ \ \ \ \ \ \ \ $ is attact	thed hereto or				
was filed on O9 NOV 1999 as Application Number PCT/GB99/0372	United States Applicated and was amended of	ation Number o on 21 JAN 20	r PCT In	ternational applicable)	
I hereby state that I have reviewed specification, including the claims, a acknowledge the duty to disclose inform 1.56. I hereby claim foreign priority be application(s) for patent or inventor's c which designated at least one country have also identified below, by checking certificate, or PCT international applica which priority is claimed:	s amended by any a ation which is material nefits under 35 U.S.C. pertificate, or 365(a) o other than the United S the box, any foreign a	mendment refe to patentability a 119(a)-(d) or 36 f any PCT inter States of Americ oplication for a p	erred to as defined 35(b) of a national a ca, listed patent or i	above. I lin 37 CFR my foreign application below and inventor`s	
Prior Foreign Application Number(s) Country	Foreign Filing Date	Priority Not Claimed	Certified Attache YES		
see attached sheet					
As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this					

application and to transact all business in the Patent and Trademark Office connected therewith: David R. Saliwanchik, Reg. 31,794; Jeff Lloyd, Reg. 35,589; Doran R. Pace, Reg. 38,261; Christine Q. McLeod, Reg. 36,213; Jay M. Sanders, Reg. 39,355; James S. Parker, Reg. 40,119 and Jean E. Kyle, Reg. 36,987; Frank C. Eisenschenk, Reg. 45,332; Seth M. Blum. Reg. 45,489

Direct all correspondence to: Saliwanchik, Lloyd & Saliwanchik 2421 N.W. 41st Street, Suite A-1 Gainesville, FL 32606-6669 USA

Country: Applicant:	GB Microscience L	Appln No: imited	9824569.9	Dated:	09 NOV	1998
Country: Applicant:	GB Microscience L	Appln No: imited	9824570.7	Dated:	09 NOV	1998
Country: Applicant:	GB Microscience L	Appln No: imited	9827814.6	Dated:	17 DEC 1	998
Country: Applicant:	GB Microscience L	Appln No: imited	9827815.3	Dated:	17 DEC 1	998
Country: Applicant:	GB Microscience L	AppIn No: imited	9827816.1	Dated:	17 DEC 1	998
Country Applicant:	GB Microscience L	Appin No: imited	9827818.7	Dated:	17 DEC 1	998
Country Applicant:	GB Microscience L	Appln No: imited	9900708.0	Dated:	13 JAN 1	999
Country Applicant:	GB Microscience L	Appln No: imited	9900710.6	Dated:	13 JAN 1	999
Country Applicant:	GB Microscience L	Appin No: imited	9900711.4	Dated:	13 JAN 1	999
Country Applicant:	GB Microscience L	Appin No:	9901915.0	Dated:	28 JAN 1	1999

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C 1001 and that such willful false statements may jeopardise the validity of the application or any patent issued thereon.

jeopardise the validity	of the application or any paten	and that such willful false statements may t issued thereon.
Full name of sole or First Inventor	Helen Rachel CROOKE	
Inventor's signature	elelen Con	he
Residence address	London, United Kingom	GBK
Post Office address	c/o Dept. of Infectious I Medicine at the Hammers W12 ONN, United Kingdo	Diseases, Imperial College School of mith Campus, Du Cane Road, London om
Country of Citizenship	United Kingdom	Date of signature 20/401
Full name of Second Inventor	Enda Elizabeth CLARKE	
Inventor's signature	- Erica Odelika	2 .
Residence address	London, United Kingdom	GBX
Post Office address	c/o Dept. of Infectious I Medicine at the Hammers W12 ONN, United Kingdo	Diseases, Imperial College School of mith Campus, Du Cane Road, London om
Country of Citizenship	United Kingdom	Date of signature 20.4-0
Full name of Third Inventor	Paul Howard EVEREST	
Inventor's signature	- 1 M	<u></u>
Residence address	London, United Kingdom	GBX
Post Office address	c/o Dept. of Infectious E Medicine at the Hammers W12 ONN, United Kingdo	Diseases, Imperial College School of mith Campus, Du Cane Road, London om
Country of Citizenship	United Kingdom	Date of signature

H:\JMT\FORMS\US--,POA

1-00	Full name of Fourth Inventor	Gordon DOUGAN
	Inventor's signature	Slody
	Residence address	London, United Kingdom GBX
	Post Office address	c/o Dept. of Infectious Diseases, Imperial College School of Medicine at the Hammersmith Campus, Du Cane Road, London W12 ONN, United Kingdom
(3)	Country of Citizenship	United Kingdom Date of signature (5/5/0)
. ma	Full name of Fifth Inventor	David William HOLDEN
	Inventor's signature	Sand w HOM
\$ 175 175 175 175 175 175 175 175 175 175	Residence address	London, United Kingdom GBX
and a second	Post Office address	c/o Dept. of Infectious Diseases, Imperial College School of Medicine at the Hammersmith Campus, Du Cane Road, London W12 ONN, United Kingdom
	Country of Citizenship	United Kingdom Date of signature 9/5/01
,-00	Full name of Sixth Inventor	Jacqueline Elizabeth SHEA
	Inventor's signature	Jacqui Stea
	Residence address	London, United Kingdom GBX
î F	Post Office address	c/o Dept. of Infectious Diseases, Imperial College School of Medicine at the Hammersmith Campus, Du Cane Road, London W12 ONN, United Kingdom
	Country of Citizenship	United Kingdom Date of signature 29/5/01

+O
(2)
141
(3
(1)
(3)
4
8
(2)
14
14
171
250

,	
- t	Full name of
-00	Seventh Inventor

Robert Graham FELDMAN

nver	tor'	e ci	ana	turo

la Recus

Residence address

London, United Kingdom GBX

Post Office address

c/o Dept. of Infectious Diseases, Imperial College School of Medicine at the Hammersmith Campus, Du Cane Road, London W12 ONN, United Kingdom

Country of Citizenship United Kingdom

Date of signature 25 ATR 2001

SECUENCE LISTING

<110> Microscience Limited

<120> VIRULENCE GENES AND PROTEINS, AND THEIR USE

<130> REP05921WO

<140>

<141>

<160> 72

<170> PatentIn Ver. 2.1

<210> 1

<211> 4333

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (1017)..(2549)

<400> 1

ccattactca gaatggcgg atacacaata aaattgttc ttcttattac cgcataaccg 60
atgccgaggc acaaaaaaat caccgatagt tttaccatcg agaattttt attcgtttta 120
tcagaatttt ctaaattatt tctgatacgt ttgaatatcc agacgcacag cgtcgtcatg 180
accactaaca ccagtaaaaa ccacaggtgt gatattaatt cccaggccaa cgtattatat 240
ttgtcataca atgacagtcc aggccaactt tccgctttcc ctttgacgta ttgcagcata 300
ataaattgcg gcaatgtcag tagggggatg gctgttaaca tcgggatacc tacacgttcg 360
acacgtactt tccaccattt tttcaaggga tagcgtaaaa aaagcatgta ggaaaagtac 420
ccggatataa cgaaaaatac ctgcatgcgg aacgagtgga tgaagtcatt aaaaagggtc 480
agccataaatg acggttcggc gctattcaca tgccatgtat ggctcgaata gattaaagaa 540
atatgaaaag ggatccctaa caacatcagc caggcgcgga tggagtcgag gaaatattca 600
cgttgcgcgg gtactgggt catattggt taactaatct cggattttc gtcttaccc 660
tgtcgggtta tgcctttagg cttgttgcca tagcgacacc gacctgaccg cgccaggcgc 720

aggetteaag gittitatge atageateat egetaceact aaccagaatg gaagegietg 780	
taagacggtt gataaataaa tttgctggca aaccctacac gaagtcgatg cttctgtctt 840	
taggagaagc acggaaagtg aaaacggttg caatcaggtg cttaatccat gagccagtgt 900	
gctgaacgat accgggattc tgttgtcgga atggcaggtt atccattaaa atagatcgga 960	
togatataag cacacaaagg gggaagtgct tactaattat gaaacataaa ctacaa atg 101 $$\operatorname{\mathtt{Met}}$$ 1	9
ata ana ata aat taa tta aat aat aan ata ata	_
atg aaa atg cgt tgg ttg agt gct gca gta atg tta acc ctg tat aca 106	,
Met Lys Met Arg Trp Leu Ser Ala Ala Val Met Leu Thr Leu Tyr Thr 5 10 15	
5 10 15	
tot toa ago tgg got tto agt att gat gtc gca aag caa gct caa 111	
Ser Ser Trp Ala Phe Ser Ile Asp Asp Val Ala Lys Gln Ala Gln	5
20 25 30	
20 23 30	
tcc tta gcc ggg aaa ggc tat gag gcg ccc aaa agc aac ttg ccc tcc 116	•
Ser Leu Ala Gly Lys Gly Tyr Glu Ala Pro Lys Ser Asn Leu Pro Ser	3
35 40 45	
33 40 43	
of the ora of the ora to ora or the ora or the ora	
gtt ttc cgc gat atg aaa tac gcg gac tat cag cag atc cag ttt aat 121	1
Val Phe Arg Asp Met Lys Tyr Ala Asp Tyr Gln Gln Ile Gln Phe Asn 50 55 60 65	
50 55 60 65	
cat gac aaa gcg tac tgg aac aat ctg aag acc cca ttc aaa ctc gag 125	9
His Asp Lys Ala Tyr Trp Asn Asn Leu Lys Thr Pro Phe Lys Leu Glu 70 75 80	
70 75 80	
	_
ttc tac cat cag ggt atg tac ttc gat acc ccg gtc aaa ata aat gaa 130	7
Phe Tyr His Gln Gly Met Tyr Phe Asp Thr Pro Val Lys Ile Asn Glu	
85 90 95	
gtg act gcc acc gca gtc aaa cga atc aaa tac agc ccg gat tat ttc 135	5
Val Thr Ala Thr Ala Val Lys Arg Ile Lys Tyr Ser Pro Asp Tyr Phe	
100 105 110	
act ttc ggc gat gtt cag cat gac aaa gac acg gta aaa gac ctt ggt 140	3
Thr Phe Gly Asp Val Gln His Asp Lys Asp Thr Val Lys Asp Leu Gly	
115 120 125	
ttt gcc ggt ttc aaa gtg ctt tac ccg atc aac agc aaa gat aaa aac 145	1
Phe Ala Gly Phe Lys Val Leu Tyr Pro Ile Asn Ser Lys Asp Lys Asn	
130 135 140 145	

gat	gaa	atc	gtc	agc	atg	ctc	ggg	gcc	agc	tat	ttc	cgc	gtg	att	ggt	1499
			Val													
				150					155					160		
			gtt													1547
Ala	Gly	Gln	Val	Tyr	Gly	Leu	Ser		Arg	Gly	Leu	Ala	Ile	Asp	Thr	
			165					170					175			
			tcg													1595
ALA	Leu	180	Ser	GIĀ	GIU	GIU	185	Pro	Arg	Phe	Lys		Phe	Trp	Ile	
		100					100					190				
gag	cat	cca	aaa	cca	act	gat	222	cat	tta	200	a++	+=+	ac =	++~	ctt	1643
			Lys													1043
	195					200	-3-	9			205	- , -		Deu	Leu	
gac	tcg	ccg	cgc	gcg	aca	ggt	gct	tac	aaa	ttc	gta	gtt	atg	cca	gga	1691
Asp	Ser	Pro	Arg	Ala	Thr	Gly	Ala	Tyr	Lys	Phe	Val	Val	Met	Pro	Gly	
210					215					220					225	
			gtt													1739
Arg	Asp	Thr	Val		Asp	Val	Gln	Ser		Ile	Tyr	Leu	Arg		Lys	
				230					235					240		
atc	aac		ctg	aaa	att	ac =		++-	200	24+		++-				1787
			Leu													1/6/
	,	,-	245	,				250		001			255	Tire	GLY	
ccg	aac	caa	ccg	tcg	cct	gca	aat	aac	tat	cgt	ccg	gag	ttg	cac	gac	1835
Pro	Asn	Gln	Pro	ser	Pro	Ala	Asn	Asn	Tyr	Arg	Pro	Glu	Leu	His	Asp	
		260					265					270				
			ctg													1883
Ser		GTA	Leu	Ser	Ile		Ala	Gly	Asn	Gly		Trp	Ile	Trp	Arg	
	275					280					285					
	++~	+		~~~		+	++-	~					.			1001
			aac Asn													1931
290	Lou				295		Leu	nia.	Val	300	Ser	rne	Ser	riec	305	
															000	
aac	ccg	caa	ggc	ttc	ggt	cta	ttq	caq	cqt	aat	cat	gat	ttc	tcc	cgc	1979
			Gly													
				310					315	-	-	-		320	-	
															gtg	2027
Phe	Glu	Asp	Leu	Asp	Asp	Arg	Tyr		Leu	Arg	Pro	Ser	Ala	Trp	Val	
			325					330					335			

act	ccg	aaa	ggg	gag	tgg	ggc	aaa	ggc	agc	gtt	gag	ctg	gtg	gaa	att	2075
Thr	Pro	Lys	Gly	Glu	Trp	Gly	Lys	Gly	Ser	Val	Glu	Leu	Val	Glu	Ile	
		340					345					350				
cca	acc	aac	gat	gaa	acc	aac	gat	aac	atc	atc	act	tac	taa	aco	cca	2123
			-	-			-	Asn		-	-			-		
	355					360					365	-,-				
	555					500					505					
ast	~~~	ata	~~~	a a a	cca	aat		gag	ato	220	+++	222	tac	200	atc	2171
-	-	-	-		-			Glu	-							21/1
•	GIII	пеп	FIU	GIU		GIY	пуз	GIU	Het		rne	пуъ	TAT	1111		
370					375					380					385	
		-						ctg						-		2219
Thr	Phe	Ser	Arg	-	Glu	Asp	Lys	Leu		Ala	Pro	Asp	Asn		Trp	
				390					395					400		
gtg	caa	caa	acg	cgt	cgt	tca	acg	ggg	gat	gtg	aag	cag	tcg	aac	ctg	2267
Val	Gln	Gln	Thr	Arg	Arg	Ser	Thr	Gly	Asp	Val	Lys	Gln	Ser	Asn	Leu	
			405					410					415			
att	cgc	cag	cct	gac	ggt	act	atc	gcc	ttt	gtg	gtc	gat	ttt	acc	ggc	2315
Ile	Arg	Gln	Pro	Asp	Gly	Thr	Ile	Ala	Phe	Val	Val	Asp	Phe	Thr	Gly	
	-	420		-	_		425					430			-	
act	gag	ato	aaa	aaa	cta	cca	gag	gat	acc	cca	atc	aca	aca	caa	acc	2363
-								Asp			-					
	435		-3-	-,-		440					445					
200	2++	aat	ant.	22+	aat	~~~	2+2	gtt	~==	200	200	ata	cat	+=+	220	2411
-			-					Val	-	-	-		-			2411
450	116	GIY	Asp	ASII	455	GIU	116	vai	GIU	460	1111	vai	ALG	ıyı	465	
450					455					460					465	
-	-					-	_	gtg	-	-					-	2459
Pro	Val	Thr	Lys	_	Trp	Arg	Leu	Val		-	Val	Lys	Val	-	-	
				470					475					480		
-	_					_	-	gct		_			-	-	-	2507
Ala	Lys	Lys	Thr	Thr	Glu	Met	Arg	Ala	Ala	Leu	Val	Asn	Ala	Asp	Gln	
			485					490					495			
acg	ttg	agt	gaa	acc	tgg	ago	tac	cag	tta	cct	gcc	aat	gaa			2549
Thr	Leu	Ser	Glu	Thr	Trp	Ser	Tyr	G1n	Leu	Pro	Ala	Asn	Glu	ı		
		500					505					510				

taagacaact gagtacattg acgcaatgcc catcgccgca agcgagaaag cggcattgcc 2609
gaagactgat atccgcgccg ttcatcaggc gctggatgcc gaacaccgca cctgggcgcg 2669

ggaggatgac tccccgcaag gctcggtaaa ggcgcgtctg gaacaagcct ggccagattc 2729 acttgctgat ggacagttaa ttaaagacga cgaagggcgc gatcagctaa aggcgatgcc 2789 agaagtaaaa cgctcctcga tgtttcccga cccgtggcgt accaacccgg taggccgttt 2849 ctqqqatcqc ctqcqtgqac qcqatqtqac qccqcqctat ctqqctcqtt tqaccaaaga 2909 agagcaggag agtgagcaaa agtggcgtac cgtcggtacc atccgccgtt acattctgtt 2969 gatectgacg etegegeaaa etgttgtege gacetggtat atgaagacea ttetteetta 3029 tcaqqqqtqq gcgctgatta atcctatgga tatggttggt caggatgtgt gggtttcctt 3089 tatgcaqctt ctgccttata tgctgcaaac cggtatcctg atcctctttg cggtactgtt 3149 ctgttgggtg tccgccggat tctggaccgg cgttgatggg cttcctgcaa ctgcttattg 3209 qtcqcqataa atacagtata tctqcqtcaa cagttqqcqa tqaaccatta aacccqqaqc 3269 atogoacggc gttgatcatg cotatotgta acgaagacgt qaaccgtgtt tttqctqqct 3329 tgcqtgcaac gtgggaatca gtaaaagcca ccgggaatgc caaacatttt gatgtctaca 3389 ttcttagtga cagttataac ccggatatct gcgtcgcaga gcaaaaagcc tggatggagc 3449 ttatcgctga agtcggtggc gaaggtcaga ttttctatcg ccgccqccqc cqtcqcqtqa 3509 agogtaaaag oggtaatato gatgacttot googtogotg gggcagocag tacagotaca 3569 tggtggtgct ggatgctgac tcggtaatga ccggtgattg tttgtgcggc ctggtgcgcc 3629 tgatggaagc caacccgaac gccgggatca ttcagtcgtc gccgaaagcg tccggcatgg 3689 atacgctgta tgcgcgctgt cagcagttcg cgacccgcgt gtatgggcca ctgtttacag 3749 ccggtttgca cttctggcaa cttggcgagt cgcactactg ggggcataac gcgattatcc 3809 gcgtgaaacc gtttatcgag cactgtgcac tggctccgct gccgggcgaa ggttcttttg 3869 ccggttcaat cctgtcacat gacttcgtgg aagcggcgtt gatgcgccgt gcaggttggg 3929 gggtctggat tgcttacgat ctcccgggtt cttatgaaga attaccgcct aacttgcttg 3989 atgagetaaa aegtgaeege egetggtgee aeggtaaeet gatgaaette egtetgttee 4049 tggtgaaggg tatgcacccg gttcaccgtg eggtgttcct gacgggegtg atgtcttatc 4109

i sale

n

135

WO 00/28038 PCT/GB99/03721

tetecegetee getgtggttt atgiteeteg egetetetae tgeattgeag gtagtacatg 4169
egitgacega acegeaatae tteetgeaae eaeggeagtt giteeeggta tggeegeagt 4229
ggegteetga getggegatt geaetititg eitegaceat ggtgetgttg tieetgeega 4289
agetattgag eaittitgett atetggtgea aaggaaegaa agaa 4333

<210> 2

<211> 511

<212> PRT

<213> Escherichia coli

<400> 2

Met Met Lys Met Arg Trp Leu Ser Ala Ala Val Met Leu Thr Leu Tyr $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$

Thr Ser Ser Ser Trp Ala Phe Ser Ile Asp Asp Val Ala Lys Gln Ala 20 25 30

Gln Ser Leu Ala Gly Lys Gly Tyr Glu Ala Pro Lys Ser Asn Leu Pro $35 \hspace{1cm} 40 \hspace{1cm} 45$

Asn His Asp Lys Ala Tyr Trp Asn Asn Leu Lys Thr Pro Phe Lys Leu 65 70 75 80

Glu Phe Tyr His Gln Gly Met Tyr Phe Asp Thr Pro Val Lys Ile Asn $85 \hspace{1cm} 90 \hspace{1cm} 95$

Glu Val Thr Ala Thr Ala Val Lys Arg Ile Lys Tyr Ser Pro Asp Tyr 100 105 110

Phe Thr Phe Gly Asp Val Gln His Asp Lys Asp Thr Val Lys Asp Leu 115 120 125

Gly Phe Ala Gly Phe Lys Val Leu Tyr Pro Ile Asn Ser Lys Asp Lys $130 \ 135 \ 140$

Gly Ala Gly Gln Val Tyr Gly Leu Ser Ala Arg Gly Leu Ala Ile Asp 165 170 175

Thr Ala Leu Pro Ser Gly Glu Glu Phe Pro Arg Phe Lys Glu Phe Trp 180 185 190

Ile Glu Arg Pro Lys Pro Thr Asp Lys Arg Leu Thr Ile Tyr Ala Leu 195 \$200\$

Leu Asp Ser Pro Arg Ala Thr Gly Ala Tyr Lys Phe Val Val Met Pro 210 215 220

Gly Arg Asp Thr Val Val Asp Val Gln Ser Lys Ile Tyr Leu Arg Asp 225 230 235 240

Lys Val Gly Lys Leu Gly Val Ala Pro Leu Thr Ser Met Phe Leu Phe 245 250 255

Gly Pro Asn Gln Pro Ser Pro Ala Asn Asn Tyr Arg Pro Glu Leu His 260 265 270

Asp Ser Asn Gly Leu Ser Ile His Ala Gly Asn Gly Glu Trp Ile Trp 275 280 285

Arg Pro Leu Asn Asn Pro Lys His Leu Ala Val Ser Ser Phe Ser Met 290 295 300

Glu Asn Pro Gln Gly Phe Gly Leu Leu Gln Arg Gly Arg Asp Phe Ser 305 310 315

Arg Phe Glu Asp Leu Asp Asp Arg Tyr Asp Leu Arg Pro Ser Ala Trp 325 330 335

Val Thr Pro Lys Gly Glu Trp Gly Lys Gly Ser Val Glu Leu Val Glu 340 345

Ile Pro Thr Asn Asp Glu Thr Asn Asp Asn Ile Val Ala Tyr Trp Thr 355 360 365

Pro Asp Gln Leu Pro Glu Pro Gly Lys Glu Met Asn Phe Lys Tyr Thr 370 375 380

Ile Thr Phe Ser Arg Asp Glu Asp Lys Leu His Ala Pro Asp Asn Ala 385 390 395 400

Trp Val Gln Gln Thr Arg Arg Ser Thr Gly Asp Val Lys Gln Ser Asn 405 415

Leu Ile Arg Gln Pro Asp Gly Thr Ile Ala Phe Val Val Asp Phe Thr
420 425 430

51

Gly Ala Glu Met Lys Lys Leu Pro Glu Asp Thr Pro Val Thr Ala Gln 435 440 445

Thr Ser Ile Gly Asp Asn Gly Glu Ile Val Glu Ser Thr Val Arg Tyr 450 460

Asn Pro Val Thr Lys Gly Trp Arg Leu Val Met Arg Val Lys Val Lys 465 470 475 480

Asp Ala Lys Lys Thr Thr Glu Met Arg Ala Ala Leu Val Asn Ala Asp 485 490 495

Gln Thr Leu Ser Glu Thr Trp Ser Tyr Gln Leu Pro Ala Asn Glu 500 505 510

<210> 3

<211> 574

<212> DNA

<213> Escherichia coli

<400> 3

ttegttgate etgteacegt ttgtteggtt atttecagee gtgccacegt tggtetgega 60 accaaacget ggaaactgtt ecetgateee ggaagagtat teaecgeege aggtgetggt 120 tgatacegat eggtteettg agatgaateg teaatgetee ettgatgatg gttttatgea 180 eggeggtgtt aaccegteat ttaacgetet ggeaacega atgggaceg eggteaceg 240 egccageaag gtgetggaaa tegecegtga ecgccacget gaacaggege tgaacgagag 300 gecagagaag etgaategge ategtegeet ggggteta agegateeg tgaegategg 360 eegtetgeat tteegegtet ggaatteee ggaggatat tetteatggg tgagttata 420 egaagggata aageteaate eactggeate gegetaaceg gatgegget egcaataaa 480 acgtagttge etgatgeget aegettatea ggeetaace gteetgeaa ttattetgag 574 etgeaagtt ttgtaaggteg 360 eggtetgeta ttgtaaggeg acgtaatea ggeetaaceg gatgegget egcaataaa 480 acgtagttge etgatggeg acgettatea ggeetaaceg gteetgeaa ttattetgaaggtg 574

<210> 4

<211> 1478

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (25)..(1449)

<400> 4

gggataatgc ctgaggggcc tgta atg cgt atc ggc atg cgg ttg ttg ctg Met Arg Ile Gly Met Arg Leu Leu Leu

							•				,					
aac	tat	+++	tta	cta	ata	aca	ata			+~~						••
			Leu													99
10	-,-				15		,		, Lu	20	rne	Val	пец	мла	25	
										20					25	
ttt	qtc	aaa	gaa	att	aaa	cca	aac	ata	спа	aga	aca	acc	gag	aaa	200	147
Phe	Val	Lvs	Glu	Val	Lvs	Pro	Glv	Val	Ara	Ara	212	Thr	Glu	611	The	23/
		-		30	-3-		,		35	9	-LLu		Olu	40	1111	
														••		
tta	atc	gac	acc	gca	acg	ttg	ctg	gcg	gag	ctg	gcg	cgt	ccc	gat	ttq	195
			Thr													
			45					50				-	55	-		
ctc	tct	ggg	gac	cca	acg	cat	ggg	caa	ctg	gcg	cag	gcg	ttt	aat	cag	243
Leu	Ser	Gly	Asp	Pro	Thr	His	Gly	Gln	Leu	Ala	Gln	Ala	Phe	Asn	Gln	
		60					65					70				
			cgc													291
Leu		His	Arg	Pro	Phe		Ala	Asn	Ile	Gly	Gly	Ile	Asn	Lys	Val	
	75					80					85					
			tat -													339
	Asn	Glu	Tyr	His		Tyr	Met	Thr	Asp		Gln	Gly	Lys	Val		
90					95					100					105	
++-	~~+		~~~													
			gca													387
	nup	501	Ala	110	шуз	лта	Val	GIY	115	Asp	Tyr	ser	Arg		Asn	
									113					120		
gac	qtc	taa	cta	acq	tta	cat	aat	can	tat	aat	aca	cac	age	aca	tta	435
			Leu													433
-		•	125					130	-,-	,		9	135		Deu	
													100			
caa	aat	cct	gcc	gat	ccc	gaa	agt	tct	gtg	atg	tat	gtt	gcc	qcq	ccq	483
			Ala													
		140					145					150				
att	atg	gac	ggc	tcg	cgg	ctt	att	ggc	gtt	ttg	agc	gta	ggc	aaa	ccg	531
Ile	Met	Asp	Gly	Ser	Arg	Leu	Ile	Gly	Val	Leu	Ser	Val	Gly	Lys	Pro	
	155					160					165					
			atg													579
	Ala	Ala	Met	Ala		Val	Ile	Lys	Arg	Ser	Glu	Arg	Arg	Ile	Leu	
170					175					180					185	
tgg	gcc	agc	gcc	att	ttg -	ttg	ggg	att	gca	ctg	gtg	att	ggc	gca	ggc	627
1,Lb	Ala	Ser	Ala	Ile	Leu	Leu	Gly	Ile	Ala	Leu	Val	Ile	Gly	Ala	Gly	

190 195 200 atg gtt tgg tgg atc aac cgc tct att gcc agg ctc act cgc tat gct Met Val Trp Trp Ile Asn Arg Ser Ile Ala Arg Leu Thr Arg Tyr Ala 205 210 215 gat tee gte act gac aat aag eee gtt eet ete eee gat ete ggt agt 723 Asp Ser Val Thr Asp Asn Lys Pro Val Pro Leu Pro Asp Leu Gly Ser 220 225 age gag ttg cgt aaa ctc gcg cag gcg ctg gaa agt atg cgc gtg aag 771 Ser Glu Leu Arg Lys Leu Ala Gln Ala Leu Glu Ser Met Arg Val Lys 235 ctq qaa qgg aaa aac tat att gag cag tat qtt tat qcq tta act cat 819 Leu Glu Gly Lys Asn Tyr Ile Glu Gln Tyr Val Tyr Ala Leu Thr His 250 255 260 265 gag cta aaa agc cca ctg gcg gcg att cgt ggc gcg gcg gaa att tta 867 Glu Leu Lys Ser Pro Leu Ala Ala Ile Arg Gly Ala Ala Glu Ile Leu 270 275 cgc gaa ggt ccg ccg ccg gaa gtg gtg gct cgt ttt acc gac aac att Arg Glu Gly Pro Pro Pro Glu Val Val Ala Arg Phe Thr Asp Asn Ile 285 290 295 ctq acq caa aat gcg cga atg cag gca ctq qtq qaa acq tta cta cqc 963 Leu Thr Gln Asn Ala Arg Met Gln Ala Leu Val Glu Thr Leu Leu Arg 300 305 310 cag gca aga ctg gag aat cgt cag gaa gtc gtt ctg act gct gtt gat 1011 Gln Ala Arg Leu Glu Asn Arg Gln Glu Val Val Leu Thr Ala Val Asp 315 320 gtg gcg gca tta ttt cgc cgc gtc agc gaa gcg cgc acc gtg cag ttg Val Ala Ala Leu Phe Arg Arg Val Ser Glu Ala Arg Thr Val Gln Leu 330 335 340 345 qca qaa aaa aac atc act ttg cat gtt atg cct act qaq gtt aac gtt Ala Glu Lys Asn Ile Thr Leu His Val Met Pro Thr Glu Val Asn Val 350 355 gct tct gaa ccg gcg tta ctg gag cag gcg ctg ggg aat tta ctg gat

365

Ala Ser Glu Pro Ala Leu Leu Glu Gln Ala Leu Gly Asn Leu Leu Asp

aac gcc atc gat ttt act ccc gag agc ggt tgc ata acg cta agc gcc Asn Ala Ile Asp Phe Thr Pro Glu Ser Gly Cys Ile Thr Leu Ser Ala

370

375

380 385 390

gaa gtg gat cag gaa tac gtc acc ctt aag gtg ctg gat acc ggt agt 125 Glu Val Asp Gln Glu Tyr Val Thr Leu Lys Val Leu Asp Thr Gly Ser 395 400

ggg att cct gac tac gcg ctg tca cgt att ttt gaa cgc ttt tac tct 129 Gly Ile Pro Asp Tyr Ala Leu Ser Arg Ile Phe Glu Arg Phe Tyr Ser 410 425

ttg ccg cgt gca aat ggg caa aaa agc agc ggt ctg ggg ttg gcg ttt 1347 Leu Pro Arg Ala Asn Gly Gln Lys Ser Ser Gly Leu Gly Leu Ala Phe 430 435 440

gtc agt gag gtc gcc cgt ttg ttt aac ggc gaa gtc acg ctg cgc aac 1395 Val Ser Glu Val Ala Arg Leu Phe Asn Gly Glu Val Thr Leu Arg Asn 455 450 455

gtg cag gaa ggt ggc gtg ctg gcc tcg ctt cga ctt cac cgt cac ttc 1443 Val Glu Glu Gly Gly Val Leu Ala Ser Leu Arg Leu His Arg His Phe 460 465 470

aca tag cttcaaattc ttcccacata gtcttcgta

1478

475

<210> 5 <211> 474 <212> PRT

<213> Escherichia coli

<400> 5

Met Arg Ile Gly Met Arg Leu Leu Gly Tyr Phe Leu Leu Val Ala 1 $$\rm 10^{\circ}$

Val Ala Ala Trp Phe Val Leu Ala Ile Phe Val Lys Glu Val Lys Pro

Gly Val Arg Arg Ala Thr Glu Gly Thr Leu Ile Asp Thr Ala Thr Leu $35 \hspace{1.5cm} 40 \hspace{1.5cm} 45 \hspace{1.5cm}$

Leu Ala Glu Leu Ala Arg Pro Asp Leu Leu Ser Gly Asp Pro Thr His 50 60

Gly Gln Leu Ala Gln Ala Phe Asn Gln Leu Gln His Arg Pro Phe Arg 65 70 75 80

Ala Asn Ile Gly Gly Ile Asn Lys Val Arg Asn Glu Tyr His Val Tyr 85 90 95

- Met Thr Asp Ala Gln Gly Lys Val Leu Phe Asp Ser Ala Asn Lys Ala $100 \hspace{1cm} 105 \hspace{1cm} 110$
- Val Gly Gln Asp Tyr Ser Arg Trp Asn Asp Val Trp Leu Thr Leu Arg 115 120 125
- Gly Gln Tyr Gly Ala Arg Ser Thr Leu Gln Asn Pro Ala Asp Pro Glu 130 135 140
- Ile Gly Val Leu Ser Val Gly Lys Pro Asn Ala Ala Met Ala Pro Val
 165 170 175
- Ile Lys Arg Ser Glu Arg Arg Ile Leu Trp Ala Ser Ala Ile Leu Leu 180 185 190
- Gly Ile Ala Leu Val Ile Gly Ala Gly Met Val Trp Trp Ile Asn Arg 195 200 205
- Ser Ile Ala Arg Leu Thr Arg Tyr Ala Asp Ser Val Thr Asp Asn Lys 210 215 220
- Pro Val Pro Leu Pro Asp Leu Gly Ser Ser Glu Leu Arg Lys Leu Ala 225 230 235 240
- Gln Ala Leu Glu Ser Met Arg Val Lys Leu Glu Gly Lys Asn Tyr Ile 245 250 255
- Glu Gln Tyr Val Tyr Ala Leu Thr His Glu Leu Lys Ser Pro Leu Ala $260 \hspace{1.5cm} 265 \hspace{1.5cm} 270 \hspace{1.5cm}$
- Ala Ile Arg Gly Ala Ala Glu Ile Leu Arg Glu Gly Pro Pro Glu 275 280 285
- Val Val Ala Arg Phe Thr Asp Asn Ile Leu Thr Gln Asn Ala Arg Met 290 295 300
- Gln Ala Leu Val Glu Thr Leu Léu Arg Gln Ala Arg Leu Glu Asn Arg 305 310 315
- Gln Glu Val Val Leu Thr Ala Val Asp Val Ala Ala Leu Phe Arg Arg 325 330 335

105

WO 00/28038 PCT/GB99/03721

Val Ser Glu Ala Arg Thr Val Gln Leu Ala Glu Lys Asn Ile Thr Leu 340 345

His Val Met Pro Thr Glu Val Asn Val Ala Ser Glu Pro Ala Leu Leu 355 360 365

Glu Gln Ala Leu Gly Asn Leu Leu Asp Asn Ala Ile Asp Phe Thr Pro $370 \hspace{1cm} 375 \hspace{1cm} 380 \hspace{1cm}$

Glu Ser Gly Cys Ile Thr Leu Ser Ala Glu Val Asp Gln Glu Tyr Val 385 $390 \hspace{1.5cm} 395 \hspace{1.5cm} 400$

Thr Leu Lys Val Leu Asp Thr Gly Ser Gly Ile Pro Asp Tyr Ala Leu
405 410 415

Ser Arg Ile Phe Glu Arg Phe Tyr Ser Leu Pro Arg Ala Asn Gly Gln
420 425 430

Lys Ser Ser Gly Leu Gly Leu Ala Phe Val Ser Glu Val Ala Arg Leu 435 445

Phe Asn Gly Glu Val Thr Leu Arg Asn Val Glu Glu Gly Gly Val Leu 450 455 460

Ala Ser Leu Arg Leu His Arg His Phe Thr 465 470

<210> 6

<211> 128

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (1)..(126)

<400> 6

atg aaa ggt cgc ctg tta gat gct gtc ccg ctc agt tcc cta acg ggc 40 Met Lys Gly Arg Leu Leu Asp Ala Val Pro Leu Ser Ser Leu Thr Gly 1 5 10 15

gtt ggc gca gcg ctt agt aac aag ctg gcg aaa atc aac ctg cat acc 96
Val Gly Ala Ala Leu Ser Asn Lys Leu Ala Lys Ile Asn Leu His Thr
20 25 30

gta cag gat tta ctc tta cac ctt cct ctg cg

128

Val Gln Asp Leu Leu His Leu Pro Leu 35 40

<210> 7

<211> 42

<212> PRT

<213> Escherichia coli

<400> 7

Met Lys Gly Arg Leu Leu Asp Ala Val Pro Leu Ser Ser Leu Thr Gly 10

Val Gly Ala Ala Leu Ser Asn Lys Leu Ala Lys Ile Asn Leu His Thr 20 25

Val Gln Asp Leu Leu Leu His Leu Pro Leu 35 40

<210> 8

<211> 1174

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (121)..(837)

<400> 8

agatgcacga tcgagtaggc cggataaggc gtttacgccg catccagcat ggaaaacgcg 60

cactttgtta tcaatctggg gccagcaaat gctggcctga tttgttcttg agggaagact 120

atg atg cgc aaa atg ctg ctg gcg gca gca ctt tca gtg acg gca atg Met Met Arg Lys Met Leu Leu Ala Ala Ala Leu Ser Val Thr Ala Met

10 15

acc get cac gec gac tac cag tgc agc gtc acg ccg cgt gac gat gtg Thr Ala His Ala Asp Tyr Gln Cys Ser Val Thr Pro Arg Asp Asp Val 20

att gtc agc ccg caa acc gtg cag gtg aag ggc gaa aac ggc aat ctg Ile Val Ser Pro Gln Thr Val Gln Val Lys Gly Glu Asn Gly Asn Leu 35

40

gtg atc acg cca gac ggc aac gtg atg tat aac ggt aag caa tat tcc 312

Val	Ile	Thr	Pro	Asp	Gly	Asn	Val	Met	Tyr	Asn	Gly	Lys	Gln	Tyr	Ser	
	50					55					60					
ctg	aat	gcc	gcc	cag	cgc	gag	cag	gcg	aag	gat	tat	cag	gct	gaa	cta	360
Leu	Asn	Ala	Ala	Gln	Arg	Glu	Gln	Ala	Lys	Asp	Tyr	Gln	Ala	Glu	Leu	
65					70				-	75					80	
cqt	agc	acc	ctq	ccq	taa	att	gat	gga	ggc	aca	aaa	agc	cac	atc	gag	408
									Gly							
9				85				,	90		_,_		9	95	OLU.	
aaa	act	cat	att	aca	cta	gat	222	att	atc	att	C 2 C	~~	ata	~~~	~~ »	456
									Ile	-	_		-		-	450
2,5		<i>,</i> 9	100			пор	2,5	105	116	Val	GIII	GIU	110	GIY	Giu	
			100					103					110			
age	age	222	ato	cac	age	cat	cta	200	aaa	ctt	~a+	~~~	~~~	a+~		504
									Lys							304
501	501	115	1100	ALG	DCI	ALG	120	1111	БуБ	Leu	АБР	125	GIII	ьец	Lys	
		113					120					125				
~~~	~~~	200		~~~	-++	2+4	~		cgc				-4			
									Arg							552
GIU	130	Mec	ASII	ALG	116	135	GIU	THE	Arg	ser	-	GIĀ	Leu	Thr	Pne	
	130					133					140					
~~~	+-+		~~~	-++												
									gcc							600
145	Tyr	гÀг	Аца	TTE	150	GIN	vai	Arg	Ala		GIY	Gin	GIn	Leu		
143					130					155					160	
	~~~	~~~	-+-	~~~	~~-	-++			gac							
									Asp							648
Asii	GIII	ALA	Mec	165	GIY	116	Беп	GIII	170	ser	TTE	Asn	GIU		GIY	
				103					170					175		
									aac							696
ALA	ьys	ALA		Leu	Lys	ser	GTA		Asn	Pro	Leu	Gln		Val	Leu	
			180					185					190			
	agc															744
		Leu					ser		atc Ile			Glu				744
																744
Gly	Ser	Leu 195	Gly	Gly	Leu	Gln	Ser 200	Ser	Ile	Gln	Thr	Glu 205	Trp	Lys	Lys	744
Gly	Ser gaa	Leu 195 aaa	Gly gat	Gly ttc	Leu cag	Gln cag	Ser 200 ttt	Ser ggc	Ile aaa	Gln gat	Thr gtt	Glu 205 tgt	Trp	Lys	Lys	744
Gly	Ser gaa Glu	Leu 195 aaa	Gly gat	Gly ttc	Leu cag	Gln cag Gln	Ser 200 ttt	Ser ggc	Ile	Gln gat	Thr gtt Val	Glu 205 tgt	Trp	Lys	Lys	
Gly	Ser gaa	Leu 195 aaa	Gly gat	Gly ttc	Leu cag	Gln cag	Ser 200 ttt	Ser ggc	Ile aaa	Gln gat	Thr gtt	Glu 205 tgt	Trp	Lys	Lys	
Gly cag Gln	gaa Glu 210	Leu 195 aaa Lys	Gly gat Asp	Gly ttc Phe	Leu cag Gln	cag Gln 215	Ser 200 ttt Phe	Ser ggc Gly	Ile aaa Lys	Gln gat Asp	Thr gtt Val 220	Glu 205 tgt Cys	Trp agc ser	Lys cgc Arg	Lys	
cag Gln gtg	gaa Glu 210	Leu 195 aaa Lys ctg	gat Asp	ttc Phe	cag Gln	cag Gln 215	Ser 200 ttt Phe	ggc Gly	Ile aaa Lys ctg	Gln gat Asp	Thr gtt Val 220	Glu 205 tgt Cys	Trp agc ser	Lys cgc Arg	Lys	
cag Gln gtg	gaa Glu 210	Leu 195 aaa Lys ctg	gat Asp	ttc Phe	cag Gln	cag Gln 215	Ser 200 ttt Phe	ggc Gly	Ile aaa Lys	Gln gat Asp	Thr gtt Val 220	Glu 205 tgt Cys	Trp agc ser	Lys cgc Arg	Lys	792

taatcctcta ttttaagacg gcataatact tttttatgcc gtttaattct tcgttttgtt 897

WO 00/28038 PCT/GB99/03721

acctgcctc	t aactttg	taa gggeg	aattc tg	cagatatc	catcacactg	gcggccgctc	957
gagcatgca	t ctagagg	gcc caatt	cgccc ta	tagtgagt	cgtattacaa	ttcactggcc	1017
gtcgtttta	c aaccgto	gtg actgg	gaaaa cc	ctggcgtt	acccaactta	atcgccttgc	1077
agcacatco	c cctttcg	cca gctgg	cgtaa ta	gcgaaaag	gcccgcaccg	atcgcccttc	1137
caacagttg	c gcacctg	atg gccaa	tggac gc	gcctg			1174
<210> 9							
<211> 239	ı						
<212> PRT							
<213> Esc	herichia	coli					
<400> 9							
	ra I.vs Me	t Len Len	בות בות	Dia Tou	Ser Val Th	m 71- W-#	
1		5	744 744	10	Ser var III	15	
						13	
Thr Ala H	is Ala As	p Tyr Gln	Cys Ser	Val Thr	Pro Arg As	p Asp Val	
	20		25		3	0	
		n Thr Val		Lys Gly	Glu Asn Gl	y Asn Leu	
	35		40		45		
Val Tla m	h- D D-	- 61	15-1 No. 5			_	
50	nr Pro As	p GIY ASN 55	vai met	Tyr Asn	Gly Lys Gl	n Tyr Ser	
30		33			60		
Leu Asn A	la Ala Gl	n Ara Glu	Gln Ala	Lvs Asp	Tyr Gln Al	a Glu Leu	
65		70		75	-,	80	
						-	
Arg Ser T	hr Leu Pr	o Trp Ile	Asp Gly	Gly Ala	Lys Ser Ar	g Val Glu	
	8	5		90		95	
Lys Ala A		a Leu Asp		Ile Val	Gln Glu Me		
	100		105		11	0	
Ser Ser 7	ve Met 7-	a ser h	Ton mb-	Tue Terr	Asp Ala Gl		
	15	a ner wrd	120	nys neu	Asp Ala GI	n Leu Lys	
-					123		
Glu Gln M	let Asn Ar	g Ile Ile	Glu Thr	Arg Ser	Asp Gly Le	u Thr Phe	

His Tyr Lys Ala Ile Asp Gln Val Arg Ala Glu Gly Gln Gln Leu Val

As Gln Ala Met Gly Gly Ile Leu Gln Asp Ser Ile As Glu Met Gly 165 \$170\$

Ala Lys Ala Val Leu Lys Ser Gly Gly Asn Pro Leu Gln Asn Val Leu 180 185 190

Gly Ser Leu Gly Gly Leu Gln Ser Ser Ile Gln Thr Glu Trp Lys Lys 195 200 205

Gln Glu Lys Asp Phe Gln Gln Phe Gly Lys Asp Val Cys Ser Arg Val 210 215 220

Val Thr Leu Glu Asp Ser Arg Lys Ala Leu Val Gly Asn Leu Lys 225 230 235

<210> 10

<211> 3406

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (1007)..(1276)

<220>

<221> CDS

<222> (1280)..(1792)

<220>

<221> CDS

<222> (1798)..(2574)

<220>

<221> CDS

<222> (2604)..(3398)

<400> 10

gatgatggtg atggagegta tttacggcat tccggtgtct gatgttgcga cgctggagaa 60
aaacggcacc aacatgaaat tgctggcgga acgcggcgtg caggtgttct tcactcaggt 120
ctttcgcgac agcttttcc atgctgatat gcaccctggc aacatcttcg taagctatga 180
acacccggaa aacccgaaat atatcggcat tgattgcggg attgttggct cgctaaacaa 240

agaagataaa cgctatctgg cggaaaactt tatcgccttc tttaatcgcg actatcgcaa 300

agtgg	cagag	ctac	acgtc	g attct	ggttg	ggt	gccacca	gata	accaa	cg 1	ttgaa	gagtt	360
cgaat	ttgcc	atto	gtacg	g tctgt	gaaco	tato	ctttgag	aaac	ccgct	gg (	ccgaa	atttc	420
gtttg	gacat	gtac	tgtta	a atctç	tttaa	taco	ggcgcgt	cgct	tcaa	ta 1	tggaa	gtgca	480
gccgc	aactg	gtgt	tactc	c agaaa	accct	gcto	ctacgtc	gaag	ggggt	ag ç	gacgo	cagct	540
ttatc	cgcaa	ctcg	attta	t ggaaa	acggo	gaag	gcctttc	ctg	gagtc	gt q	ggatt	aaaga	600
tcagg	teggt	atto	ctgcg	c tggtg	agago	att	taaagaa	aaag	gcgcc	gt 1	tctgg	gtcga	660
aaaaa	tgcca	gaac	tgcct	g aactg	gttta	cgad	cagtttg	cgc	caggg	ca a	agtat	ttaca	720
gcata	gtgtt	ggta	agatt	g cccgc	gagct	tcaç	gtcaaat	cat	gtacg	tc a	aggga	caatt	780
cgcgt	tattt	tete	ggaat	t ggcgc	tacgt	tagt	tatttaa	gtg	gcaca	tt d	cttgt	tggtc	840
agccg	acctg	aatg	ggggc	t gatgo	ccggc	: tggt	ttaatgg	cag	gtggt	ct (	gatco	jcctgg	900
tttgt	ccggt	tggc	gcaaa	a cacgo	tgatt	ttt	tcatcgc	tcaa	aggcg	gg (	ccgtg	gtaacg	960
tataa	tgcgg	cttt	gttta	a tcato	atcta	ccad	cagagga	acat				-	1015
									m	1	Gly 6	, <u>-</u> y	
atc a	of at	t taa	can i	tta tto	t att	att (	acc ata	3+0		1		•	1063
							gcc gtc		gtt	1 gta	ctg	ctt	1063
					Ile		gcc gtc Ala Val	Ile	gtt	1 gta	ctg	ctt	1063
	er Il			Leu Leu	Ile				gtt	1 gta	ctg	ctt	1063
Ile S	er Il 5	e Trp	Gln 1	Leu Leu 10	Ile	Ile A		Ile 15	gtt Val	1 gta Val	ctg Leu	ctt Leu	1063
Ile S	Ser Il 5 1gc ac	e Trp	Gln i	Leu Leu 10 ctc ggo	Ile tcc	Ile A	Ala Val	Ile 15 gat	gtt Val	1 gta Val ggt	ctg Leu	ctt Leu tcg	
Ile S	Ser Il 5 1gc ac	e Trp	Gln i	Leu Leu 10 ctc ggo	Ile tcc	Ile A	Ala Val	Ile 15 gat Asp	gtt Val	1 gta Val ggt	ctg Leu	ctt Leu tcg	
ttt g	ser Il 5 gc ac	e Trp c aaa r Lys	aag (	Leu Leu 10 ctc ggo Leu Gly 25	tcc Ser	atc of	ggt tcc Gly Ser	Ile 15 gat Asp	gtt Val ctt Leu	gta Val ggt Gly	ctg Leu gcg Ala	ctt Leu tcg Ser 35	
ttt g Phe G 20	ser Il 5 ggc ac Gly Th	e Trp	aag d Lys :	teu Leu  ctc ggc Leu Gly  25	tcc Ser	atc of lie of	ggt too Gly Ser 30 gat gat	Ile 15 gat Asp	gtt Val ctt Leu	gta Val ggt Gly	ctg Leu gcg Ala	ctt Leu tcg Ser 35	
ttt g Phe G 20	ser Il 5 ggc ac Gly Th	e Trp	aag (Lys :	teu Leu  ctc ggc Leu Gly  25	tcc Ser	atc of lie of	ggt tcc Gly Ser 30 gat gat Asp Asp	Ile 15 gat Asp	gtt Val ctt Leu	gta Val ggt Gly	ctg Leu gcg Ala cag	ctt Leu tcg Ser 35	1111
ttt g Phe G 20	ser Il 5 ggc ac Gly Th	e Trp	aag d Lys :	teu Leu  ctc ggc Leu Gly  25	tcc Ser	atc of lie of	ggt too Gly Ser 30 gat gat	Ile 15 gat Asp	gtt Val ctt Leu	gta Val ggt Gly	ctg Leu gcg Ala	ctt Leu tcg Ser 35	1111
ttt g Phe G 20 atc a	ser Il 5 ggc ac Gly Th	e Trp	aag (Lys :	ctc ggc Leu Gly 25 aaa gca	tcc Ser	atc quality atc quality atc quality atc.	ggt tcc Gly Ser 30 gat gat Asp Asp	Ile 15 gat Asp gaa	gtt Val ctt Leu cca	gta Val ggt Gly aag	ctg Leu gcg Ala cag Gln 50	ctt Leu tcg Ser 35 gat Asp	1111
ttt g Phe G 20 atc a Ile I	ser Il 5 Igc ac Sly Th Laa gg	c aaa r Lys c ttt y Phe	aag (Lys:	ctc ggc Leu Gly 25 aaa gca Lys Ala	tcc Ser atg	atc (Ile (Ile (Ile (Ile (Ile (Ile (Ile (Ile	ggt tcc Gly Ser 30 gat gat Asp Asp	Ile 15 gat Asp gaa Glu	gtt Val ctt Leu cca Pro	gta Val ggt Gly aag Lys	ctg Leu gcg Ala cag Gln 50	tcg Ser 35 gat Asp	1111
ttt g Phe G 20 atc a Ile I	ser Il 5 Igc ac Sly Th Laa gg	c aaa r Lys c ttt y Phe	aag (Lys:	ctc ggc Leu Gly 25 aaa gca Lys Ala	tcc Ser atg	atc (Ile (Ile (Ile (Ile (Ile (Ile (Ile (Ile	ggt too Gly Ser 30 gat gat Asp Asp 45	Ile 15 gat Asp gaa Glu	gtt Val ctt Leu cca Pro	gta Val ggt Gly aag Lys	ctg Leu gcg Ala cag Gln 50 gat Asp	tcg Ser 35 gat Asp	1111
ttt g Phe G 20 atc a Ile I aaa a Lys T	ggc accaggy Th	c aaa r Lys c ttt y Phe c cag r Gln 55	aag Lys :	ctc ggc Leu Gly 25 aaa gca Lys Ala gct gat Ala Asp	tcc Ser atg	atc of lie of series and of the lie of the l	ggt too Gly Ser 30 gat gat Asp Asp 45 gcg aaa	Ile 15 gat Asp gaa Glu act	gtt Val ctt Leu cca Pro atc	gta Val ggt Gly aag Lys gcc Ala	ctg Leu gcg Ala cag Gln 50 gat Asp	tcg Ser 35 gat Asp	1111 1159 1207
ttt g Phe G 20 atc a Ile I aaa a Lys T	ggc according to the second se	c aaa r Lys c ttt y Phe c cag r Gln 55	aag Lys :	Leu Leu 10 ctc ggc Leu Gly 25 aaa gcz Ala gct gat Ala Asp	tcc Ser atg	atc g Ile g agc g Ser g act g Thr g 60	ggt too Gly Ser 30 gat gat Asp Asp 45 gcg aaa Ala Lys	Ile 15 gat Asp gaa Glu act Thr	gtt Val ctt Leu cca Pro atc Ile	gta Val ggt Gly aag Lys gcc Ala 65	ctg Leu gcg Ala cag Gln 50 gat Asp	ctt Leu tcg ser 35 gat Asp	1111
ttt g Phe G 20 atc a Ile I aaa a Lys T	ge according to a general second acc	c aaa r Lys c ttt y Phe c cag r Gln 55	aag Lys :	Leu Leu 10 ctc ggc Leu Gly 25 aaa gcz Ala gct gat Ala Asp	tcc Ser atg	atc g Ile g agc g Ser g act g Thr g 60	ggt too Gly Ser 30 gat gat Asp Asp 45 gcg aaa	Ile 15 gat Asp gaa Glu act Thr	gtt Val ctt Leu cca Pro atc Ile	gta Val ggt Gly aag Lys gcc Ala 65	ctg Leu gcg Ala cag Gln 50 gat Asp	ctt Leu tcg ser 35 gat Asp	1111 1159 1207
ttt g Phe G 20 atc a Ile I aaa a Lys T	ge according to a general second acc	c aaa r Lys c ttt y Phe c cag r Gln 55	aag Lys :	Leu Leu 10 ctc ggc Leu Gly 25 aaa gcz Ala gct gat Ala Asp	tcc Ser atg	atc g Ile g agc g Ser g act g Thr g 60	ggt too Gly Ser 30 gat gat Asp Asp 45 gcg aaa Ala Lys	Ile 15 gat Asp gaa Glu act Thr	gtt Val ctt Leu cca Pro atc Ile	gta Val ggt Gly aag Lys gcc Ala 65	ctg Leu gcg Ala cag Gln 50 gat Asp	ctt Leu tcg ser 35 gat Asp	1111 1159 1207

His	Asp 85	Lys	Glu	Gln	Val	90		Val	Phe	Asp	Ile	Gly 95	Phe	ser	Glu	
												ej À aaa				1351
												cgc Arg				1399
												gag Glu				1447
												gcg Ala				1495
												tta Leu 175				1543
												cct Pro				1591
												aaa Lys				1639
												acg Thr				1687
												gtg Val				1735
												cct Pro 255				1783
	aaa Lys 260		taaa					lu As					eu I		eg cat nr His	1833
ctg	att	gag	ctg	cgt	aag	cgt	ctg	ctg	aac	tgc	att	atc	tcg	gtg	atc	1881

WU	00/28	8038													PCT/GE	199/03721
Leu	Ile 275	Glu	Leu	Arg	Lys	Arg 280	Leu	Leu	Asn	Cys	Ile 285	Ile	Ser	Val	Ile	
a+ a		++0	cta	+ a+	cta	gtc		++-	~~~	+						1000
						Val										1929
290				-,-	295		-,-			300	лор	110			305	
						aag										1977
Val	Ser	Ala	Pro		Ile	Lys	Gln	Leu	Pro	Gln	Gly	ser	Thr	Met	Ile	
				310					315					320		
gcc	acc	gac	gtg	gcc	tcg	ccg	ttc	ttt	acg	ccg	atc	aag	ctg	acc	ttt	2025
Ala	Thr	Asp	Val	Ala	Ser	Pro	Phe	Phe	Thr	Pro	Ile	Lys	Leu	Thr	Phe	
			325					330					335			
atg	gtg	tcg	ctg	att	ctg	tca	gcg	ccg	gtg	att	ctc	tat	cag	gtg	tgg	2073
Met	Val		Leu	Ile	Leu	ser	Ala	Pro	Val	Ile	Leu	Tyr	Gln	Val	Trp	
		340					345					350				
gcg	ttt	atc	gcc	cca	gcg	ctg	tat	aag	cat	gaa	cgt	cgc	ctg	gtg	gtg	2121
Ala	Phe	Ile	Ala	Pro	Ala	Leu	Tyr	Lys	His	Glu	Arg	Arg	Leu	Val	Val	
	355					360					365					
ccg	ctg	ctg	gtt	tcc	agc	tct	ctg	ctg	ttt	tat	atc	ggc	atg	gcg	ttc	2169
Pro	Leu	Leu	Val	Ser	Ser	Ser	Leu	Leu	Phe	Tyr	Ile	Gly	Met	Ala	Phe	
370					375					380					385	
gcc	tac	ttt	gtg	gtc	ttt	ccg	ctg	gca	ttt	ggc	ttc	ctt	gcc	aat	acc	2217
															Thr	
				390					395					400		
															agc	2265
Ala	Pro	Glu		Val	Gln	Val	Ser		Asp	Ile	Ala	Ser	Tyr	Leu	Ser	
			405					410					415			
ttc	gtt	atg	gcg	ctg	ttt	atg	gcg	ttt	ggt	gtc	tcc	ttt	gaa	gtg	ccg	2313
Phe	Val		Ala	Leu	Phe	Met	Ala	Phe	Gly	Val	Ser	Phe	Glu	Val	Pro	
		420					425					430				
gtg	gca	att	gtg	ctg	ctg	tgc	tgg	atg	ggg	att	acc	tcg	cca	gaa	gac	2361
															Asp	
	435					440					445					
tta	cgc	aaa	aaa	cgc	ccg	tat	gtq	cta	gtt	ggt	qca	ttc	gtt	ato	ggg	2409
															Gly	
450				Ī	455	-				460					465	
atg	ttg	ctg	acg	ccg	ccg	gat	gtc	ttc	tcg	caa	acg	ctg	ttg	gcg	atc	2457

w	J 00/2	8038													PCT/G	B99/03721
Met	Leu	Leu	Thr	Pro	Pro	Asp	Val	Phe	Ser	Gln	Thr	Leu	Leu	Ala 480	Ile	
				470					1/3					400		
	atg		-						-				-			2505
Pro	Met	Tyr	-	Leu	Phe	Glu	Ile	_	Val	Phe	Phe	Ser	_	Phe	Tyr	
			485					490					495			
	ggt															2553
Val	Gly	-	Gly	Arg	Asn	Arg	Glu 505	Glu	Glu	Asn	Asp		Glu	Ala	Glu	
		500					505					510				
-	gaa					taa	atto	aaco	gc o	cgto	agg	gc g	jttgi	tcat	atg	2606
Ser	Glu	Lys	Thr	Glu	Glu										Met	
	515					520										
	tac															2654
Glu	Tyr	Arg		Phe	Asp	Ile	Gly		Asn	Leu	Thr	Ser		Gln	Phe	
			525					530					535			
gcg	aaa	gac	cgt	gat	gat	gtt	gta	gcg	cgc	gct	ttt	gac	gcg	gga	gtt	2702
Ala	Lys	-	Arg	Asp	Asp	Val		Ala	Arg	Ala	Phe	•	Ala	Gly	Val	
		540					545					550				
aat	ggg	cta	ctc	atc	acc	ggt	acc	aat	ctg	cgt	gaa	agc	cag	cag	gcg	2750
Asn	Gly	Leu	Leu	Ile	Thr	_	Thr	Asn	Leu	Arg		Ser	Gln	Gln	Ala	
	555					560					565					
	aag															2798
	Lys	Leu	Ala	Arg		Tyr	Ser	Ser	Cys		Ser	Thr	Ala	Gly		
570					575					580					585	
												-	-		att	2846
His	Pro	His	Asp	Ser 590	Ser	Gln	Trp	Gln		Val	Thr	Glu	Glu			
				590					595					600		
															ggt	2894
Ile	Glu	Leu	Ala 605	Ala	Gln	Pro	Glu		Val	Ala	Ile	Gly		_	Gly	
			605					610					615			
															gct	2942
Lev	Asp			Arg	Asn	Phe		Thr	Pro	Glu	Glu			Arg	Ala	
		620					625					630				
ttt	gtt	gcc	cag	cta	cgc	att	gcc	gca	gaa	tta	aac	atg	ccg	gta	ttt	2990
Phe			Gln	Leu	Arg		Ala	Ala	Glu	Leu			Pro	Val	Phe	
	635					640					645					
ato	g cac	tgt	cgc	gat	gcc	cac	gag	cgg	ttt	atg	aca	ttg	ctg	gaç	ccg	3038

Met	His	Cys	Arg	Asp	Ala	His	Glu	Arg	Phe	Met	Thr	Leu	Leu	Glu	Pro	
650					655					660					665	
tgg	ctg	gat	aaa	ctg	cct	ggt	gcg	gtt	ctt	cat	tgc	ttt	acc	ggc	aca	3086
Trp	Leu	Asp	Lys	Leu	Pro	Gly	Ala	Val	Leu	His	Cys	Phe	Thr	Gly	Thr	
				670					675		-			680		
cgc	gaa	gag	atg	cag	qcq	tqc	ata	aca	tat	σσa	att	tat	atc	aac	att	3134
	-	-	-			-			-		Ile					
•			685			•		690	- 3 -	,		-,-	695	,		
acc	aat	taa	att	tac	gat	gaa	cga	cac	aaa	cta	gag	cta	caa	gaa	tta	3182
											Glu					0101
		700		- 2 -			705	,	,			710	9	O.L.	Deu	
tta	cca	tta	att	cca	aca	σασ	aaa	tta	cta	atc	gaa	act	na+	aca	~~~	3230
											Glu					0250
	715					720	-,-				725		Аор	ALU	110	
											, 20					
tat	cta	ctc	cct	cac	gat	ctc	асо	cca	aad	cca	tca	tcc	caa	cac	220	3278
											Ser					3270
730					735				-,-	740			9	712 9	745	
										, 10					743	
σaσ	cca	acc	cat	cta	ccc	cat	att	tta	caa	cat	att	aca	<b>C2</b> C	+	aat	3326
											Ile					3320
				750					755	9		7.14	1123	760	ALG	
				,					,55					700		
gga	gaa	gat	acc	σca	taa	cta	act	acc	acc	aca	gat	acc	224	ata	222	3374
											Asp					33/4
2			765					770		****	лор	A14	775	Val	Буз	
													,,,			
aca	cta	ttt	qqq	att	aca	+++	tan	anti	++ ~~							3406
	-		Gly				9	296	9 - 1	,						3400
		780	-17	-10			785									
		, 50					, 33									

<210> 11 <211> 89 <212> PRT <213> Escherichia coli

<400> 11

Met Gly Gly Ile Ser Ile Trp Glh Leu Leu Ile Ile Ala Val Ile Val 1 10 15

Val Leu Leu Phe Gly Thr Lys Lys Leu Gly Ser Ile Gly Ser Asp Leu 20 \$25\$

Gly Ala Ser Ile Lys Gly Phe Lys Lys Ala Met Ser Asp Asp Glu Pro  $35 \hspace{1cm} 40 \hspace{1cm} 45 \hspace{1cm}$ 

Lys Gln Asp Lys Thr Ser Gln Asp Ala Asp Phe Thr Ala Lys Thr Ile  $50 \hspace{1cm} 55$ 

Ala Asp Lys Gln Ala Asp Thr Asn Gln Glu Gln Ala Lys Ile Glu Asp 65 70 75 80

Ala Lys Arg His Asp Lys Glu Gln Val 85

<210> 12

<211> 171

<212> PRT

<213> Escherichia coli

<400> 12

Val Phe Asp Ile Gly Phe Ser Glu Leu Leu Leu Val Phe Ile Ile Gly
1 5 10 15

Leu Val Val Leu Gly Pro Gln Arg Leu Pro Val Ala Val Lys Thr Val 20 25 30

Ala Gly Trp Ile Arg Ala Leu Arg Ser Leu Ala Thr Thr Val Gln Asn  $35 \hspace{1cm} 40 \hspace{1cm} 45$ 

Glu Leu Thr Gln Glu Leu Lys Leu Gln Glu Phe Gln Asp Ser Leu Lys  $50 \hspace{1cm} 55 \hspace{1cm} 60 \hspace{1cm}$ 

Lys Val Glu Lys Ala Ser Leu Thr Asn Leu Thr Pro Glu Leu Lys Ala 65 70 75 80

Ser Met Asp Glu Leu Arg Gln Ala Ala Glu Ser Met Lys Arg Ser Tyr \$85\$ 90 95

Val Ala Asn Asp Pro Glu Lys Ala Ser Asp Glu Ala His Thr Ile His 100 105 110

Asn Pro Val Val Lys Asp Asn Glu Thr Ala His Glu Gly Val Thr Pro 115 120 125

Ala Ala Ala Gin Thr Gin Ala Ser Ser Pro Giu Gin Lys Pro Giu Thr 130 135 140

Thr Pro Glu Pro Val Val Lys Pro Ala Ala Asp Ala Glu Pro Lys Thr 145 150 150 160 Ala Ala Pro Ser Pro Ser Ser Ser Asp Lys Pro 165 170

<210> 13

<211> 258

<212> PRT

<213> Escherichia coli

<400> 13

Arg Lys Arg Leu Leu Asn Cys Ile Ile Ser Val Ile Val Ile Phe Leu  $20 \hspace{1cm} 25 \hspace{1cm} 30 \hspace{1cm}$ 

Cys Leu Val Tyr Phe Ala Asn Asp Ile Tyr His Leu Val Ser Ala Pro \$35\$

Leu Ile Lys Gln Leu Pro Gln Gly Ser Thr Met Ile Ala Thr Asp Val 50 55 60

Ala Ser Pro Phe Phe Thr Pro Ile Lys Leu Thr Phe Met Val Ser Leu 65 70 75 80

Ile Leu Ser Ala Pro Val Ile Leu Tyr Gln Val Trp Ala Phe Ile Ala 85 90 95

Pro Ala Leu Tyr Lys His Glu Arg Arg Leu Val Val Pro Leu Leu Val 100 105 110

Ser Ser Ser Leu Leu Phe Tyr Ile Gly Met Ala Phe Ala Tyr Phe Val 115 120 125

Val Phe Pro Leu Ala Phe Gly Phe Leu Ala Asn Thr Ala Pro Glu Gly 130 135 140

Val Gln Val Ser Thr Asp Ile Ala Ser Tyr Leu Ser Phe Val Met Ala 145 150 155 160

Leu Phe Met Ala Phe Gly Val Ser Phe Glu Val Pro Val Ala Ile Val
165 : 170 175

Leu Cys Trp Met Gly Ile Thr Ser Pro Glu Asp Leu Arg Lys Lys 180 185 190

Arg Pro Tyr Val Leu Val Gly Ala Phe Val Val Gly Met Leu Leu Thr

Pro Pro Asp Val Phe Ser Gln Thr Leu Leu Ala Ile Pro Met Tyr Cys 

Leu Phe Glu Ile Gly Val Phe Phe Ser Arg Phe Tyr Val Gly Lys Gly 

Arg Asn Arg Glu Glu Glu Asn Asp Ala Glu Ala Glu Ser Glu Lys Thr 

Glu Glu

<210> 14

<211> 264

<212> PRT

<213> Escherichia coli

GUSECTON

No.

 Met Glu Tyr Arg Met Phe Asp Ile Gly Val Asn Leu Thr Ser Ser Gln 

Phe Ala Lys Asp Arg Asp Val Val Ala Arg Ala Phe Asp Ala Gly 

Val Asn Gly Leu Leu Ile Thr Gly Thr Asn Leu Arg Glu Ser Gln Gln 

Ala Gln Lys Leu Ala Arg Gln Tyr Ser Ser Cys Trp Ser Thr Ala Gly 

Val His Pro His Asp Ser Ser Gln Trp Gln Ala Val Thr Glu Glu Ala 

Ile Ile Glu Leu Ala Ala Gln Pro Glu Val Val Ala Ile Gly Glu Cys 

Gly Leu Asp Phe Asn Arg Asn Phe Ser Thr Pro Glu Glu Glu Glu Arg 

Ala Phe Val Ala Gln Leu Arg Ile Ala Ala Glu Leu Asn Met Pro Val 

Phe Met His Cys Arg Asp Ala His Glu Arg Phe Met Thr Leu Leu Glu 

Pro Trp Leu Asp Lys Leu Pro Gly Ala Val Leu His Cys Phe Thr Gly

13 14

10 199 1

143 14

> 171 193

(16)

WO 00/28038 PCT/GB99/03721

150 145 155 160

Thr Arg Glu Glu Met Gln Ala Cys Val Ala Cys Gly Ile Tyr Ile Gly 170

Ile Thr Gly Trp Val Cys Asp Glu Arg Arg Gly Leu Glu Leu Arg Glu 185

Leu Leu Pro Leu Ile Pro Ala Glu Lys Leu Leu Ile Glu Thr Asp Ala 195 200

Pro Tyr Leu Leu Pro Arg Asp Leu Thr Pro Lys Pro Ser Ser Arg Arg 210

Asn Glu Pro Ala His Leu Pro His Ile Leu Gln Arg Ile Ala His Trp 225 230 235 240

Arg Gly Glu Asp Ala Ala Trp Leu Ala Ala Thr Thr Asp Ala Asn Val 245 250 255

Lys Thr Leu Phe Gly Ile Ala Phe 260

<210> 15

<211> 586

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (170)..(370)

<400> 15

tottaaacaa cogtogottt gogoogoogo aattattatg atgtttttt actoggogot 60

tgattcacct tgttacagat tgctattgtg tgcgcgcgtc gaatgaccgt taatattete 120

tggtttttaa ggcgcgttct gttgccggtt atatgtcaag aaggtatct atg ggt gag 178 Met Gly Glu 1

att agt att acc aaa ctg ctg gta gtt gcg gcg ctg gtc gtt ctg ctg 226 Ile Ser Ile Thr Lys Leu Leu Val Val Ala Ala Leu Val Val Leu Leu 10

ttt ggg act aag aag tta cgt acg ctg ggc gga gac ctt gga gcg gcc 274

Phe Gly Thr Lys Leu Arg Thr Leu Gly Gly Asp Leu Gly Ala Ala 20 25 30 35

att aaa ggg ttc aag aag gcg atg aat gat gac gat gct gcg gcg aaa 322 Ile Lys Gly Phe Lys Lys Ala Met Asn Asp Asp Asp Ala Ala Ala Lys 40 50

aaa ggc gca gac gtt gat ctt cag gct gaa aag ctc tct cat aaa gag 370 Lys Gly Ala Asp Val Asp Leu Gln Ala Glu Lys Leu Ser His Lys Glu

tgacgtggcg agcaggacgc tccctcaata tcttgttcga tacaaaaacc cgcttcaaaa 430
agcgggtttt ttatcagaca gatgtaagta attattacag gattacttaa cttccatccc 490
tttcgcctgc aaatcggcgt ggtaagaaga gcggacaaac ggaccgcatg cagcatgggt 550

aaagcccatc gccagcgctt cgctttcatt tcgtcg

586

<210> 16 <211> 67

<212> PRT

<213> Escherichia coli

<400> 16

Met Gly Glu Ile Ser Ile Thr Lys Leu Leu Val Val Ala Ala Leu Val
1 5 10 15

Val Leu Leu Phe Gly Thr Lys Lys Leu Arg Thr Leu Gly Gly Asp Leu 20 25 30

Gly Ala Ala Ile Lys Gly Phe Lys Lys Ala Met Asn Asp Asp Ala 35 40 45

Ala Ala Lys Lys Gly Ala Asp Val Asp Leu Gln Ala Glu Lys Leu Ser

His Lys Glu 65

<210> 17

<211> 4200

<212> DNA

<213> Salmonella typhimurium

<220>

<221> CDS

<222> (947)..(1444)

<220>

<221> CDS

<222> (1450)..(1722)

<400> 17

cgcaagtcaa tgtcgtcccg gtcgtatgta aaagtatgtg aatagggcgg gcgaaagcgg 60 ctaacaaaga ggcagcgtga aggataatgt gtataatgcg gccctaataa ttcatcatct 120 atcacagagg aacatgtatg ggtggtatca gtatttggca gttgttgatt gttgccgtta 180

tegtegtact getgttegge accaaaaac teggtteeat eggtteegat ettggegegt 240

ctatcaaagg ctttaaaaag gccatgagcg atgatgatgc caaacaggat aaaaccagtc 300

aggacgctga ttttaccgct aaatctatcg cggataagca aggcgaagcg aaaaaggaag 360

acgctaaaaag ccaagataaa gagcaggtat aatccgtgtt tgatatcggt tttagcgaac 420

tgctgttagt gttcgttatc ggcctcattg tgttggggcc gcaacgattg ccagtagcgg 480

taaaaacggt agcgggctgg attcgcgcgt tgcggtccct tgcgacaacg gttcagaatg 540

aactgactca ggaactgaaa cttcaggagt tccaggacag tctgaaaaaa gtcgaaaagg 600

cgagcctgga aaatctgact cccgaactga aagcatctat ggatgaactg cgtcaggcgg 660

cggagtcgat gaaacgcacc tacagcgcta acgatcccga acaagcgagc gatgaagcgc 720

ataccatcca taatccggtg gtaaaaggga acgaaacgca gcatgagggc gtcacccctg 780

ccqccqctga aacacaggcg agcgcccgg aacaaaagcc ggagcccgtt aaagctaacg 840 tgcctgagtc gacggaaacc gcttccgtag ccacgataga cgccgagaag aaatccgctg 900

egeetgttgt egaatettee eeetegtega gtgataaace gtaaac atg get gta 955 Met Ala Val

1

gaa gat act caa ccg ctt atc acg cat ctg atc gag ttg cgt aag cgc 1003 Glu Asp Thr Gln Pro Leu Ile Thr His Leu Ile Glu Leu Arg Lys Arg 5 10 15

ctg cta aac tgc atc gtc gca gta ctt ctg att ttt ctg gcg tta att 1051

Leu 20	Leu	Asn	Cys	Ile	Val 25	Ala	Val	Leu	Leu	Ile 30	Phe	Leu	Ala	Leu	Ile 35	
										gcc Ala						1099
										acg Thr						1147
										gtg Val						1195
gcg Ala	cct Pro 85	gtc Val	att Ile	ttg Leu	tac Tyr	cag Gln 90	gtt Val	tgg Trp	gcc Ala	ttt Phe	atc Ile 95	gcc Ala	ccg Pro	gcg Ala	ctg Leu	1243
										ctg Leu 110						1291
										tat Tyr						1339
ttg Leu	gcc Ala	ttt Phe	ggt Gly 135	ttc Phe	ctg Leu	acg Thr	cat Kis	acg Thr 140	gcg Ala	ccg Pro	gaa Glu	Gly ggg	gta Val 145	cag Gln	gtt Val	1387
										gtc Val						1435
	ttt Phe 165		tago					co Va					eu Le		jc tgg /s Trp	1485
										aaa Lys						1533
ctg Leu 195	gtc Val	G1y ggg	gca Ala	ttc Phe	att Ile 200	gtg Val	gga Gly	atg Met	ctg Leu	ctt Leu 205	acg Thr	ccg Pro	cca Pro	gat Asp	gtt Val 210	1581
ttc	tcg	caa	acg	ttg	ctg	gcg	ata	ccg	atg	tac	tgc	ctg	ttt	gaa	att	1629

Phe Ser Gln Thr Leu Leu Ala Ile Pro Met Tyr Cys Leu Phe Glu Ile 215 220 225

ggc gtt ttc tgc tca cgc ttt tat gtc ggt aag cga cgg acg cgc gac Gly Val Phe Cys Ser Arg Phe Tyr Val Gly Lys Arg Arg Thr Arg Asp

230 235

gaa gat aac gag gcc gaa acc gaa aag gcc gag cac act gaa gac 1722 Glu Asp Asn Glu Ala Glu Thr Glu Lvs Ala Glu His Thr Glu Asp 245

taaacacaac cgcccgccag ggcggttgtc atatgggggc aagcatgttt gatattggcg 1782 ttaatttaac cagtagccag tttgcaaaag atcgtgatga tgtggtcgcc cgtgcgtttg 1842 cggcgggagt aaaaggtatg ctactgaccg gaacgaacat ccatgaaagt cagcaggcgt 1902 taaaactggc gcggcgctac ccccattgtt ggtcgacggc tggcgtccat ccccatgaca 1962 gcagtcagtg gtcacccgcg tctgaagacg ccattattgc gctggcgaac cagccggaag 2022 togtogotat oggtgagtgo gggotggatt toaatogoaa tttttocacg cogcaggago 2082 aggagcgtgc ctttcaggcg cagctacaaa ttgccgccga attgcagata ccaatcttta 2142 tgcactgccg ggacgcgcat gagcgatttc tggtattgct tgatccctgg ctggataqtc 2202 ttcctggtgc aatactgcac tgctttaccg gttcacgcca gcaaatgcag gcctgtgtgg 2262 atagagggct ctatatcggt attaccgggt gggtttgcga cgaacgacgc gggcttgagc 2322 tacgtgaact cttaccgttt attccagcgg aaaagctact gataqaaacc gacgcqccqt 2382 atotgttgcc tcgcgatctt acgccgaaac caacgtcacg acgcaacgag cccgcgtatc 2442 tgcctcacat cctqqaqcgc atagcgctat ggcgtggtga aqatccqcaa tqqttaqcqq 2502 cgatqacaqa tgccaacgcc agaaccttat ttgaggttgt attctgaacg atcgctaaat 2562 cttgcgaaaa ccggtgtttt ttacgctctg cttcacttct ttattgagta aattaagcag 2622 taacatcgaa cgcgtttcgc catccggttc ggtaaaaatc qctttcagcc cttcaaatgc 2682 gccttccgtg atgatgacgc tatcgccggg atagggggtt tcaggatcga caacgccttc 2742 gggcttgtag atagaaagct gatgaataac gctggaaggc acgatcgcag gatgccgcca 2802 aagcqcacaa aatggctgac gccgcgcgtg gcgttgattg tagtggtatg tatcacttcc 2862

ggatcaaatt caacgaacag ataattagga aagagcggtt cgctgacgga ggtacqtttt 2922 ccqcqtacca tttttccag ggtgatcatc ggtgtcaggc aacttaccgc ttgtctttcg 2982 aggtqttcct gagcacgctg aagttgcccg cgtttgcagt acagtaaata ccaggattgc 3042 ataatgactc ttatccgctt gttcggggcg caagcatagc aaaagccatg cgcqaaqtta 3102 attatacact tcatccttta agccgtatct ggattagcgt tggttgccag agttcacgct 3162 aatttaacaa aaatacagca tcccgatqat gaacqccgta taatgatgcg cttaccaaga 3222 qqctacaatg gacgccatga aatatcacga tttacgcgac ttcctgacgc tacttgagca 3282 gcagggggaa ctaaaacgca tcacgctacc tgtggatcct catctqqaaa tcacqqaaat 3342 cgctgaccgc acgctgcgtg ccggtggacc ggcgttgctg tttgaaaatc ctaaaggtta 3402 cgccatgccg gtgctgtgca acctttttgg cacgccaaaa cgcgtggcga tggqcatqqg 3462 gcaggatgat gtttccgcct tacgggaagt gggtaaatta ttagcgtttc ttaaagaacc 3522 tqaqccqccg aaagcgtttc gcgatctgtt tgacaagctg ccgcagttta agcaagtgct 3582 gaatatgccg acgaaacggt tacgcggcgc gccttgccag cagaaaatcg cgtctggcga 3642 tgatgtcgat ttaacgcgtc ttcctgtcat gacctgttgg ccggacgacg ccgcgccgct 3702 gattacctgg ggactgacgg taacgcgtgg tccgcacaaa gagcggcaaa acctgggcat 3762 ttatcqtcag cagttgatag gtaaaaataa gctgattatg cgctggctgt ctcaccgcgg 3822 eggegegetg gatttteagg agtggttage egegegteeq qqtqaacqtt teeeqqtete 3882 cgtcgcattg ggcgccgatc cggcacgata cttggcgccg tgactcctgt tcccgatact 3942 ctgtcggagt atgcctttgc gggcctgctg cgcggcacga aaactgaagt ggttaatgct 4002 ttctacgatc tggagtgctg cagcgcgaga tatcttgaag tacatgagcg gagagatgcg 4062 cggagacqta tgcgatcata cqqcatatat qaqtqatagc tcgtcttacg tcacgcaata 4122 acagogtaga tgcatctata tcactatacg cgcgcatgag ctcgtatagg tgcctcatat 4182 ctcqtctatc tcaaaqtc 4200

<210> 18

<211> 166

<212> PRT

<213> Salmonella typhimurium

5

<400> 18

10

Met Ala Val Glu Asp Thr Gln Pro Leu Ile Thr His Leu Ile Glu Leu

Arg Lys Arg Leu Leu Asn Cys Ile Val Ala Val Leu Leu Ile Phe Leu 25

Ala Leu Ile Tyr Phe Ala Asn Asp Ile Tyr His Leu Val Ala Ala Pro 35 40

Leu Ile Lys Gln Met Pro Gln Gly Ala Thr Met Ile Ala Thr Asp Val 55

Ala Ser Pro Phe Phe Thr Pro Ile Lys Leu Thr Phe Met Val Ser Leu 65 70

Ile Leu Ser Ala Pro Val Ile Leu Tyr Gln Val Trp Ala Phe Ile Ala 85 90

Pro Ala Leu Tyr Lys His Glu Arg Arg Leu Val Val Pro Leu Leu Val 100 105

Ser Ser Ser Leu Leu Phe Tyr Ile Gly Met Ala Phe Ala Tyr Phe Val 115 120 125

Val Phe Pro Leu Ala Phe Gly Phe Leu Thr His Thr Ala Pro Glu Gly 130 135 140

Val Gln Val Ser Thr Asp Ile Ala Ser Tyr Leu Ser Phe Val Met Ala 150 155

Leu Phe Met Ala Phe Ala 165

<210> 19

<211> 91

<212> PRT

<213> Salmonella typhimurium

Phe Glu Val Pro Val Ala Ile Val Leu Leu Cys Trp Met Gly Ile Thr 10 15

Thr Pro Glu Asp Leu Arg Lys Lys Arg Pro Tyr Ile Leu Val Gly Ala
20 25 30

Phe Ile Val Gly Met Leu Leu Thr Pro Pro Asp Val Phe Ser Gln Thr

Leu Leu Ala Ile Pro Met Tyr Cys Leu Phe Glu Ile Gly Val Phe Cys 50 60

Ser Arg Phe Tyr Val Gly Lys Arg Arg Thr Arg Asp Glu Asp Asn Glu 65 70 75 80

Ala Glu Thr Glu Lys Ala Glu His Thr Glu Asp

<210> 20

<211> 2601

<212> DNA

<213> Neisseria meningitidis

<220>

<221> CDS

<222> (1572)..(2339)

<400> 20

agacaaaacc ctaaaaaaag tgattgaaga ggcgggcgaa gtgttgatgg catccaaaga 60
caaaaacccg tcccacctgg tttacgaagt tgccgactta tggtttcaca ccatgattct 120
tctgacacac cacgacctga aggcggaaga cgtattggac gaacttgcgc gccgccaagg 180
tttgtcgggc ttggccgaaa aagccgctcg cacagaatct tgaatttata ttaaaatccg 240
cactttccca cattcaatcc gtctgaccgc tgttcagacg gcatcggagc cgttatggac 300
aactgtattt tctgcaaaat cgccgccaaa gacattccgg cgcaaaccgt ctatgaagac 360
ggcgaaatgg tttgtttcaa agacatcaac cccgctgctc cggttcatct gctgctgatt 420
cccaaagtcc atttcgattc gttggcacac gccgcgcccg aacatcagcc ccttttggga 480
aaaatgatgc tgaaagttcc cgaaatcgcc aaagcggcag gactggcaga cggcttcaaa 540
accctqatca acaccggaaa aggcggcgga caagaggtct tccacctqca tatacacatc 600

atgggcacac cegtataaac cgttatttca caatcaaccc ctaatactta cttaaggata 660 catcatgggc agtttttctc tgacgcactg gattatcgta ctgattatcg tcgttttgat 720 atteggeace aaaaaactge geaacgtegg caaagacete ggeggtgegg tteatgaett 780 caaacagggg ctgaacgaag gtacagacgg caaagaagcc caaaaaagacg atgtaatcga 840 acacaaaaaa qacgaagaca aagegtaatt tatgtttgat tteggtttgg gegagetggt 900 ttttqtcqqc attatcgccc tgattgtcct cggccccgaa cgcctgcccg aggccgcccg 960 caccqccqga cggctcatcg gcaggctgca acgctttgtc ggcagcgtca aacaggaatt 1020 tgacacgcaa atcgaactgg aagaactaag gaaggcaaag caggaatttg aagctgccgc 1080 tgctcaggtt cgaqacagcc tcaaagaaac cggtacggat atggagggta atctgcacga 1140 catttccgac ggtctgaagc cttgggaaaa actgcccgaa cagcgcacgc ctgctgattt 1200 cggtgtcgat gaaaacggca atccctttcc cgatgcggca aacaccctat tagacggcat 1260 ttccgacqtt atgccgtccg aacgttccta cgcttccgcc gaaacccttg gggacagcgg 1320 gcaaaccggc agtacagccg aacccgcgga aaccgaccaa gaccgtgcat ggcgggaata 1380 cctgactgct tctgccgccg cacccgtcgt acagaccgtc gaagtcagct atatcgatac 1440 cgctgttgaa acccctgttc cgcataccac ttcgctgcgt aaacaggcaa taagccgcaa 1500 acqcgatttq cqtcctaaat cccqcqccaa acctaaattq cqcqtccqta aatcataaag 1560 agggcaatcc q qtq tcc qaa aca caa aac gaa caa ccc gtc caa ccg ctt 1610 Val Ser Glu Thr Gln Asn Glu Gln Pro Val Gln Pro Leu gtc gag cat etc atc gag etg ege ege ege etg atg tgg acg gtt gte 1658 Val Glu His Leu Ile Glu Leu Arg Arg Arg Leu Met Trp Thr Val Val 25 15 20 ggt atc tta gtc tgc ttt ttc ggc cta atg ccg ttt gcc caa caa ctc 1706 Gly Ile Leu Val Cys Phe Phe Gly Leu Met Pro Phe Ala Gln Gln Leu 45 35 40 30

tat act ttt atc gcc gac ccg ctg atg gca aac ctg ccc aaa gac acc  $\,$  175 Tyr Thr Phe Ile Ala Asp Pro Leu Met Ala Asn Leu Pro Lys Asp Thr  $\,$  50  $\,$  60  $\,$ 

agc	atg	att	gcc	acc	gat	gtc	atc	gca	cca	ttt	ttc	gtg	ccg	gtc	aaa	1802
Ser	Met	Ile	Ala	Thr	Asp	Val	Ile	Ala	Pro	Phe	Phe	Val	Pro	Val	Lys	
			65					70					75			
-		-	_		-				-	-	-	cat	-			1850
Val	Thr	Leu	Met	Ala	Ala	Phe	Leu	Ile	Ser	Leu	Pro	His	Thr	Leu	Tyr	
		80					85					90				
			-		-	-		-				aac	-		-	1898
Gln		Trp	Ala	Phe	Val		Pro	Ala	Leu	Tyr		Asn	Glu	Lys	Arg	
	95					100					105					
ata	-++	200		ata	atc	ata	+00	200	a+c	300	at a	ttt	++0	2+0	~~~	1946
-		-	-		-			-	-	-	-	Phe				1940
110	110			204	115					120	Deu				125	
atq	qca	ttt	qcc	tac	ttt	ttg	gtt	ttc	ccc	gtc	att	ttc	aaa	ttc	ctt	1994
_	-		-				-					Phe				
				130					135				-	140		
gcc	agc	gtt	acc	cct	gtc	ggt	gtc	aat	atg	g <b>cg</b>	aca	gac	atc	gac	aaa	2042
Ala	Ser	Val	Thr	Pro	Val	Gly	Val	Asn	Met	Ala	Thr	Asp	Ile	Asp	Lys	
			145					150					155			
					-		-		-	-		ggt		-		2090
Tyr	Leu		Phe	Ile	Leu	Gly		Phe	Val	Ala	Phe	Gly	Thr	Thr	Phe	
		160					165					170				
	-			-										-	aca	2138
GIU	175	PIO	He	val	Val	11e	Leu	Leu	THE	гух	185	Gly	val	vaı	Thr	
	1/3					100					100					
acc	raa	can	ctc	aaa	cac	acc	cac	ccc	tat	ata	att	atc	aac	aca	ttt	2186
	-	-			-	-	-					-			Phe	
190				-3-	195				-,-	200			3		205	
gtc	att	gcc	gcc	atc	atc	acg	ccg	ccc	gat	gtg	att	tca	caa	acc	ctg	2234
Val	Ile	Ala	Ala	Ile	Ile	Thr	Pro	Pro	Asp	Val	Ile	Ser	Gln	Thr	Leu	
				210					215					220		
ctt	gcc	att	ccg	ctg	att	ctc	tta	tac	gaa	gca	ggt	att	tgg	ttc	gga	2282
Leu	Ala	Ile	Pro	Leu	Ile	Leu	Leu	Tyr	Glu	Ala	Gly	Ile	Trp	Phe	Gly	
			225				-	230					235			
cgc	ttt	ttc	acg	cca	cgt	tca	gaa	cag	gat	ggc	gac	ata	cag	ccg	cct	2330
Arg	Phe	Phe	Thr	Pro	Arg	Ser	Glu	Gln	Asp	Gly	Asp	Ile	Gln	Pro	Pro	
		240					245					250				

gca aca acc tgacactatg ccgtccgaac ctccgcctca taccgccaca
Ala Thr Thr

2379

255

gattaaggaa tacctttgaa taccctctat ttaggttcaa acagcccgcg ccgaatggaa 2439

atectgacac agttgggcta teaggtegte aagetgeetg ecaacatega egaaacggte 2499

agacagaacg aagaccctgc ccgttacgtt caaaggatgg cagaagaaaa aaaccgaacc 2559

geoctgacce tettttgega aaccaaegge acaatgeeeg at

2601

<210> 21

<211> 256

<212> PRT

<213> Neisseria meningitidis

<400> 21

Val Ser Glu Thr Gln Asn Glu Gln Pro Val Gln Pro Leu Val Glu His

1 5 10 15

Leu Ile Glu Leu Arg Arg Leu Met Trp Thr Val Val Gly Ile Leu  $20 \hspace{1cm} 25 \hspace{1cm} 30$ 

Val Cys Phe Phe Gly Leu Met Pro Phe Ala Gln Gln Leu Tyr Thr Phe  $35 \hspace{1cm} 40 \hspace{1cm} 45 \hspace{1cm}$ 

Ile Ala Asp Pro Leu Met Ala Asn Leu Pro Lys Asp Thr Ser Met Ile  $50 \hspace{1.5cm} 55 \hspace{1.5cm} 60$ 

Ala Thr Asp Val Ile Ala Pro Phe Phe Val Pro Val Lys Val Thr Leu 65 70 75 80

Met Ala Ala Phe Leu Ile Ser Leu Pro His Thr Leu Tyr Gln Ile Trp 85 90 95

Ala Phe Val Ala Pro Ala Leu Tyr Gln Asn Glu Lys Arg Leu Ile Thr 100 105 110

Pro Leu Val Leu Ser Ser Val Ser Leu Phe Phe Ile Gly Met Ala Phe 115 120 125

Ala Tyr Phe Leu Val Phe Pro Val Ile Phe Lys Phe Leu Ala Ser Val 130 135 140

Phe Ile Leu Gly Met Phe Val Ala Phe Gly Thr Thr Phe Glu Val Pro 165 170 175

Ile Val Val Ile Leu Leu Thr Lys Ile Gly Val Val Thr Thr Glu Gln
180 185 190

Leu Lys Arg Ala Arg Pro Tyr Val Ile Val Gly Ala Phe Val Ile Ala 195 200 205

Ala Ile Ile Thr Pro Pro Asp Val Ile Ser Gln Thr Leu Leu Ala Ile 210 215 220

Pro Leu Ile Leu Leu Tyr Glu Ala Gly Ile Trp Phe Gly Arg Phe Phe 225 230 235 240

Thr Pro Arg Ser Glu Gln Asp Gly Asp Ile Gln Pro Pro Ala Thr Thr 245 250 250

<210> 22 <211> 4604

<212> DNA

<213> Escherichia coli

<220> <221> CDS

<222> (2982)..(4082)

<220>

<221> CDS

<222> (1534)..(2637)

<220>

<221> CDS

<222> (749)..(1531)

<220>

<221> CDS

<222> (6) .. (746)

<400> 2

ggcta gtt gat gat aat ttg aaa ggt caa ggt gca gga aaa aat ttt tta 50  $\,$  Val Asp Asp Asn Leu Lys Gly Gln Gly Ala Gly Lys Asn Phe Leu  $\,$  1  $\,$  5  $\,$  10  $\,$  15

tcg ctg ata aag tac agc gag aca gat tat aca att tat tgt gac caa 98

Ser	Leu	Ile	Lys		Ser	Glu	Thr	Asp	Tyr	Thr	Ile	Tyr	Cys	Asp	Gln	
				20					25					30		
~a+	~a+		+		<b>~</b> > -											
										gaa						146
мър	Asp	11e	35	Leu	GIU	Asn	ьys	40	Pne	Glu	Leu	Val	-	Tyr	Ala	
			33					40					45			
aat	gaa	att	aaa	ttg	aat	gta	tca	gat	aca	cct	tca	cta	att	tat	act	194
										Pro						
		50					55					60		-,-		
										aca						242
Asp		Tyr	Ala	Tyr	Met		Gly	G1u	Gly	Thr		Asp	Phe	Ser	Gly	
	65					70					75					
ata	tet	aac	aat	cat	act	ga+	~==	++=	224	gat						
										Asp						290
80					85				-,-	90		Бец	FIIC	File	95	
															33	
ggt	gga	tac	caa	gga	tgt	tct	att	atg	ttc	aat	cgt	gca	atg	acc	aaa	338
										Asn						
				100					105					110		
										cta						386
Phe	Leu	Leu		Tyr	Arg	Gly	Phe		Tyr	Leu	His	Asp	Asp	Ile	Thr	
			115					120					125			
aca	tta	act	αca	tac	act	ctt	aat	222	a++	tat	+++	ata			***	424
										Tyr						434
		130		-			135	-,-		-,-		140	110	Lys	- 7 -	
ctt	atg	tta	tat	aga	cag	cac	acg	aat	gcg	gta	act	ggt	atc	aaa	aca	482
Leu	Met	Leu	Tyr	Arg	Gln	His	Thr	Asn	Ala	Val	Thr	Gly	Ile	Lys	Thr	
	145					150					155					
										tca						530
160	Arg	ASI	GIY	Leu	165	ser	гÀг	Phe	ьys	Ser	Pro	Val	Asn	Tyr		
100					163					170					175	
tta	tca	cga	aaa	cat	tat	cao	gta	aaa	aaa	tct	ttt	ttt	gaa	tat	aac	578
										Ser						3/8
		-	•	180	•			-,-	185				OLU	190	7211	
							-									
										gtt						626
Ser	Ser	Ile	Leu	Ser	Glu	Thr	Asn	Lys	Lys	Val	Phe	Leu	Asp	Phe	Ile	
			195					200					205			
τca	ttt	tat	gaa	tca	aat	aat	aaa	ttt	aca	gat	+++	+++	227	++ -	+ ~~	671

Ser	Phe	Cys	Glu	Ser	Asn	Asn	Lys	Phe	Thr	Asp	Phe	Phe	Lys	Leu	Trp	
		210					215					220				
	ggt															722
Arg	Gly	Gly	Phe	Arg	Leu		Asn	Ser	Arg	Thr	Lys	Leu	Leu	Leu	Lys	
	225					230					235					
	tta Leu															769
240	пец	116	ALG	ALG	245	riie	ser	-	net.		ser. 250	ile i	seu :	Thr I	ro	
										•						
act	ttt	aat	cgg	caa	cat	act	tta	tca	agg	cta	ttc	aat	tct	ctt	ata	817
	Phe															01,
255					260				-	265			_		270	
tta	caa	act	gat	aaa	gat	ttt	gag	tgg	ata	ata	att	gat	gat	ggt	agt	865
Leu	Gln	Thr	Asp	Lys	Asp	Phe	Glu	Trp	Ile	Ile	Ile	Asp	Asp	Gly	Ser	
				275					280					285		
	gat															913
TTE	Asp	AIA	290	AIA	Va⊥	Leu	Val		Asp	Phe	Arg	Lys		Cys	Asp	
			290					295					300			
ttt	gac	tta	att	tat	tac	tat	cad	gaa	aat	aat	aat	aad	ccc	2+4	act	961
	Asp															301
		305		-	-	-	310				,	315				
tta	aac	gct	ggt	gtt	aaa	gct	tgt	aga	ggc	gat	tat	atc	ttt	att	gtt	1009
Leu	Asn	Ala	Gly	Val	Lys	Ala	Cys	Arg	Gly	Asp	Tyr	Ile	Phe	Ile	Val	
	320					325					330					
	agt															1057
335	Ser	Asp	Asp	ALA	140	Thr	Pro	Asp	Ala		Lys	Leu	Ile	Lys		
333					340					345					350	
tca	ata	cat	gat	tac	tta	tct	gag	aad	ma a	ant	++~	200	~~~	at a	~~+	1105
	Ile															1103
			-	355					360				,	365	1	
											•					
ttt	aga	aaa	gca	tat	ata	aaa	ggg	ggg	att	att	ggt	aat	gat	tta	aat	1153
Phe	Arg	Lys	Ala	Tyr	Ile	Lys	Gly	Gly	Ile	Ile	Gly	Asn	Asp	Leu	Asn	
			370					375					380			
							-									
	tct															1201
Asn	Ser		Glu	His	Ile	Tyr		Leu	Asn	Ala	Thr		Ile	Ser	Asn	
		385					390					395				

tta ata aat ggt gat gtt gca tat tgt ttt aaa aaa gaa agt ttg gta 1249

Leu																
	Ile	Asn	Gly	Asp	Val	Ala	Tyr	Cvs	Phe	Lvs	Lvs	Glu	Ser	Leu	Val	
	400		•	•		405	-2-			-,-	410			Deu	***	
aaa	aat	cca	ttc	ccc	cgt	ata	gaa	gat	gaa	aaa	ttt	gtt	cca	gaa	tta	1297
						Ile										
415					420					425					430	
						act										1345
Tyr	Ile	Trp	Asn		Ile	Thr	Asp	Lys		Lys	Ile	Arg	Phe	Asn	Ile	
				435					440					445		
			- 4 -													
						tgt										1393
ser	ьys	val	450	Tyr	Leu	Cys	GIU		Leu	Asp	Asp	Gly		Ser	Lys	
			450					455					460			
aat	ttc	cat	aac	cad	ctt	aaa	222	tac	cca	224	~~~					
						Lys										1441
		465				-,-	470	-,-		-,-	O _x y	475	Lys	116	TAT	
tac	aaa	gat	caa	aga	aaa	cga	gag	aaa	act	tat	ata	aaa	aaa	aca	aaq	1489
Tyr	Lys	Asp	Gln	Arg	Lys	Arg	Glu	Lys	Thr	Tyr	Ile	Lys	Lys	Thr	Lys	
	480					485					490				-	
						caa								aa a	atg	1536
Met 495	Leu	Ile	Arg	Tyr		Gln	Cys	Cys	Tyr		Glu	Lys	Ile	ı	1et	
495					500					505						
aaa	ata	cta	+++	atc	att	202	aat	++=	aac							1504
						aca Thr										1584
						aca Thr									Lys	1584
Lys					Ile					Leu						1584
Lys 510	Ile	Leu	Phe	Val	Ile 515	Thr	Gly	Leu	Gly	Leu 520	Gly	Gly	Ala	Glu	Lys 525	
Lys 510 cag	Ile gtt	Leu tgt	Phe ctt	Val tta	Ile 515 gct		Gly aaa	Leu tta	Gly agt	Leu 520 tta	Gly agc	gaa	Ala	Glu	Lys 525 gta	1632
Lys 510 cag	Ile gtt	Leu tgt	Phe ctt	Val tta	Ile 515 gct	Thr gat	Gly aaa	Leu tta	Gly agt	Leu 520 tta	Gly agc	gaa	Ala	Glu	Lys 525 gta	
Lys 510 cag	Ile gtt	Leu tgt	Phe ctt	Val tta Leu	Ile 515 gct	Thr gat	Gly aaa	Leu tta	Gly agt Ser	Leu 520 tta	Gly agc	gaa	Ala	Glu cat His	Lys 525 gta	
Lys 510 cag Gln	Ile gtt Val	tgt Cys	Phe ctt Leu tca	tta Leu 530	Ile 515 gct Ala gga	Thr gat Asp	Gly aaa Lys atg	tta Leu tct	agt ser 535	Leu 520 tta Leu	agc ser	gly ggg gtc	Ala cac His	Glu cat His 540	Lys 525 gta Val	
Lys 510 cag Gln	Ile gtt Val	tgt Cys	Phe ctt Leu tca ser	tta Leu 530	Ile 515 gct Ala gga	Thr gat Asp	Gly aaa Lys atg	tta Leu tct ser	agt ser 535	Leu 520 tta Leu	agc ser	gly ggg gtc	Ala cac His	Glu cat His 540	Lys 525 gta Val	1632
Lys 510 cag Gln	Ile gtt Val	tgt Cys	Phe ctt Leu tca	tta Leu 530	Ile 515 gct Ala gga	Thr gat Asp	Gly aaa Lys atg	tta Leu tct	agt ser 535	Leu 520 tta Leu	agc ser	gly ggg gtc	Ala cac His	Glu cat His 540	Lys 525 gta Val	1632
Lys 510 cag Gln aag Lys	gtt Val att	tgt Cys att	Phe ctt Leu tca ser 545	tta Leu 530 ctt Leu	Ile 515 gct Ala gga Gly	Thr gat Asp cat His	Gly aaa Lys atg Met	tta Leu tct ser 550	agt Ser 535 aat Asn	Leu 520 tta Leu aat Asn	agc Ser aaa Lys	ggg Gly gtc Val	Ala cac His ttt Phe 555	Glu cat His 540 cct Pro	Lys 525 gta Val agc ser	1632
Lys 510 cag Gln aag Lys	gtt Val att Ile	tgt Cys att Ile	Phe ctt Leu tca ser 545 gtt	tta Leu 530 ctt Leu	Ile 515 gct Ala gga Gly	Thr gat Asp cat His	Gly aaa Lys atg Met	tta Leu tct ser 550	agt Ser 535 aat Asn	Leu 520 tta Leu aat Asn	age Ser aaa Lys	ggg Gly gtc Val	Ala cac His ttt Phe 555	Glu cat His 540 cct Pro	Lys 525 gta Val agc ser	1632
Lys 510 cag Gln aag Lys	gtt Val att Ile	tgt Cys att Ile aat Asn	Phe ctt Leu tca ser 545 gtt	tta Leu 530 ctt Leu	Ile 515 gct Ala gga Gly	Thr gat Asp cat His	aaa Lys atg Met aat Asn	tta Leu tct ser 550	agt Ser 535 aat Asn	Leu 520 tta Leu aat Asn	age Ser aaa Lys	ggg Gly gtc Val	Ala cac His ttt Phe 555	Glu cat His 540 cct Pro	Lys 525 gta Val agc ser	1632
Lys 510 cag Gln aag Lys	gtt Val att Ile	tgt Cys att Ile	Phe ctt Leu tca ser 545 gtt	tta Leu 530 ctt Leu	Ile 515 gct Ala gga Gly	Thr gat Asp cat His	Gly aaa Lys atg Met	tta Leu tct ser 550	agt Ser 535 aat Asn	Leu 520 tta Leu aat Asn	age Ser aaa Lys	ggg Gly gtc Val	Ala cac His ttt Phe 555	Glu cat His 540 cct Pro	Lys 525 gta Val agc ser	1632
Lys 510 cag Gln aag Lys gaa Glu	gtt Val att Ile aat Asn	tgt Cys att Ile aat Asn 560	Phe ctt Leu tca ser 545 gtt Val	tta Leu 530 ctt Leu aat	Ile 515 gct Ala gga Gly gtc Val	Thr gat Asp cat His	aaa Lys atg Met aat Asn 565	tta Leu tct ser 550 gta Val	agt Ser 535 aat Asn aat	Leu 520 tta Leu aat Asn atg Met	agc Ser aaa Lys tca Ser	ggg Gly gtc Val aaa Lys 570	Ala cac His ttt Phe 555 aac Asn	Glu cat His 540 cct Pro	Lys 525 gta Val agc ser tct	1632 1680 1728
Lys 510 cag Gln aag Lys gaa Glu	Ile gtt Val att Ile aatt Asn	tgt Cys att Ile aat Asn 560	Phe ctt Leu tca ser 545 gtt Val	tta Leu 530 ctt Leu aat Asn	Ile 515 gct Ala gga Gly gtc Val	Thr  gat Asp  cat His att Ile	aaaa Lys atg Met aat Asn 565	tta Leu tct ser 550 gta Val	agt Ser 535 aat Asn aat	Leu 520 tta Leu aat Asn atg Met	agc Ser aaa Lys tca Ser	ggg Gly gtc Val aaa Lys 570 ata	Ala cac His ttt Phe 555 aac Asn	Glu cat His 540 cct Pro att Ile	Lys 525 gta Val agc ser tct ser	1632
Lys 510 cag Gln aag Lys gaa Glu	Ile gtt Val att Ile aatt Asn	tgt Cys att Ile aat Asn 560	Phe ctt Leu tca ser 545 gtt Val	tta Leu 530 ctt Leu aat Asn	Ile 515 gct Ala gga Gly gtc Val	Thr gat Asp cat His	aaaa Lys atg Met aat Asn 565	tta Leu tct ser 550 gta Val	agt Ser 535 aat Asn aat	Leu 520 tta Leu aat Asn atg Met	agc Ser aaa Lys tca Ser	ggg Gly gtc Val aaa Lys 570 ata	Ala cac His ttt Phe 555 aac Asn	Glu cat His 540 cct Pro att Ile	Lys 525 gta Val agc ser tct ser	1632 1680 1728

aaa cca gac att gta cac agt cat atg ttt cat gca aac att atc act 1824

wc	00/2	8038													PCT/GB	99/03721
Lve	Pro	Aen	Tlo	V-1	ui e	C	***		D1-			Asn				
590	110	ASP	116	Val	595	Sel	nis	met	Pne		Ala	Asn	Ile	Ile		
550					393					600					605	
242	tta	+a+	at a	2++	~~~	24.0										
nea nea	Tou	200	y ca	Tlo	gga	atc	aaa	aac	aga -	cct	ggt	att	ata	tca	act	1872
ALG	ьец	ser	Val	610	GTA	TIE	гуѕ	Asn		Pro	Gly	Ile	Ile		Thr	
				010					615					620		
gca	cat	aat	222	aat	gaa.	aat		+-+	++-			ctc				
Ala	His	Asn	T.Ve	Asn	Glu	Glu	999	Tree	Dho	aga	acg	Leu	aca	tat	aga	1920
			625			GLY	GLy	630	File	Arg	met	Leu		Tyr	Arg	
								050					635			
ata	acc	gat	tat	tta	agt	gat	tat	tat	aca	aat	att	agc	222	<b>4</b> 22	~	1968
Ile	Thr	Asp	Cys	Leu	Ser	Asp	Cvs	Cvs	Thr	Asn	Val	Ser	Tyre	Glu	nia nia	1968
		640	-			•	645	-,-			, 44	650	шуз	GIU	ALA	
												050				
gtg	gat	gag	ttt	tta	cgg	ata	aaa	qcc	ttt	aat	ccc	gct	aaa	gca	att	2016
Val	Asp	Glu	Phe	Leu	Arg	Ile	Lys	Ala	Phe	Asn	Pro	Ala	Lvs	Ala	Tle	2010
	655					660					665		-,-			
act	atg	tat	aat	ggg	ata	gat	acc	aat	aaa	ttt	aaa	ttt	gat	tta	tta	2064
Thr	Met	Tyr	Asn	Gly	Ile	Asp	Thr	Asn	Lys	Phe	Lys	Phe	Asp	Leu	Leu	
670					675					680					685	
gca	agg	agg	gaa	att	cga	gac	ggt	att	aat	ata	aaa	aat	gat	gat	ata	2112
Ala	Arg	Arg	Glu		Arg	Asp	Gly	Ile	Asn	Ile	Lys	Asn	Asp	Asp	Ile	
				<b>69</b> 0					695					700		
tta	tta	ctt	gct	gca	ggt	cgt	tta	acg	tta	gct	aaa	gat	tat	cct	aat	2160
Leu	ьeu	ьец	705	Ата	GIY	Arg	Leu		Leu	Ala	Lys	Asp		Pro	Asn	
			703					710					715			
++-	++~	+	~~~													
Len	Leu	nen	nia.	Mot	The s	ten	CLL	CCL	gaa	cac	ttt	aaa	ctt	att	att	2208
Deu	Бец	720	A.a	nec	1111	Leu	725	PFO	GIU	Hls	Phe	Lys	Leu	Ile	Ile	
		120					123					730				
att	aat	cat	aat	as a	++~	cat	<b>~~</b>	~			- 4	ctt				
Tle	Glv	Asn	G) v	Glu	Leu	Dra	nac nac	yaa Clu	ALC	aat	atg	Leu	ata	aaa -	aaa	2256
	735		,			740	лэр	Gru	TTE	ASII	745	rea	TTE	гуs	Lys	
											/45					
tta	caa	tta	tct	aat	agg	ata	tee	tta	++~	~~~	~++	aaa				2224
Leu	Gln	Leu	Ser	Asn	Aro	Val	Ser	Lev	Lev	gya Glv	Val	Lys	Luc	Adc Ner	TIO	2304
750					755				_ou	760	, u1	nys	пув	noll	765	
							-								, 03	
gct	ccc	tat	ttt	tct	gca	tgt	qat	att	ttt	att	ctc	tct	tet	cat	taa	2352
Ala	Pro	Tyr	Phe	Ser	Ala	Cys	Asp	Ile	Phe	Val	Lev	Ser	Ser	Ara	Trn	-552
				770			-		775					780		

gaa gga ttt gga tta gtc gtg gca gaa gct atg tca tgt gag cga att 2400

								) ) I O O I Z I
Glu Gl	y Phe G	3ly Leu	Val Val	Ala Gl	u Ala Me	t Ser Cys Gl	Arg Ile	
		785		79		79:	-	
						a gtt att gg		2448
Val Val		hr Asp	ser Gly		1 Arg Gl	u Val Ile Gl	y Asp Asp	
	800			805		810		
gat tt	. att a	*** ***						
						a ctt gca ag n Leu Ala Se		2496
815			820	mp se	I IIII GI	825	r Lys IIe	
						023		
gaa aaa	ttg t	ct ttg	agc cag	ata cg	t gat ca	att ggt tt	coo aat	2544
Glu Lys	Leu S	er Leu	Ser Gln	Ile Ar	g Asp Hi	s Ile Gly Ph	Arg Asn	2011
830			835		84		845	
cgt gag	g cgt a	tt tta	aaa aat	ttc tc	a ata ga	t act att att	atg cag	2592
Arg Glu	Arg I		Lys Asn	Phe Se		Thr Ile Ile	Met Gln	
		850			855		860	
taa aas		+				a aaa cat gaa		
Tro Glr	Glu L	en Tur	Glu Thr	TIA TI	t tgc tca	a aaa cat gaa r Lys His Glu	agg	2637
115 011		65	GLY IIII	87		с Lys ніз GI 87:	-	
				• • •		07.	,	
tagattt	ata tt	tggaacg	t gtctt	ttgtt t	gaatttaai	t tcaatctcaa	ttgagatttt	2697
tgtattt	caa aa	ataccat	c atage	taacg a	tgattggta	a tttattttaa	gatgctttct	2757
ataaata	tat tg	acgtttt	t aatgc	gccga a	acgattgg	g ctgggaacag	agaagtaaaa	2817
ctatttt	es nen	tasasa	+ ++++		++ - + + -	ttaaaaattg		
ocyccc	.yay aa	cyaayay	it tittige	agatg t	LLALGGALA	ttaaaaattg	atccagtgaa	2877
ttaatta	ttt at	aataaat	c aagati	taat σ	ttaatáaat	gataatcttt	tata:	2027
						gacaaccccc	cccyacacce	2937
atattaa	tta tg	agtggta	c gtttg	gtaaa c	ggtaaacta	ttat atg ad	a gct aga	2993
							r Ala Arg	
							880	
aca act	aaa g	tt ttg	cac tta	caa tt	a ctc cca	ctc tta agt	ggc gtt	3041
Thr Thr	Lys V		His Leu	Gln Le		Leu Leu Se	-	
		885			890		895	
caa ann	ota a	ca tte	220 022	att so	t and ++-	a tat act gat		
Gln Ard	Val T	hr Leu	Asn Glu	Ile Se	r Ala Jei	i tat act gai I Tyr Thr Asi	tat gat	3089
3		00		90		1 TYL THE ASI 910		
					-	310	•	
tat aca	cta g	tt tgc	tca aaa	aaa gg	t cca cta	aca aaa gca	ttg ctg	3137
Tyr Thr	Leu V	al Cys	Ser Lys	Lys Gl	y Pro Leu	Thr Lys Ala	Leu Leu	

ga	a tat	gat	gtc	gat	tgt	cat	tgt	atc	ccc	gaa	ctt	acg	aga	gaa	att	3185
Gl	ı Tyr	Asp	Val	Asp	Cys	His	Cys	Ile	Pro	Glu	Leu	Thr	Arg	G1u	Ile	
	930					935					940					
	gta:															3233
	: Val	Lys	Asn	Asp	Phe	Lys	Ala	Leu	Phe	Lys	Leu	Tyr	Lys	Phe	Ile	
945	5				950					955					960	
	aaa															3281
Lys	Lys	Glu	Lys		Asp	Ile	Val	His		His	Ser	ser	Lys	Thr	Gly	
				965					970					975		
	ttg															3329
114	Leu	GIŸ		Val	Ala	Ala	Lys		Ala	Arg	Val	G1 y		Val	Ile	
			980					985					990			
uat	act	gra v-1	Cat	ggt	222	tet	TTE.	cca -	gcc	gca	tct	agt	aaa	aaa	agt	3377
пта	Thr	995	HIS	GIY	rne		Pne 1000	Pro	Ala	Ala			Lys	Lys	Ser	
		333					1000				•	L005				
tat	tac	ctt	tat	+++	ttc	at a	~~~	+ ~~		~						
Tvi	Tyr	Leu	Tvr	Phe	Phe	Met	Glu	Trn	Tle	Dla	Luc	Dho	Dho	acg	gat	3425
-	1010		-3			1015					1020	rne	rne	Ing	Asp	
										•	.020					
aaç	tta	atc	gtc	ttg	aat	gta	gat	gat	gaa	tat	ata	σca	ata	aac	aaa	3473
aaç Lys	tta Leu	atc Ile	gtc Val	ttg Leu	aat Asn	gta Val	gat Asp	gat Asp	gaa Glu	tat Tyr	ata Ile	gca Ala	ata Ile	aac Asn	aaa Lvs	3473
Lys 102	Leu	atc Ile	gtc Val	Leu	aat Asn 1030	gta Val	gat Asp	gat Asp	Glu	tat Tyr 1035	ata Ile	gca Ala	ata Ile	Asn	aaa Lys	3473
Lys 102	: Leu !5	Ile	Val	Leu	Asn 1030	Val	Asp	Asp	Glu	Tyr L035	Ile	Ala	Ile	Asn	Lys 1040	3473
Lys 102	Leu	Ile	Val	Leu	Asn 1030	Val	Asp	Asp	Glu	Tyr L035	Ile	Ala	Ile	Asn	Lys 1040	3473 3521
Lys 102	: Leu !5	Ile	Val aag	Leu	Asn 1030 gat	Val aaa	Asp gtt	Asp ttt	Glu tta	Tyr 1035 att	Ile cct	Ala aat	Ile gga	Asn gta	Lys 1040 gac	
Lys 102	: Leu :5 : aaa	Ile	Val aag Lys	Leu	Asn 1030 gat	Val aaa	Asp gtt	Asp ttt Phe	Glu tta	Tyr 1035 att	Ile cct	Ala aat	Ile gga Gly	Asn gta	Lys 1040 gac	
Lys 102 tta Let	: Leu :5 : aaa : Lys	Ile ttc Phe	Val aag Lys	cgg Arg	Asn 1030 gat Asp	Val aaa Lys	Asp gtt Val	ttt Phe	tta Leu	Tyr 1035 att Ile	Ile cct Pro	Ala aat Asn	gga Gly	Asn gta Val	Lys 1040 gac Asp	
tta Lev	E Leu	Ile ttc Phe	Val aag Lys ttt	cgg Arg 1045	Asn 1030 gat Asp	Val aaa Lys tta	Asp gtt Val gaa	ttt Phe	tta Leu 1050	Tyr 1035 att Ile	cct Pro	Ala aat Asn	gga Gly	Asn gta Val 1055	Lys 1040 gac Asp	
tta Lev	: Leu :5 : aaa : Lys	ttc Phe	aag Lys ttt Phe	cgg Arg 1045	Asn 1030 gat Asp	Val aaa Lys tta	Asp gtt Val gaa	ttt Phe	tta Leu 1050	Tyr 1035 att Ile	cct Pro	Ala aat Asn	gga Gly	Asn gta Val 1055	Lys 1040 gac Asp	3521
tta Lev	E Leu	ttc Phe	Val aag Lys ttt	cgg Arg 1045	Asn 1030 gat Asp	Val aaa Lys tta	gtt Val gaa Glu	ttt Phe	tta Leu 1050	Tyr 1035 att Ile	cct Pro	Ala aat Asn agt Ser	gga Gly	Asn gta Val 1055	Lys 1040 gac Asp	3521
tta Let Let The	E Leu	ttc Phe aag Lys	aag Lys ttt Phe	cgg Arg 1045 tct Ser	Asn 1030 gat Asp cct Pro	val aaa Lys tta Leu	gtt Val gaa Glu	ttt Phe aat Asn	tta Leu 1050 aaa Lys	Tyr 1035 att Ile att Ile	cct Pro tat Tyr	aat Asn agt Ser	gga Gly agc ser	gta Val 1055 acc	Lys 1040 gac Asp ttg Leu	3521
tta Let Thr	Leu Lys Gat Asp	ttc Phe aag Lys	aag Lys ttt Phe	cgg Arg 1045 tct ser	Asn 1030 gat Asp cct Pro	val aaa Lys tta Leu	gtt Val gaa Glu tta	ttt Phe aat Asn	tta Leu 1050 aaa Lys	Tyr 1035 att Ile att Ile	Ile cct Pro tat Tyr	Ala aat Asn agt ser	gga Gly agc ser	gta Val 1055 acc Thr	Lys 1040 gac Asp ttg Leu	3521
tta Let Thr	E Leu	ttc Phe aag Lys gta Val	aag Lys ttt Phe	cgg Arg 1045 tct ser	Asn 1030 gat Asp cct Pro	val aaa Lys tta Leu aga Arg	gtt Val gaa Glu tta Leu	ttt Phe aat Asn	tta Leu 1050 aaa Lys	Tyr 1035 att Ile att Ile	cct Pro tat Tyr	aat Asn agt ser gat Asp	gga Gly agc ser	gta Val 1055 acc Thr	Lys 1040 gac Asp ttg Leu	3521 3569
tta Let Thr	E Leu	ttc Phe aag Lys	aag Lys ttt Phe	cgg Arg 1045 tct ser	Asn 1030 gat Asp cct Pro	val aaa Lys tta Leu aga Arg	gtt Val gaa Glu tta	ttt Phe aat Asn	tta Leu 1050 aaa Lys	Tyr 1035 att Ile att Ile	cct Pro tat Tyr	Ala aat Asn agt ser	gga Gly agc ser	gta Val 1055 acc Thr	Lys 1040 gac Asp ttg Leu	3521 3569
Lys 102 tta Lev act Thr	E Leu	ttc Phe aag Lys gta Val	aag Lys ttt Phe 1060 atg	cgg Arg 1045 tct Ser gtt Val	Asn 1030 gat Asp cct Pro ggt Gly	aaa Lys tta Leu aga Arg	gtt Val gaa Glu tta Leu	Asp ttt Phe aat Asn 1065 tcc ser	tta Leu 1050 aaa Lys aag	Tyr i035 att Ile att Ile caa Gln	cct Pro tat Tyr	aat Asn agt ser gat Asp	gga Gly agc ser 1070 cct Pro	gta Val 1055 acc Thr gag	Lys 1040 gac Asp ttg Leu aca	3521 3569 3617
tta 102 tta Lev act Thr	E Leu	ttc Phe aag Lys gta Val 1075	aag Lys ttt Phe 1060 atg Met	cgg Arg 1045 tct Ser gtt Val	Asn 1030 gat Asp cct Pro ggt Gly	Val aaa Lys tta Leu aga Arg	gtt Val gaa Glu tta Leu 1080	Asp tttt Phe aat Asn 1065 tcc ser	tta Leu 1050 aaa Lys aag	Tyr 1035 att Ile att Ile caa Gln	cct Pro tat Tyr aaa Lys	Ala aat Asn agt Ser gat Asp	gga Gly agc Ser 1070 cct Pro	Asn gta Val 1055 acc Thr gag Glu	Lys 1040 gac Asp ttg Leu aca Thr	3521 3569
tta 102 tta Lev act Thr	E Leu E S E Gat E Asp E Cta E Leu E ttg E Leu E Leu	ttc Phe aag Lys gta Val 1075	aag Lys ttt Phe 1060 atg Met	cgg Arg 1045 tct Ser gtt Val	Asn 1030 gat Asp cct Pro ggt Gly	Val aaa Lys tta Leu aga Arg	gtt Val gaa Glu tta Leu 1080	Asp tttt Phe aat Asn 1065 tcc ser	tta Leu 1050 aaa Lys aag	Tyr 1035 att Ile att Ile caa Gln gaa Glu	cct Pro tat Tyr aaa Lys	Ala aat Asn agt Ser gat Asp	gga Gly agc Ser 1070 cct Pro	Asn gta Val 1055 acc Thr gag Glu	Lys 1040 gac Asp ttg Leu aca Thr	3521 3569 3617
tta 102 tta Lev act Thr	E Leu	ttc Phe aag Lys gta Val 1075	aag Lys ttt Phe 1060 atg Met	cgg Arg 1045 tct Ser gtt Val	Asn 1030 gat Asp cct Pro ggt Gly	Val aaa Lys tta Leu aga Arg	gtt Val gaa Glu tta Leu 1080	Asp  ttt Phe aat Asn 1065 tcc ser	tta Leu 1050 aaa Lys aag	Tyr 1035 att Ile att Ile caa Gln gaa Glu	cct Pro tat Tyr aaa Lys	Ala aat Asn agt Ser gat Asp 085	gga Gly agc Ser 1070 cct Pro	Asn gta Val 1055 acc Thr gag	Lys 1040 gac Asp ttg Leu aca Thr	3521 3569 3617
Lys 102 tta Leu act Thr aat Asr	ttg	ttc Phe aag Lys gta Val 1075 ctt	aaag Lys ttt Phe 1060 atg Met	cgg Arg 1045 tct Ser gtt Val	Asn 1030 gat Asp cct Pro ggt Gly gaa Glu	Val aaa Lys tta Leu aga Arg J aaa Lys 095	gtt Val gaa Glu tta Leu 1080 ctg	ttt Phe aat Asn 065 tcc Ser ctg Leu	tta Leu 1050 aaa Lys aag Lys	Tyr 1035 att Ile att Ile caa Gln gaa Glu	cct Pro tat Tyr aaaa Lys aat Asn	aat Asn agt Ser gat Asp 1085 gtt Val	gga Gly agc Ser 1070 cct Pro	Asn :: gta Val 1055 acc Thr gag Glu gtt Val	Lys 040 gac Asp ttg Leu aca Thr	3521 3569 3617 3665
Lys 102 tta Let act Thr aat Asr	E Leu E S E Gat E Asp E Cta E Leu E ttg E Leu E Leu	ttc Phe aag Lys gta Val 1075 ctt Leu	Val aaag Lys ttt Phe 1060 atg Met Ala	cgg Arg 1045 tct Ser gtt Val	Asn 1030 gat Asp cct Pro ggt Gly gaa Glu gat	Val aaa Lys tta Leu aga Arg J aaa Lys 095	gtt Val gaa Glu tta Leu 1080 ctg Leu	ttt Phe aat Asn 065 tcc Ser ctg Leu	tta Leu 1050 aaa Lys aag Lys aat Asn	Tyr 1035 att Ile att Ile caa Gln gaa Glu J	cct Pro tat Tyr aaaa Lys aat Asn	aat Asn agt Ser gat Asp 1085 gtt Val	gga Gly agc Ser 070 cct Pro	Asn :: gta Val 1055 acc Thr gag Glu gtt Val	Lys 040 gac Asp ttg Leu aca Thr	3521 3569 3617

ttc	aaa	cgg	caa	gat	gga	cgt	ata	att	ttt	cat	gga	tgg	tca	gat	aac	3761
Phe	Lys	Arg	Gln	Asp	Gly	Arg	Ile	Ile	Phe	His	Gly	Trp	Ser	Asp	Asn	
				1125				:	1130				:	1135		

- att gtt aat att tta aaa gtt aat gat ctt ttt ata tta cct tct ctt 3809 Ile Val Asn Ile Leu Lys Val Asn Asp Leu Phe Ile Leu Pro Ser Leu 1140
- tgg gag ggt atg cca tta gca att tta gaa gca ttg agc tgt gga ctt 3857 Trp Glu Gly Met Pro Leu Ala Ile Leu Glu Ala Leu Ser Cys Gly Leu 1155 1160 1165
- cca tgt ata gtc act aat att cca ggt aat aat agc tta ata gaa gat 3905 Pro Cys Ile Val Thr Asn Ile Pro Gly Asn Asn Ser Leu Ile Glu Asp 1170 1180
- ggc tat aat ggt tgt ttg ttt gaa att aga gat tgt cag tta tta tct 3953 Gly Tyr Asn Gly Cys Leu Phe Glu Ile Arg Asp Cys Gln Leu Leu Ser 1185 1190 1195 1200
- caa aaa atc atg tca tat gtt ggt aag cca gaa ctg att gca cag caa 4001 Gln Lys Ile Met Ser Tyr Val Gly Lys Pro Glu Leu Ile Ala Gln Gln 1205 1210 1215
- tct acc aat gca cga tca ttt att ctg aaa aat tat gga tta gtt aaa 4049 Ser Thr Asn Ala Arg Ser Phe Ile Leu Lys Asn Tyr Gly Leu Val Lys 1220 1225 1230
- aga aat aat aag gtc aga cag cta tat gat aat taaatgaaac cgaaaagtta 4102 Arg Asn Asn Lys Val Arg Gln Leu Tyr Asp Asn 1235 1240

aaaaagaaca ggtttttcaa agtgaaaata aaattacagt ttttttattg caatgattaa 4162
cgtaacatct gcattacatt caagccgcac aaccccgcgg tgaccaccc tgacaggagt 4222
aaacaatgtc aaagcaacag atcggcgtcg tcggtatggc agtgatggga cgcaacctcg 4282
cgctcaacat cgaaagccgt ggttataccg tctctatttt caaccgttcc cgtgaaaaga 4342
cggaagaagt tattgccgaa aatccaggca agaaactggt tccttactat acggtgaaag 4402
agttcgttga atctcttgaa acgcctcgtc gcatcctgtt aatgggttaa agcaggtgca 4462
ggcacggatg ctgctattga ttccctgaaa ccatactcg ataaaggcga tatcatcatt 4522
gatgggtggg taataccttc tttcaggaca ccattcgtcg taaccgcag ctttctgcac 4582

aaggetttae tteateggta ce

4604

<210> 23

<211> 247

<212> PRT

<213> Escherichia coli

<400> 23

Val Asp Asp Asn Leu Lys Gly Gln Gly Ala Gly Lys Asn Phe Leu Ser 1 5 10 15

Leu Ile Lys Tyr Ser Glu Thr Asp Tyr Thr Ile Tyr Cys Asp Gln Asp  $20 \hspace{1.5cm} 25 \hspace{1.5cm} 30$ 

Asp Ile Trp Leu Glu Asn Lys Ile Phe Glu Leu Val Lys Tyr Ala Asn \$35\$

Glu Ile Lys Leu Asn Val Ser Asp Ala Pro Ser Leu Val Tyr Ala Asp
50 55 60

Gly Tyr Ala Tyr Met Asp Gly Glu Gly Thr Ile Asp Phe Ser Gly Ile 65 70 75 80

Ser Asn Asn His Ala Asp Gln Leu Lys Asp Phe Leu Phe Phe Asn Gly 85 90 95

Gly Tyr Gln Gly Cys Ser Ile Met Phe Asn Arg Ala Met Thr Lys Phe  $100 \hspace{1cm} 105 \hspace{1cm} 110 \hspace{1cm}$ 

Leu Leu Asn Tyr Arg Gly Phe Val Tyr Leu His Asp Asp Ile Thr Thr 115 120 125

Leu Ala Ala Tyr Ala Leu Gly Lys Val Tyr Phe Leu Pro Lys Tyr Leu 130 135 140

Met Leu Tyr Arg Gln His Thr Asn Ala Val Thr Gly Ile Lys Thr Phe 145 155 160

Arg Asn Gly Leu Thr Ser Lys Phe Lys Ser Pro Val Asn Tyr Leu Leu 165 170 175

Ser Arg Lys His Tyr Gln Val Lys Lys Ser Phe Phe Glu Cys Asn Ser 180 185 190

Ser Ile Leu Ser Glu Thr Asn Lys Lys Val Phe Leu Asp Phe Ile Ser 195 200 205

Phe Cys Glu Ser Asn Asn Lys Phe Thr Asp Phe Phe Lys Leu Trp Arg 210 215 220

Gly Gly Phe Arg Leu Asn Asn Ser Arg Thr Lys Leu Leu Leu Lys Phe 225 230 235 240

Leu Ile Arg Arg Lys Phe Ser 245

<210> 24

<211> 261

<212> PRT

<213> Escherichia coli

<400> 24

Met Ile Ser Ile Leu Thr Pro Thr Phe Asn Arg Gln His Thr Leu Ser  $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$ 

Arg Leu Phe Asn Ser Leu Ile Leu Gln Thr Asp Lys Asp Phe Glu Trp  ${\tt 20} \hspace{1.5cm} {\tt 25} \hspace{1.5cm} {\tt 30}$ 

Ile Ile Ile Asp Asp Gly Ser Ile Asp Ala Thr Ala Val Leu Val Glu  $35 \hspace{1cm} 40 \hspace{1cm} 45 \hspace{1cm}$ 

Asp Phe Arg Lys Lys Cys Asp Phe Asp Leu Ile Tyr Cys Tyr Gln Glu 50 55 60

Asn Asn Gly Lys Pro Met Ala Leu Asn Ala Gly Val Lys Ala Cys Arg 65 70 75 80

Gly Asp Tyr Ile Phe Ile Val Asp Ser Asp Asp Ala Leu Thr Pro Asp 85 90 95

Ala Ile Lys Leu Ile Lys Glu Ser Ile His Asp Cys Leu Ser Glu Lys 100 105 110

Glu Ser Phe Ser Gly Val Gly Phe Arg Lys Ala Tyr Ile Lys Gly Gly 115 120 125

Ile Ile Gly Asn Asp Leu Asn Asn Ser Ser Glu His Ile Tyr Tyr Leu 130 135 140

Asn Ala Thr Glu Ile Ser Asn Leu Ile Asn Gly Asp Val Ala Tyr Cys 145 150 155 160

Phe Lys Lys Glu Ser Leu Val Lys Asn Pro Phe Pro Arg Ile Glu Asp

Glu Lys Phe Val Pro Glu Leu Tyr Ile Trp Asn Lys Ile Thr Asp Lys 180 185 190

Ala Lys Ile Arg Phe Asn Ile Ser Lys Val Ile Tyr Leu Cys Glu Tyr
195 200 205

Leu Asp Asp Gly Leu Ser Lys Asn Phe His Asn Gln Leu Lys Lys Tyr 210 215 220

Pro Lys Gly Phe Lys Ile Tyr Tyr Lys Asp Gln Arg Lys Arg Glu Lys 225 230 235

Thr Tyr Ile Lys Lys Thr Lys Met Leu Ile Arg Tyr Leu Gln Cys Cys 245 250 255

Tyr Tyr Glu Lys Ile 260

<210> 25

<211> 368

<212> PRT

<213> Escherichia coli

<400> 25

Met Lys Ile Leu Phe Val Ile Thr Gly Leu Gly Leu Gly Gly Ala Glu  $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$ 

Lys Gln Val Cys Leu Leu Ala Asp Lys Leu Ser Leu Ser Gly His His 20 25 30

Val Lys Ile Ile Ser Leu Gly His Met Ser Asn Asn Lys Val Phe Pro 35 40 45

Ser Glu Asn Asn Val Asn Val Ile Asn Val Asn Met Ser Lys Asn Ile 50 60

Ser Gly Val Ile Lys Gly Cys Val Arg Ile Arg Asp Val Ile Ala Asn 65 70 75 80

Phe Lys Pro Asp Ile Val His Ser His Met Phe His Ala Asn Ile Ile 85 90 95

Thr Arg Leu Ser Val Ile Gly Ile Lys Asn Arg Pro Gly Ile Ile Ser 100 105 110

Thr Ala His Asn Lys Asn Glu Gly Gly Tyr Phe Arg Met Leu Thr Tyr 115 120 125

- Arg Ile Thr Asp Cys Leu Ser Asp Cys Cys Thr Asn Val Ser Lys Glu 130 \$135\$
- Ile Thr Met Tyr Asn Gly Ile Asp Thr Asn Lys Phe Lys Phe Asp Leu 165 170 175
- Leu Ala Arg Arg Glu Ile Arg Asp Gly Ile Asn Ile Lys Asn Asp Asp 180 185 190
- Ile Leu Leu Ala Ala Gly Arg Leu Thr Leu Ala Lys Asp Tyr Pro 195 200 205
- Asn Leu Leu Asn Ala Met Thr Leu Leu Pro Glu His Phe Lys Leu Ile 210 215 220
- Ile Ile Gly Asp Gly Glu Leu Arg Asp Glu Ile Asn Met Leu Ile Lys 225 230 235
- Lys Leu Gln Leu Ser Asn Arg Val Ser Leu Leu Gly Val Lys Lys Asn 245 250 255
- Ile Ala Pro Tyr Phe Ser Ala Cys Asp Ile Phe Val Leu Ser Ser Arg 260 265 270
- Trp Glu Gly Phe Gly Leu Val Val Ala Glu Ala Met Ser Cys Glu Arg 275 280 285
- Ile Val Val Gly Thr Asp Ser Gly Gly Val Arg Glu Val Ile Gly Asp 290 295 300
- Asp Asp Phe Leu Val Pro Ile Ser Asp Ser Thr Gln Leu Ala Ser Lys 305 310 315
- Ile Glu Lys Leu Ser Leu Ser Gln Ile Arg Asp His Ile Gly Phe Arg 325 330 335
- Asn Arg Glu Arg Ile Leu Lys Asn Phe Ser Ile Asp Thr Ile Ile Met 340 345 350
- Gln Trp Gln Glu Leu Tyr Gly Thr Ile Ile Cys Ser Lys His Glu Arg 355 360 365

<210> 26

<211> 367

<212> PRT

<213> Escherichia coli

<400> 26

Met Thr Ala Arg Thr Thr Lys Val Leu His Leu Gln Leu Leu Pro Leu 1 5 10 15

Leu Ser Gly Val Gln Arg Val Thr Leu Asn Glu Ile Ser Ala Leu Tyr 20 25 30

Thr Asp Tyr Asp Tyr Thr Leu Val Cys Ser Lys Lys Gly Pro Leu Thr 35 40 45

Lys Ala Leu Leu Glu Tyr Asp Val Asp Cys His Cys Ile Pro Glu Leu 50 55 60

Thr Arg Glu Ile Thr Val Lys Asn Asp Phe Lys Ala Leu Phe Lys Leu 65 70 75 80

Tyr Lys Phe Ile Lys Lys Glu Lys Phe Asp Ile Val His Thr His Ser 85 90 95

Ser Lys Thr Gly Ile Leu Gly Arg Val Ala Ala Lys Leu Ala Arg Val

Gly Lys Val Ile His Thr Val His Gly Phe Ser Phe Pro Ala Ala Ser 115 120 125

Ser Lys Lys Ser Tyr Tyr Leu Tyr Phe Phe Met Glu Trp Ile Ala Lys

Phe Phe Thr Asp Lys Leu Ile Val Leu Asn Val Asp Asp Glu Tyr Ile 145 150 155 160

Ala Ile Asn Lys Leu Lys Phe Lys Arg Asp Lys Val Phe Leu Ile Pro 165 170 175

Asn Gly Val Asp Thr Asp Lys Phe Ser Pro Leu Glu Asn Lys Tle Tyr 180 185

Ser Ser Thr Leu Asn Leu Val Met Val Gly Arg Leu Ser Lys Gln Lys 195 200 205

Asp Pro Glu Thr Leu Leu Leu Ala Val Glu Lys Leu Leu Asn Glu Asn 210 215 220

Val Asn Val Lys Leu Thr Leu Val Gly Asp Gly Glu Leu Lys Glu Gln 225 230 235 240

Leu Glu Ser Arg Phe Lys Arg Gln Asp Gly Arg Ile Ile Phe His Gly
245 250 255

Trp Ser Asp Asn Ile Val Asn Ile Leu Lys Val Asn Asp Leu Phe Ile 260 265 270

Leu Pro Ser Leu Trp Glu Gly Met Pro Leu Ala Ile Leu Glu Ala Leu 275 280 285

Ser Cys Gly Leu Pro Cys Ile Val Thr Asn Ile Pro Gly Asn Asn Ser 290 295 300

Leu Ile Glu Asp Gly Tyr Asn Gly Cys Leu Phe Glu Ile Arg Asp Cys 305 310 315 320

Gln Leu Leu Ser Gln Lys Ile Met Ser Tyr Val Gly Lys Pro Glu Leu 325 330 335

Ile Ala Gln Gln Ser Thr Asn Ala Arg Ser Phe Ile Leu Lys Asn Tyr 340 345 350

Gly Leu Val Lys Arg Asn Asn Lys Val Arg Gln Leu Tyr Asp Asn 355 360 365

<210> 27

<211> 1272

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (319)..(1269)

<220>

<221> CDS

<222> (3)..(215)

<400> 27

cc ggg aag cac tcg gcg ctg att gtt gca cat cgt ctg acc acc gcg 47
Gly Lys His Ser Ala Leu Ile Val Ala His Arg Leu Thr Thr Ala
1 5 10

														gcg Ala 30		95
														acc Thr		143
			-		-	-	-		-			-	-	cac His		191
-	-		gaa Glu		-		tag	ttad	etgga	aca (	cgtaa	itgta	it ti	aaaaa	acaca	245
gtca	agaaq	geg (	geggt	tacco	gt ga	atag	geege	tti	taati	att	tata	ctga	aca 1	teet	taattt	305
ttaa	agaç	gta 1	-	-	-		-						-	atc (	-	354
											-			act Thr	-	402
		-		-		-	-		-				-	cca Pro	-	450
							-				_		-	gcc Ala 130	_	498
									-				-	gat Asp		546
		-	Glu			-	-	-	-			-	-	gat Asp		594
														tat Tyr		642
			atc						gct	gag	acg	att	gca	ctg	tcc	690

180					185					190					195	
								gga Gly								738
								aac Asn 220								786
								gaa Glu								834
								att Ile							-	882
								gat <b>As</b> p								930
								tgg Trp								978
								aat Asn 300								1026
								gaa Glu								1074
								gat Asp								1122
								cgt Arg								1170
								Gly								1218
gct	cgt	tac	gca	ccg	gaa	acg	ttc	ggt	ctg	gtg	ctc	agc	cac	tct	cct	1266

Ala Arg Tyr Ala Pro Glu Thr Phe Gly Leu Val Leu Ser His Ser Pro

380

385

caa tqc Gln

<210> 28

<211> 70

<212> PRT

<213> Escherichia coli

<400> 28

DAME

Gly Lys His Ser Ala Leu Ile Val Ala His Arg Leu Thr Thr Ala Gln 10

Arg Cys Asp Leu Ile Ala Val Ile Asp Lys Gly Leu Leu Ala Glu Tyr 20 25

Gly Thr His Glu Gln Leu Leu Ser Ala Gly Gly Leu Tyr Thr Arg Leu 35 40 45

Trp His Asp Ser Val Ser Ser Thr Ala Leu His Arg Gln His Asn Met 55

Lys Glu Glu Thr Pro Gly 65

<210> 29

<211> 317

<212> PRT

<213> Escherichia coli

<400> 29

Met Leu Asn Met Gln Gln His Leu Ser Ala Ile Ala Ser Leu Arg Asn 10

Gln Leu Ala Ala Gly His Ile Ala Asn Leu Thr Asp Phe Trp Arq Glu 20

Ala Glu Ser Leu Asn Val Pro Leu Val Thr Pro Val Glu Gly Ala Glu 35 40 45

Asp Glu Arg Glu Val Thr Phe Leu Trp Arg Ala Arg His Pro Leu Gln 50 60

Gly Val Tyr Leu Arg Leu Asn Arg Val Thr Asp Lys Glu His Val Glu 65 70 75

Lys Gly Met Met Ser Ala Leu Pro Glu Thr Asp Ile Trp Thr Leu Thr 85 90 95

- Leu Arg Leu Pro Ala Ser Tyr Cys Gly Ser Tyr Ser Leu Leu Glu Ile 100 105 110
- Pro Pro Gly Thr Thr Ala Glu Thr Ile Ala Leu Ser Gly Gly Arg Phe 115 120 125
- Ala Thr Leu Ala Gly Lys Ala Asp Pro Leu Asn Lys Met Pro Glu Ile 130 135 140
- Asn Val Arg Gly Asn Ala Lys Glu Ser Val Leu Thr Leu Asp Lys Ala 145 150 155 160
- Pro Ala Leu Ser Glu Trp Asn Gly Gly Phe His Thr Gly Gln Leu Leu
  165 170 175
- Thr Ser Met Arg Ile Ile Ala Gly Lys Ser Arg Gln Val Arg Leu Tyr 180 185 190
- Ile Pro Asp Val Asp Ile Ser Gln Pro Leu Gly Leu Val Val Leu Pro
  195 200 205
- Asp Gly Glu Thr Trp Phe Asp His Leu Gly Val Cys Ala Ala Ile Asp 210 215 220
- Ala Ala Ile Asn Asn Gly Arg Ile Val Pro Val Ala Val Leu Gly Ile
  225 230 235 240
- Asp Asn Ile Asn Glu His Glu Arg Thr Glu Ile Leu Gly Gly Arg Ser 245 250 255
- Lys Leu Ile Lys Asp Ile Ala Gly His Leu Leu Pro Met Ile Arg Ala 260 265 270
- Glu Gln Pro Gln Arg Gln Trp Ala Asp Arg Ser Arg Thr Val Leu Ala 275 280 285
- Gly Gln Ser Leu Gly Gly Ile Ser Ala Leu Met Gly Ala Arg Tyr Ala 290 295 300
- Pro Glu Thr Phe Gly Leu Val Leu Ser His Ser Pro Gln 305 310 315

wo	00/2	8038													PCT/GB	99/03721
<210	)> 3(	)														
	> 40															
	2> Di															
		che	richi	ia co	oli											
<220	)>															
<221	> CI	os														
<222	?> (:	L) :	(285)	)												
<220	)>															
<221	> CI	os														
<222	?> (3	370).	. (13	326)												
<400	)> 3(	)														
cct	tca	atg	tgg	tgg	acq	cca	qaa	aga	acc	agt	cga	cca	aac	tta	ttc	48
		Met					-	-		-	-			-		
1				5				_	10		-		•	15		
agc	gaa	acc	gat	acc	tca	tgg	qtq	agt	qaq	cat	ctq	ctt	tct	acc	cca	96
		Thr														
			20			-		25					30			
ccg	cag	ggc	gta	cgt	atc	agc	ctg	tgc	gtg	gga	tcg	ctg	gaa	ggt	tcg	144
Pro	Gln	Gly	Val	Arg	Ile	Ser	Leu	Cys	Val	Gly	Ser	Leu	Glu	Gly	Ser	
		35					40					45		_		
aca	gtg	cct	cac	gtt	cag	cag	ctt	cac	cag	cgg	ctg	att	acc	gct	ggc	192
Thr	Val	Pro	His	Val	Gln	Gln	Leu	His	Gln	Arg	Leu	Ile	Thr	Ala	Gly	
	50					55					60				•	
gtc	gaa	agc	cat	tgc	gca	atc	tac	acc	ggt	ggt	cac	gat	tac	gca	tgg	240
Val	Glu	Ser	His	Cys	Ala	Ile	Tyr	Thr	Gly	Gly	His	Asp	Tyr	Ala	Trp	
65					70					75		_	-		80	
tgg	cgc	ggt	gca	ctg	att	gac	ggg	att	ggt	tta	cta	cag	ggt	tga		285
Trp	Arg	Gly	Ala	Leu	Ile	Asp	Gly	Ile	Gly	Leu	Leu	Gln	Gly			
				85					90					95		
gtt	gacc	cac	aaac	actt	tc a	ggaa	acgg	t ac	agac	ttcc	tga	ataa	atc	aaat	agtcac	345
ctg	cgga	aaa	ggaat	taat	ca t	cag a	atg ·	tat	gcc ·	cgc	gag	tat	cgc	tca	aca	396
						3	Met '	Tyr .	Ala i	Arg	Glu '	Tyr :	Arg	Ser	Thr	
							-				100					

cgc ccg cat aaa gcg att ttc ttt cat ctt tct tgc ctc acc ctt atc

Arg Pro His Lys Ala Ile Phe Phe His Leu Ser Cys Leu Thr Leu Ile

105 110 120

tgt	agt	gcg	caa	gtt	tat	gcg	aag	ccg	gat	atg	cgg	cca	ctg	ggg	ccg	492
Cys	ser	Ala	Gln	Val	Tyr	Ala	Lys	Pro	Asp	Met	Arg	Pro	Leu	Gly	Pro	
				125					130					135		
aat	ata	gcc	gat	aaa	ggc	tcc	gtg	ttt	tac	cat	ttc	agc	gtc	acc	tct	540
Asn	Ile	Ala	Asp	Lys	Gly	Ser	Val	Phe	Tyr	His	Phe	ser	Val	Thr	Ser	
			140					145					150			
ttc	gac	tct	gtc	gat	ggc	aca	cgc	cat	tat	cgg	gta	tgg	acg	gcc	gtg	588
Phe	Asp	Ser	Val	Asp	Gly	Thr	Arg	His	Tyr	Arg	Val	Trp	Thr	Ala	Val	
		155					160					165				
ccg	aat	aca	acc	gca	ccg	gca	tcg	ggt	tac	ccg	att	tta	tat	atg	ctt	636
Pro	Asn	Thr	Thr	Ala	Pro	Ala	Ser	Gly	Tyr	Pro	Ile	Leu	Tyr	Met	Leu	
	170					175					180					
gac	ggt	aac	gca	gtt	atg	gat	cgc	ctg	gat	gac	gaa	ctg	ctc	aaa	caa	684
Asp	Gly	Asn	Ala	Val	Met	Asp	Arg	Leu	Asp	Asp	Glu	Leu	Leu	Lys	Gln	
185					190					195					200	
ttg	tca	gaa	aaa	aca	ccg	cca	gtg	atc	gtg	gct	gtc	ggg	tat	cag	acc	732
Leu	Ser	Glu	Lys	Thr	Pro	Pro	Val	Ile	Val	Ala	Val	Gly	Tyr	Gln	Thr	
				205					210					215		
aac	ctc	cct	ttc	gat	ctc	aac	agc	agg	gct	tac	gac	tat	acg	cca	gca	780
Asn	Leu	Pro	Phe	Asp	Leu	Asn	Ser	Arg	Ala	Tyr	Asp	Tyr	Thr	Pro	Ala	
			220					225					230			
-	-	agc	-			-					-		-	-	-	828
Ala	Glu	Ser	Arg	Lys	Thr	Asp		His	Ser	Gly	Arg	Phe	Ser	Arg	Lys	
		235					240					245				
-		ggc	-				-	_		_	-	-	-		-	876
ser	-	Gly	Ser	Asn	Asn	Phe	Arg	Gln	Leu	Leu	Glu	Thr	Arg	Ile	Ala	
	250					255					260					
		gtg											-			924
Pro	Lys	Val	Glu	Gln	-	Leu	Asn	Ile	Asp	-	Gln	Arg	Arg	Gly		
265					270					275					280	
		cac								-	-			-		972
Trp	Gly	His	Ser	Tyr	Gly	Gly	Leu	Phe			Asp	ser	Trp	Leu	Ser	
				285			•		290					295		
tcc	tct	tac	ttc	cgg	tcg	tac	tac	agc	geo	ago	ccg	tcg	<b>t</b> tg	ggc	aga	1020
Ser	Ser	Tyr	Phe	Arg	Ser	Tyr	Tyr	Ser	Ala	Ser	Pro	Ser	Leu	Gly	Arg	
			300					305					310	)		

	gct Ala									1068
	aaa Lys									1116
	gaa Glu									1164
	ata Ile									1212
	ctg Leu 380	Gly			Phe			Arg	cag Gln	1260

gca ctg tta gat atc agt ggt gaa aac gca aat tac aca gca ggt tgt 1308 Ala Leu Leu Asp Ile Ser Gly Glu Asn Ala Asn Tyr Thr Ala Gly Cys 395 400 405

cat gag tta agc cac taa acactgcccg cttttacgcg ggcagtacgc 1356 His Glu Leu Ser His 410

ctgaaacact acgatcagaa tgatgcggta actccggcat agtaagcccg gcctggctcg 1416

ttataggtat tcgccccttc agaagatcgg aagatctgtt tattgaggat attactgacg 1476

ccgacattaa gacgcagatt tttattaata tcgtaattga agttcgtccc caccagtgaa 1536

taagcgccca gctctttacc tgacagaccg ccagtatctt cactgcgggt ttccgcatga 1596

gtacgcggtt tttgtctgcc atataacgtc cagttgacgc tggcagaaaa cgcctgggtg 1656

atggtccagt taagcgagtt attgatagta tatttcggga tgaccgacag aggattaccg 1716

gtgtcttttt gctccgaagt gatcatccat gtggcattgg tattccagtt cagacgatct 1776

ttcaccagtg ggaaagacat actggcttcg ataccgtcca ccagagcttt cccgccattc 1836

tgccacttga ggatatatgc gcctgaagcg gtttgcccga taacgttatc cccggccacg 1896

atcttattct ggtaatcatt gcggaagtag gtcacacttg cgtggtaatc ttcccaggtg 1956

aactccaqcc caatttcttt attgacqctq atttccqqat cqaqatcttt attaccqatc 2016 aggtageacc cgcctgatgt aatatetttt ggacagecat tgcctttega gtagageaga 2076 tagcetteae tggattgata caggtttggg getttaaagg ttegggeaae eeetgetttg 2136 actttqaaat aatcgcccaa ttcctqcqaa aqattcaqac tqqqqctqaa qttcccqccq 2196 gagtegetga gataateaaa gegeaggeeg ggaatgatat tegtgeeagg aaceggetea 2256 atgttatctt caatatacag cgcactgatt tgagaatgat ttttactgct gcgatccgca 2316 gcagagccag aaataccgct gatatcactg tcattcaccg tcaggctggt agaggaagga 2376 tcatcgagct tatcgcggtt ccactctgca ccaacggtca gcgtttgatc aaccatcaca 2436 ttcaaaqqaa tattaaqctc qccqctqqtt cqccaqqaac tcaqqcqatt qqtcqtaaac 2496 ttttcacccg ctaaaatacg cccttcacca ccgccggata atccttcatt catgcgggta 2556 ttattqqttt tctcgtaata aacaccaaag cgactttgtc cccagtccca gataccatta 2616 tgcgtaatgc cataattctg tcggtacagg cggctcgtct cttgtgccgg attttgccag 2676 getttteggt aactgeactg gaagaactgt tttgegtate geegeataga tatteeeetg 2736 geggetatat ceggettega aategagaat etgetgegga tittaatitee aegagacaac 2796 gccgttaata tctttgttac gtaccccttc atgcccggct gcgtttttcg taccgaccqg 2856 agaattaata toocaactgt cagcatoogt tttattoaga ttaccataca aacgogtggt 2916 aagagcatta ccagccagag gcccactaag gctgaaattg gcgcgacgcg tagcgccctc 2976 atogotaett tooggotgat tggtgtataa cgacagogaa cogtgocagt cgttggtggg 3036 acgtttggta atgatgttca ccacccccc ggctgccccc qaaccgtaqc qcqccqccgc 3096 agggccgcgg atcacttcaa tacgctcaac ctgttccggt ggcacccagt tggtgtcacc 3156 gegggtatea egeteteeae geeagetata aegeaeggag ttaegtgaeg teaeeggtae 3216 accatcaatt aaaattaagg tgttttccgg ccccatacca cgaatatcga tctggcggtt 3276 gttaccgcgt gtgcccgagg cgctattgcc ggtaagattg acgccaggca ttttacgaat 3336 aatatetgaa aggtegttta eeggaggggt etttttaata teetegetgg taataacega 3396

cacgoccogo tgotgittia atacotgoto agoggiggot tocaccaca gagictogic 3456
attatoatog toggaggatt tggotactga tacotggota ticaacccaa coaggagoac 3516
agitagogac cagaggatti tgitaattot catacctati coctaataaa tgootaacit 3576
aaaatgittig atogitaago toacatooti gooagatati tittacigoo attatigitti 3636
titatataaga atgataatta atatoatita goaaaagaaa aagoaatooo toacaagata 3696
aatatatoga titticataa atatoaatii gatatataac atatgittii tatitoatig 3756
tacotcagio aaataaatti olgaagoaci gotagtagig coagitoago titootitiig 3816
actoatoog goaaagoag tacogitoat olitigaco gatgitgooa oligaaaato 3876
ggigogottig togatoatog ggaattiigi cacaattot aacggatagi gitoacatig 3936
titotaacct goattitoag acacggogo tgottatgia tataagatoa goatoactag 3996
gtottitotgo aacactactg oliticaacaa ggicaggoat tito

<210> 31

<211> 94

<212> PRT

<213> Escherichia coli

<400> 31

Pro Ser Met Trp Trp Thr Pro Glu Arg Thr Ser Arg Pro Gly Leu Phe

1 5 10 15

Ser Glu Thr Asp Thr Ser Trp Val Ser Glu His Leu Leu Ser Ala Pro 20 25 30

Pro Gln Gly Val Arg Ile Ser Leu Cys Val Gly Ser Leu Glu Gly Ser 45

Thr Val Pro His Val Gln Gln Leu His Gln Arg Leu Ile Thr Ala Gly 50 55 60

Val Glu Ser His Cys Ala Ile Tyr Thr Gly Gly His Asp Tyr Ala Trp
65 70 . 75 80

Trp Arg Gly Ala Leu Ile Asp Gly Ile Gly Leu Leu Gln Gly 85 90

<210> 32

<211> 318

<212> PRT

<213> Escherichia coli

<400> 32

Met Tyr Ala Arg Glu Tyr Arg Ser Thr Arg Pro His Lys Ala Ile Phe  $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$ 

Phe His Leu Ser Cys Leu Thr Leu Ile Cys Ser Ala Gln Val Tyr Ala
20 25 30

Lys Pro Asp Met Arg Pro Leu Gly Pro Asn Ile Ala Asp Lys Gly Ser 35 40 45

Val Phe Tyr His Phe Ser Val Thr Ser Phe Asp Ser Val Asp Gly Thr 50 55 60

Arg His Tyr Arg Val Trp Thr Ala Val Pro Asn Thr Thr Ala Pro Ala 65 70 75 80

Ser Gly Tyr Pro Ile Leu Tyr Met Leu Asp Gly Asn Ala Val Met Asp 85 90 95

Arg Leu Asp Asp Glu Leu Leu Lys Gln Leu Ser Glu Lys Thr Pro Pro 100 105 110

Val Ile Val Ala Val Gly Tyr Gln Thr Asn Leu Pro Phe Asp Leu Asn 115 120 125

Ser Arg Ala Tyr Asp Tyr Thr Pro Ala Ala Glu Ser Arg Lys Thr Asp 130 135 140

Leu His Ser Gly Arg Phe Ser Arg Lys Ser Gly Gly Ser Asn Asn Phe 145 155 160

Arg Gln Leu Leu Glu Thr Arg Ile Ala Pro Lys Val Glu Gln Gly Leu 165 170 175

Asn Ile Asp Arg Gln Arg Arg Gly Leu Trp Gly His Ser Tyr Gly Gly 180 185 190

Leu Phe Val Leu Asp Ser Trp Leu Ser Ser Ser Tyr Phe Arg Ser Tyr
195 200 205

Tyr Ser Ala Ser Pro Ser Leu Gly Arg Gly Tyr Asp Ala Leu Leu Ser 210 215 220

Arg Val Thr Ala Val Glu Pro Leu Gln Phe Cys Ala Lys His Leu Ala 225 230 235 240

Ile Met Glu Gly Ser Ala Thr Gln Gly Asp Asn Arg Glu Thr His Ala  $245 \hspace{1.5cm} 250 \hspace{1.5cm} 255$ 

Val Gly Val Leu Ser Lys Ile His Thr Thr Leu Thr Ile Leu Lys Asp 260 265 270

Lys Gly Val Asn Ala Val Phe Trp Asp Phe Pro Asn Leu Gly His Gly 275 280 285

Pro Met Phe Asn Ala Ser Phe Arg Gln Ala Leu Leu Asp Ile Ser Gly 290 295 300

Glu Asn Ala Asn Tyr Thr Ala Gly Cys His Glu Leu Ser His 305 310 315

<210> 33 <211> 3292

<211> 3292

<213> Escherichia coli

<400> 33

ccgctgcggt tgattgccgg atgcggcgtg aacgccttat ccggcctaca atcattgcaa 60 attcaataaa ttgcagcgtt ctgtaggctg gataagatgc gtcagcatcg catccggcaa 120 aggcagatct cagcgatagc gccggcttag tcagatttaa tctgcgcgcg tggtggatat 180 tttttcagga tctccatata cgcgtgcatt tcggtctgta gcggtacacc catcggaata 240 tggcgcacgc cgatagagtc gctttcctgc ggatcggtgt acaggttaaa caccgacgat 300 cccgccgttt gcattactgt gccggtgaat ccaccctgat atccgctctg ggtataaqcg 360 taaggttgct gaatcaggac gtgatacttg aactcatcca tacgcacagc agaaagttta 420 ccgttgagga agtagtgctc ggccttacgg ttagactgac catttgttcc caggaagaaa 480 gatgtctggt ccacaccatc gataaaggtg gttttcggta ctaaattcgc tactttcgcc 540 ccaqqatgcc ccgccagatc cagcgccgta gggaagagat ccgccagatc gacaatgccg 600 tcagatttac gcggttggat catgcctttc cagtaaacga aggttggcac acgaacgccg 660 ccttcccatg tagaaccttt cgcaccgcgg aacggcgtgc gaccgtgcgg cggaacttcg 720 gcttccggac cgttatcaga ggtgaacaca atcagcgtgt tatcaagctg accgtttttc 780 tccaqtgctt tatacagatt ggcgaagata tcgttcatct ccaccatgca gtcgccgtaa 840 gaggtqcgcg ccggagagct acccgcatat ttggcgttcg ggtagttatc gaagtgacag 900 ccgcgagtgc cgtaatagag gaagaaaggc ttatcactct tcgccatctt gtcgaggaac 960 ttaacgccat attccatcca gcgttgatcc aggtcttcca tatatttcgg cgtaatgtcg 1020 gcaatggctt cetgttcacc gccgcgcacg gcatgaacgt catctttgct gaacggcagt 1080 ttttggatgt attcagaacg agccgggctc agggcgactt ccgggttgac atgaacatca 1140 cgccattcgg tatacatatc ggacaccgag ttaaagccgc ggaaatcatc aaagccaacg 1200 ttctgcggct gcgactcttt gttttccccc atatgccatt tcccgatagc ctgggtgacg 1260 taqccctgat cqtgcagcaa ctgcggcagc gtggttaacc cttgcagacc gcccggttgc 1320

ccqtacattq qcqqcatcaq aatqccqtqq tggatggagt attqtccqqt gagaatcqtq 1380 gcqcgggttg gggaagaact cggttgagaa tacgccgaag ttaaaatcaq cccctqqctq 1440 gcaacggcgt cgatatctgg tgtagggtta cccaccgcca cgccgccgcc gttaaagcca 1500 acqtccatcc agcccacatc atccagcaaq aaaacaacca cqttcqgttt cttaccqqtt 1560 tttttctcaa qttccgccag tttctgctgg gtttctttgt cttgtgcagg atgctgcatc 1620 accqqcatca tgttgtcggc aatagtggtc gccggtttaa ccagatactg gtttgqgtga 1680 tegtateegg caaageettt gegtgeggtg geggttgaeg gggtatetge tgegetgget 1740 atqaqaqqaa qaqctqcqqc qacaqcaaca acaaqaagtt tqqqtqaaaa cqaaaattcc 1800 atgcaaaatg ctccggtttc atgtcgtcaa aatgatgacg taattaagca ttgataattg 1860 agatecetet ecetqacagg atgattgcat aaataatagt gataaaaata aattatttat 1920 ttatccagaa atgaattgaa aaatcaggag agcattttca atcctacctc tggcgcaggt 1980 gatattgtaa ggcggtgatg ttatatcgcg ttgattattg atgctgtttt tagttttaac 2040 qqcattaata tatatgttat taattqaatq acttttatta ttcattatat atatqtqtaq 2100 aattqtqcqc agqagaaata ttcactcaqq aagttattac tcaqqaaqca aaqaqqatta 2160 caqaattatc tcataacaag tgttaaggga tgttatttcc cggttctctg tggcataata 2220 aacgagtaga tgctcattcc atctcttatg ttcgccttag tgcctcataa actccggaat 2280 gacgcagage cgtttacggt gcttatcgtc cactgacaga tgtcgcttat gcctcatcag 2340 acaccatqqa cacaacgttg agtgaagcac ccacttgttg tcatacaqac ctgttttaac 2400 qcctgctccg taataagagc aggcgttttt ttatatatca gaaaggcccc ggaggtgctt 2460 gcctccgggt gagaaagagc tactgtggcg ggttgttctg caacgttaac atcaaaccgt 2520 eggacgeat egetgegget tetteegget tgtgcagtet gtecagegeg teggeaagee 2580 atgcgtaatc gtaggcgtcc ggacgttgtt tcagcgctgc gcggaaggcg agcgatgctt 2640 cctgccattc tccgtgtttc atcagcgact gacccagtgt gctccacaac agcgggcgat 2700 cgcccacgtt tttgatctgt tggcgcagca ctttttccaa gctgttcccg ggttaattgg 2760 qttttcaqac qccqqggatc qqcaqcagca qqccqaatcq tcatactqqc qtttcaqqcc 2820 atcgatgata atttgctggg cagtatcatg atcgtcacac tcaataagat gttccgccat 2880 tgccacctgc aaggccacct gatgacgcgt tttccggctt tggtttttcc accagttacg 2940 caaaccttca ctaccgttat cggcacgcgc ctgatccatc aggccaatcc atgcctgttg 3000 ttccaqcatt qcacqatqtt cttcatcacc aacatqqqct ttcqccattq atqqqatqat 3060 atccaqcaqc gaactccatg caccagtgcg gatatacgcc tgttccqcca qacqtaatac 3120 ttccqqatqq cqtqqcqtaa cttccaqcaq cttatccacq ccqtqacqtq ctqcatqqtt 3180 tteattacqq gecagttqca qacqtacacq qqtqatttet accqqaatqq tqteattqcc 3240 ggccagctcc gctgcgcgtt ccagatgttg gttggcgcgt gcttcagcat cc 3292

```
<210> 34

<211> 11165

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (3791)..(4834)
```

<220> <221> CDS

<222> (10459)..(10776)

```
<220>
 <221> CDS
 <222> (10134) .. (10427)
 <220>
 <221> CDS
 <222> (9836)..(10081)
 <220>
 <221> CDS
 <222> (7816)..(9480)
<220>
 <221> CDS
 <222> (4878) .. (7802)
<220>
<221> CDS
<222> (3460)..(3702)
<220>
<221> CDS
<222> (3054)..(3407)
<220>
<221> CDS
<222> (2613)..(3041)
<220>
 <221> CDS
 <222> (2198)..(2530)
 <220>
 <221> CDS
 <222> (1939)..(2196)
 <220>
 <221> CDS
 <222> (1573)..(1893)
<220>
 <221> CDS
 <222> (1102)..(1485)
```

<220> <221> CDS <222> (2)..(1099)

<400> 34

С	agc	gat	atg	cag	cgc	ggt	atc	cag	gct	gca	acg	gct	gca	ctt	cag	ggc	49
	Ser	Asp	Met	Gln	Arg	Gly	Ile	Gln	Ala	Ala	Thr	Ala	Ala	Leu	Gln	Gly	
	1				5					10					15		

- ctg gtg ggc ggc aat atg gca ggc gcg ctg gca ggt gct tca gcg ccg g Leu Val Gly Gly Asn Met Ala Gly Ala Leu Ala Gly Ala Ser Ala Pro 20 25 30
- gag ctg gcg aac atc atc ggt cat cac gcg ggt att gat gac aat aca 14 Glu Leu Ala Asn Ile Ile Gly His His Ala Gly Ile Asp Asp Asn Thr
- gcg gca aaa gcc att gcc cat gcc att ctc ggt ggt gtg aca gca gcc 193
  Ala Ala Lys Ala Ile Ala His Ala Ile Leu Gly Gly Val Thr Ala Ala
  50 55 60
- ctt cag ggc aac agt gcg gca gca ggc gca att ggt gcg ggt act ggt 241
  Leu Gln Gly Asn Ser Ala Ala Ala Gly Ala Ile Gly Ala Gly Thr Gly
  65 70 75 80
- gaa gtg atc gcg tca gcc att gcg aaa agc ctc tac ccg ggc gta gat 289 Glu Val Ile Ala Ser Ala Ile Ala Lys Ser Leu Tyr Pro Gly Val Asp 85 90 95
- ccg tcg aaa ctg aca gaa gat cag aag caa act gta agc acg ctg gca 33
  Pro Ser Lys Leu Thr Glu Asp Gln Lys Gln Thr Val Ser Thr Leu Ala
  100 105 110
- acg ctg tca gcg ggt atg gcc ggc ggc att gcc agt ggc gat gtg gct 388 Thr Leu Ser Ala Gly Met Ala Gly Gly Ile Ala Ser Gly Asp Val Ala 115 120
- ggc gcg gct gct gga gct ggt gcc ggg aag aac gtt gtt gag aat aat 43 Gly Ala Ala Ala Gly Ala Gly Ala Gly Lys Asn Val Val Glu Asn Asn 130 135 140
- gcg ctg agt ctg gtt gcc aga ggc tgt gcg gtc gca gca cct tgc agg 483 Ala Leu Ser Leu Val Ala Arg Gly Cys Ala Val Ala Ala Pro Cys Arg 145 150 160
- act aaa gtt gca gag cag ttg cta gaa atc ggg gcg aaa gcg ggc atg 52:
  Thr Lys Val Ala Glu Gln Leu Leu Glu Ile Gly Ala Lys Ala Gly Met
  165 170 175
- gcc ggg ctt gcc ggg gcg gca gtc aag gat atg gcc gac agg atg acc 577. Ala Gly Leu Ala Gly Ala Ala Val Lys Asp Met Ala Asp Arg Met Thr
  180 185 190

tcc	gat	gaa	ctg	gag	cat	ctg	att	acc	ctg	caa	atg	atq	qqt	aat	gat	625
				Glu												
		195					200					205	-		•	
gag	atc	act	act	aag	tat	ctc	agt	tcg	ttg	cat	gat	aag	tac	ggt	tcc	673
Glu	Ile	Thr	Thr	Lys	Tyr	Leu	Ser	Ser	Leu	His	Asp	Lys	Tyr	Gly	Ser	
	210					215					220	-	-	_		
ggg	gct	gcc	tcg	aat	ccg	aat	atc	ggt	aaa	gat	ctg	acc	gat	gcg	gaa	721
Gly	Ala	Ala	ser	Asn	Pro	Asn	Ile	Gly	Lys	Asp	Leu	Thr	Asp	Ala	Glu	
225					230					235			•		240	
aaa	gta	gaa	ctg	ggc	ggt	tcc	ggc	tca	gga	acc	ggt	aca	cca	cca	cca	769
Lys	Val	Glu	Leu	Gly	Gly	ser	Gly	Ser	Gly	Thr	Gly	Thr	Pro	Pro	Pro	
				245					250					255		
tcg	gaa	aat	gat	cct	aag	cag	caa	aat	gaa	aaa	act	gta	gat	aag	ctt	817
Ser	Glu	Asn	Asp	Pro	Lys	Gln	Gln	Asn	Glu	Lys	Thr	Val	Asp	Lys	Leu	
			260					265					270			
aat	cag	aag	caa	gaa	agt	gcg	att	aag	aag	atc	gat	aac	act	ata	aaa	865
Asn	Gln	Lys	Gln	Glu	Ser	Ala	Ile	Lys	Lys	Ile	Asp	Asn	Thr	Ile	Lys	
		275					280					285				
				gat												913
Asn	Ala	Leu	Lys	Asp	His	Asp	Ile	Ile	Gly	Thr	Leu	Lys	Asp	Met	Asp	
	290					295					300					
				cct												961
	Lys	Pro	Val	Pro	Lys	Glu	Asn	Gly	Gly	Tyr	Trp	Asp	His	Met	Gln	
305					310					315					320	
															ttg	1009
Glu	Met	Gln	Asn	Thr	Leu	Arg	Gly	Leu		Asn	His	Ala	Asp	Thr	Leu	
				325					330					335		
															aca	1057
Lys	Asn	Val		Asn	Pro	Glu	Ala		Ala	Ala	Tyr	Gly	Arg	Ala	Thr	
			340					345					350			
				aaa										at	atg	1104
Asp	Ala		Asn	Lys	Ile	Glu		Ala	Leu	Lys	Gly	-	Gly		Met	
		355					360					365				
															cct	1152
ITe	Thr		Arg	Lys	Leu	Ile		Asn	Ile	Asn	Met		Lys	Glu	Pro	
		370					375					380				

		caa Gln														1200
	385	0211	501		Deu	390	Deu		rne	GIL	395	116	116	мар	Val	
		gaa														1248
	Leu	Glu	Lys	Leu		Val	Glu	Asp	Leu	Cys	Arg	Ala	Ile	Arg	Gln	
400					405					410					415	
		tgt -														1296
Asn	Leu	Cys	Ile		Gln	Leu	Met	Pro		Val	Leu	Glu	Val		Thr	
				420					425					430		
		ccg														1344
Lys	GIU	Pro	435	Ата	GIA	Glu	Tyr		Asp	Gly	Glu	Leu		Ala	Ala	
								440					445			
		acg														1392
Leu	Ser	Thr 450	116	Буъ	GIY	GIU	455	Leu	ьys	Asp	Gin		Ser	Thr	Phe	
												460				
		ata														1440
Thr	G1n 465	Ile	Arg	Gin	Leu		Asn	Gln	Leu	Glu		Ser	Asp	Ile	Asn	
						470					475					
		tta														1485
	Asp	Leu	Arg	Lys		Ile	Leu	Lys	Ile		Gln	Ile	Ile	Val		
480					485					490						
taad	ctaat	cc o	ggco	cacto	ga go	cga	gatci	tc	ttgi	tgtg	ccg	ggcat	tgt 1	tcag	cagctt	1545
g <b>gg</b> g	ggtga	aaa q	gtccc	ctgt	tc ca	agcc1	g at	tg gt	g g	eg a	ag ge	g ti	tc g	g t	ac gca	1599
							Me	et Va	al A	la L	ys A.	la Pi	he A	la T	yr Ala	
								95					00			
		cag														1647
Leu		Gln	Trp	Pro	Ala		Thr	Tyr	Tyr	Ala	Asn	Asp	Gly	Trp	Val	
	505					510					515					
gaa	atc	gac	aac	aac	atc	gct	gaa	aat	gcc	ctg	cgg	gcg	gtc	agt	ctg	1695
Glu	Ile	Asp	Asn	Asn	Ile	Ala	Glu	Asn	Ala	Leu	Arg	Ala	Val	ser	Leu	
520					525					530					535	
ggt	cgt	aaa	aac	ttc	ctg	ttc	ttc	ggc	tct	gac	cat	ggt	ggt	gag	cgg	1743
		Lys														
				540					545					550		

gga gcg cta ctg tac agc ctg atc ggg acg tgc aaa ctg aat gac gtg 1791

wo	00/28	8038												1	PCT/GB	99/0372
Gly	Ala	Leu	Leu 555	Tyr	Ser	Leu	Ile	Gly 560	Thr	Cys	Lys	Leu	Asn 565	Asp	Val	
		gaa Glu 570														1839
_	-	aac Asn		-	-	-	_		-		-		-	_		1887
-	gaa Glu	taad	cacat	tcc d	cgto	aata	ac go	gecet	cgct	t gta	acgci	ttac	aga		tg ctg et Leu	
_		gta Val	_		-	-									-	19 <b>9</b> 2
	His	acc Thr														2040
-		ccg	-		-	_	-	-	_	Asp						2088
-	-			Thr		-								Ala	gtg Val	2136
-	-	-	Ala	-	-	-					-		Arg		tcc Ser	2184
_	-	Ser				al A					ys s				igt cg Ser Ar	
	Let					Met					Glu				cgc Arg 715	228
			_	-	Glu					Glr				-	g gga Gly	232

aaa tac atg acg gtc agt gaa ctg aaa acg gag gtg ttt ggc atc atg

/GB99/0372	'CT/G	P												030	00/20	WO
t	Met	Ile	Gly 745	Phe	Val	<b>Gl</b> u	Thr	Lys 740	Leu	Glu	Ser	Val	Thr 735	Met	Tyr	Lys
c 2425	tac Tyr	cgc Arg	cgt Arg	tta Leu 760	cag Gln	gag Glu	gaa Glu	gcg Ala	ccg Pro 755	atc Ile	cat His	cgg Arg	aac Asn	ttt Phe 750	gct Ala	cag Gln
		cag Gln		caa					ggc					gtc		
a 2521	gca	cgt	ata	atg	775	tat	cgt	aac	att	770 tta	cag	aat	cta	gcg	765 atg	gaa
	Ala 795	Arg				790					785					780
2570									atgc					Gln	Lys	Gly
		gga t Gly (		Met '		cttg	gatt	g gc	EECE	<b>J</b> gct1		cgag		LLC	gcca	agai
c 2672 s	cac His	cca Pro	tca Ser	ctt Leu 815	gcg Ala	cat His	gac Asp	tcc Ser	ttt Phe 810	gcc Ala	cag Gln	gaa Glu	gct Ala	tta Leu 805	tgg Trp	gct Ala
g 2720 r	acg Thr	gat Asp	gcc Ala	ctg Leu	830 Gly ggg	gcc Ala	gat Asp	cgc Arg	tcg Ser	gca Ala 825	agt Ser	tac Tyr	ccg Pro	tgg Trp	gct Ala 820	agt Ser
r	acc Thr 850	gac Asp	gac Asp	gcc Ala	tgg Trp	cgg Arg 845	cag Gln	aaa Lys	tgt Cys	act Thr	ccc Pro 840	tat Tyr	ggc Gly	ggc Gly	gcg Ala	ggc Gly 835
g 2816 p	tgg Trp	atc Ile 865	gat Asp	cta Leu	gcc Ala	cct Pro	ctt Leu 860	caa Gln	ctg Leu	cta Leu	cgt Arg	gcc Ala 855	aaa Lys	ctg Leu	ggg Gly	gtt Val
c 2864 a	gcc Ala	gag Glu	gaa Glu 880	tat Tyr	gtg Val	gta Val	cag Gln	tcg Ser 875	cag Gln	gac Asp	atc Ile	aaa Lys	aaa Lys 870	ttt Phe	gcg Ala	acg Thr
		cag Gln														
c 2960 a	gcc Ala	gtc Val	acc Thr	ggc	gat Asp	gtt Val	aac Asn	ggt Gly	ggc	tat Tyr	agc Ser	cca Pro	tat Tyr	gtt	cgc Arg	ggg

HORRIDET DYEST

		0.1

	500					303					910					
Asn		gcc Ala			Leu					Arg					Ser	3008
915 ata	gcg	gca	tgt	acg	920 gca	ttc	gac	agc	ata	925 cgt	tago	rcact	ac (	co a	930 ta ata	a 3059
		Ala									-			-	et Val	
		cag Gln								-		-	-		acg Thr	3107
		tcg Ser														3155
		gca Ala														3203
		agc Ser					Val					Asp				3251
	Trp	aat Asn 1010				Ile					Asp					3299
Asn		gtg Val			Leu					Leu					ctg Leu	3347
	Ala			Trp					Val					Asn	gga Gly 1055	3395
		gcg Ala		tga	ttgg	gag	gtgai	tteg	cc a	atct	cact	t tc	ctat	acac		3447
ata	taaa	atg ·		et L					ne G					er I	ta tt	t 3 <b>49</b> 8 e
	Thr					Arg					Pro				atg Met	3546

WO 00/28038 PCT/GB99/03721

att ttt gca ttg ccc tca atc att tta ggt caa ttt acg acc aac caa	3594
Ile Phe Ala Leu Pro Ser Ile Ile Leu Gly Gln Phe Thr Thr Asn Gln	
1090 1095 1100	
tta act aac ttt gtg ata tgt atg ggt aac acc gtt gaa cgt cgg ctg	3642
Leu Thr Asn Phe Val Ile Cys Met Gly Asn Thr Val Glu Arg Arg Leu	
1105 1110 1115 1120	
1120	
ggt gtt gtt cat aat ccc ttt aaa agg tct ggg gat ggc cat gac ctc	3690
Gly Val Val His Asn Pro Phe Lys Arg Ser Gly Asp Gly His Asp Leu	5050
1125 1130 1135	
1100 1100	
agg gcg gta gcg tgaccaaagt tcatatccat accaattatt tttatttaaa	3742
Arg Ala Val Ala	3/42
1140	
1140	
atatcaactt attcgagttg ttttatttag ttcaaagaag gtatcaaa ttg ata gtt	3799
Leu Ile Val	
ata gat ttt ttt tgt ggc tgt ggt gga gcc agt gaa ggg cta cgt cag	3847
Ile Asp Phe Phe Cys Gly Cys Gly Gly Ala Ser Glu Gly Leu Arg Gln	
1145 1150 1155	
gct ggc ttt gat atc gag ctt gga tta gat att gac caa caa gca tca	3895
Ala Gly Phe Asp Ile Glu Leu Gly Leu Asp Ile Asp Gln Gln Ala Ser	
1160 1165 1170 1175	
gaa aca ttt aaa gct aat ttc cct gat gca aaa ttc atc caa gat gat	3943
Glu Thr Phe Lys Ala Asn Phe Pro Asp Ala Lys Phe Ile Gln Asp Asp	
1180 1185 1190	
att agg aaa atc gaa cct caa gat atc tcc gac atc att gat att aaa	3991
Ile Arg Lys Ile Glu Pro Gln Asp Ile Ser Asp Ile Ile Asp Ile Lys	0002
1195 1200 1205	
1203	
gct aaa cgg cct ttg tta ctg agt gca tgt gca cca tgt caa cca ttt	4020
	4039
Ala Lys Arg Pro Leu Leu Ser Ala Cys Ala Pro Cys Gln Pro Phe	
1210 1215 1220	
tog caa cag aat aaa aat aaa act agt gac gac toa agg aga aat cta	4087
Ser Gln Gln Asn Lys Asn Lys Thr Ser Asp Asp Ser Arg Asn Leu	
1225 1230 1235	
cta aat gaa act cat cgt ttt att aga gaa ctt ctt cct gaa tat att	4135
Leu Asn Glu Thr His Arg Phe Ile Arg Glu Leu Leu Pro Glu Tyr Ile	

WO 00/28038 PCT/GB99/03721

atg																
	ctt	gaa	aat	gtt	cct	gga	atg	caa	aaa	att	gat	gaa	gaa	aaa	gaa	4183
Met	Leu	Glu	Asn	Val	Pro	Gly	Met	Gln	Lys	Ile	Asp	Glu	Glu	Lys	Glu	
			1	L260				1	265		_		1	270		
aac	cca	ttt	caσ	gag	ttt	att	aan	cta	ctt	222	nan	tta	nan	tat	220	4231
														Tyr		1231
OLy	110		1275	OIU	2116	***	-	1280	Бец	пуз	GIU		1285	TAT	ASII	
			12.75					1200					.203			
				- 4 -												
														caa		4279
Tyr			Phe	IIe	ALa			GLu	Asn	Tyr	-		Pro	Gln	Arg	
	-	1290					1295				1	L300				
aga	aaa	aga	ctc	g <b>tg</b>	ctc	tta	gct	agt	cga	gta	ggt	aaa	gtt	acc	cta	4327
Arg	Lys	Arg	Leu	Val	Leu	Leu	Ala	Ser	Arg	Val	Gly	Lys	Val	Thr	Leu	
1	305				1	1310				1	1315					
cca	gag	ata	acc	cat	ggt	aaa	aat	aaa	atc	cca	ttc	aaa	act	gta	cga	4375
Pro	Glu	Ile	Thr	His	Gly	Lys	Asn	Lys	Ile	Pro	Phe	Lys	Thr	Val	Arg	
1320					1325			-		1330		-			1335	
gat	tat	atc	cag	gac	ttc	aca	аад	tta	tat	tca	aga	maa	200	gac	ccc	4423
				-			_		_			-		Asp		4423
	-,-			1340		****	2,5		1345	Ser	Gry	Giu		-	FLO	
				1340					1345					1350		
	-		tta			-			-	-						4471
	-	Pro	Leu			-	Gly	Thr	-	-				cta Leu		4471
	-	Pro				-	Gly		-	-		Leu				4471
	-	Pro	Leu			-	Gly	Thr	-	-		Leu	Asn			4471
Lys	Asp	Pro	Leu 1355	His	Arg	Ala	Gly	Thr 1360	Leu	Ser	Pro	Leu	Asn 1365		Lys	4471
Lys aga	Asp	Pro	Leu 1355 cac	His act	Arg	Ala	Gly gga	Thr 1360 ggg	Leu	Ser	Pro aga	Leu	Asn 1365 tgg	Leu	Lys gaa	
Lys aga	Asp att Ile	Pro	Leu 1355 cac	His act	Arg	Ala gaa Glu	Gly gga	Thr 1360 ggg	Leu	Ser	Pro aga Arg	Leu	Asn 1365 tgg	Leu	Lys gaa	
Lys aga	Asp att Ile	Pro atg Met	Leu 1355 cac	His act	Arg	Ala gaa Glu	gga Gly	Thr 1360 ggg	Leu	Ser	Pro aga Arg	Leu aat Asn	Asn 1365 tgg	Leu	Lys gaa	
Lys aga Arg	Asp att Ile	etg Met 1370	Leu 1355 cac His	His act Thr	Arg cca Pro	Ala gaa Glu	gga Gly 1375	Thr 1360 ggg Gly	Jeu gat Asp	ser aga Arg	Pro aga Arg	aat Asn	Asn 1365 tgg Trp	Leu cca Pro	Lys gaa Glu	4519
Lys aga Arg	Asp att Ile tta	atg Met 1370	Leu 1355 cac His	His act Thr	Arg cca Pro	Ala gaa Glu	gga Gly 1375	Thr 1360 ggg Gly	Leu gat Asp	ser aga Arg	aga Arg	aat Asn 1380	Asn 1365 tgg Trp	Cca Pro	Lys gaa Glu act	
Lys aga Arg gag	Asp att Ile tta Leu	atg Met 1370	Leu 1355 cac His	His act Thr	CCa Pro tgc Cys	Ala gaa Glu cat	gga Gly 1375	Thr 1360 ggg Gly	Leu gat Asp	ser aga Arg gat Asp	aga Arg ggc Gly	aat Asn 1380	Asn 1365 tgg Trp	Leu cca Pro	Lys gaa Glu act	4519
Lys aga Arg gag	Asp att Ile tta	atg Met 1370	Leu 1355 cac His	His act Thr	CCa Pro tgc Cys	Ala gaa Glu	gga Gly 1375	Thr 1360 ggg Gly	Leu gat Asp	ser aga Arg gat Asp	aga Arg	aat Asn 1380	Asn 1365 tgg Trp	Cca Pro	Lys gaa Glu act	4519
aga Arg gag Glu	Asp att Ile tta Leu 1385	atg Met 1370 gtt Val	Leu 1355 cac His aat Asn	act Thr aaa Lys	cca Pro tgc Cys	Ala gaa Glu cat His	gga Gly 1375 aaa Lys	Thr 1360 ggg Gly aat Asn	gat Asp tat Tyr	aga Arg gat Asp	aga Arg ggc Gly	aat Asn 1380 cac	Asn 1365 tgg Trp aca Thr	Cca Pro gat Asp	Lys gaa Glu act Thr	<b>4519</b> <b>4567</b>
aga Arg gag Glu	Asp att Ile tta Leu 1385	atg Met 1370 gtt Val	Leu 1355 cac His aat Asn	act Thr aaa Lys	cca Pro tgc Cys	Ala gaa Glu cat His 1390	gga Gly 1375 aaa Lys	Thr 1360 ggg Gly aat Asn	gat Asp tat Tyr	aga Arg gat Asp	aga Arg ggc Gly 1395	aat Asn 1380 cac His	Asn 1365 tgg Trp aca Thr	Cca Pro gat Asp	Lys gaa Glu act Thr	4519
aga Arg gag Glu tat	Asp att Ile tta Leu 1385 gga Gly	atg Met 1370 gtt Val	Leu 1355 cac His aat Asn	act Thr aaa Lys agt	cca Pro tgc Cys	Ala gaa Glu cat His 1390	gga Gly 1375 aaa Lys	Thr 1360 ggg Gly aat Asn	gat Asp tat Tyr	aga Arg gat Asp	aga Arg ggc Gly 1395	aat Asn 1380 cac His	Asn 1365 tgg Trp aca Thr	Cca Pro gat Asp	Lys gaa Glu act Thr	<b>4519</b> <b>4567</b>
aga Arg gag Glu	Asp att Ile tta Leu 1385 gga Gly	atg Met 1370 gtt Val	Leu 1355 cac His aat Asn	act Thr aaa Lys agt	cca Pro tgc Cys	Ala gaa Glu cat His 1390	gga Gly 1375 aaa Lys	Thr 1360 ggg Gly aat Asn	gat Asp tat Tyr	aga Arg gat Asp	aga Arg ggc Gly 1395	aat Asn 1380 cac His	Asn 1365 tgg Trp aca Thr	Cca Pro gat Asp	Lys gaa Glu act Thr	<b>4519</b> <b>4567</b>
aga Arg gag Glu tat Tyr	Asp att Ile tta Leu 1385 gga Gly	atg Met 1370 gtt Val aga Arg	Leu 1355 cac His aat Asn atg Met	His act Thr aaa Lys agt Ser	cca Pro tgc Cys tgg Trp	Ala gaa Glu cat His 1390 gat Asp	gga Gly 1375 aaa Lys aag	Thr 1360 ggg Gly aat Asn cct	Leu gat Asp tat Tyr gcg Ala	aga Arg gat Asp cct Pro	aga Arg ggc Gly 1395 aca	aat Asn 1380 cac His ctt Leu	Asn 1365 tgg Trp aca Thr	Cca Pro gat Asp	gaa Glu act Thr	<b>4519</b> <b>4567</b>
aga Arg gag Glu tat Tyr 1400	Asp att Ile tta Leu 1385 gga Gly	Pro atg Met 1370 gtt Val aga Arg	Leu 1355 cac His aat Asn atg Met	His act Thr aaaa Lys agt Ser	Cca Pro tgc Cys tgg Trp 1405	Ala gaa Glu cat His 1390 gat Asp	gga Gly 1375 aaa Lys Lys	Thr 1360 ggg Gly aat Asn cct Pro	Leu gat Asp tat Tyr gcg Ala	aga Arg gat Asp cct Pro 1410 cat	aga Arg ggc Gly 1395 aca Thr	aat Asn 1380 cac His ctt Leu	Asn 1365 tgg Trp aca Thr	Leu  cca Pro  gat Asp  acg Thr	Lys gaa Glu act Thr aaa Lys 1415	<b>4519</b> <b>4567</b>
aga Arg gag Glu tat Tyr 1400	Asp att Ile tta Leu 1385 gga Gly	Pro atg Met 1370 gtt Val aga Arg	Leu 1355 cac His aat Asn atg Met	His act Thr aaaa Lys agt Ser	Cca Pro tgc Cys tgg Trp 1405	Ala gaa Glu cat His 1390 gat Asp	gga Gly 1375 aaa Lys Lys	Thr 1360 ggg Gly aat Asn cct Pro	Leu gat Asp tat Tyr gcg Ala	aga Arg gat Asp cct Pro 1410 cat	aga Arg ggc Gly 1395 aca Thr	aat Asn 1380 cac His ctt Leu	Asn 1365 tgg Trp aca Thr	Cca Pro gat Asp	Lys gaa Glu act Thr aaa Lys 1415	4519 4567 4615
aga Arg gag Glu tat Tyr 1400	Asp att Ile tta Leu 1385 gga Gly	Pro atg Met 1370 gtt Val aga Arg	Leu 1355 cac His aat Asn atg Met	His act Thr aaaa Lys agt Ser	Cca Pro tgc Cys tgg Trp 1405	Ala gaa Glu cat His 1390 gat Asp	gga Gly 1375 aaa Lys Lys	Thr 1360 ggg Gly aat Asn cct Pro	Leu gat Asp tat Tyr gcg Ala	aga Arg gat Asp cct Pro 1410 cat	aga Arg ggc Gly 1395 aca Thr	aat Asn 1380 cac His ctt Leu	Asn 1365 tgg Trp aca Thr	Leu  cca Pro  gat Asp  acg Thr	Lys gaa Glu act Thr aaa Lys 1415	4519 4567 4615
aga Arg gag Glu tat Tyr 1400	Asp att Ile tta Leu 1385 gga Gly	Pro atg Met 1370 gtt Val aga Arg	Leu 1355 cac His aat Asn atg Met	His act Thr aaaa Lys agt Ser	Cca Pro tgc Cys tgg Trp 1405	Ala gaa Glu cat His 1390 gat Asp	gga Gly 1375 aaa Lys Lys	Thr 1360 ggg Gly aat Asn cct Pro	Leu gat Asp tat Tyr gcg Ala	aga Arg gat Asp cct Pro 1410 cat	aga Arg ggc Gly 1395 aca Thr	aat Asn 1380 cac His ctt Leu	Asn 1365 tgg Trp aca Thr	Cca Pro gat Asp acg Thr	Lys gaa Glu act Thr aaa Lys 1415	4519 4567 4615

1435

His Arg Ala Ile Ser Ile Arg Glu Ala Ser Arg Leu Gln Thr Phe Pro

wo	00/2	8038												1	PCT/GB	99/03721
	Ser					Gly			a <b>at</b> Asn		Met	-	_			4759
Gly		-	-		Cys	-		-	aga Arg	Leu						4807
ata Ile 1480	Glu		-	Thr		-	-		taga	itata	itg ç	gctaa	aata	ıa		4854
gaac	aaaq	ggc 1	cgaç	getti	g ga			eu G					le A		gt ata ly Ile	4907
Pro					Glu				aat Asn	Ala		-	-			4955
	Asn			Val					aaa Lys					Ile	-	5003
			Gly					Thr	gat Asp 1540			-	G1u			5051
		Ile					Lys		atc Ile			Asp				5099
	Pro					Asn			ttt Phe		Pro		-			5147
Lys					Leu				gca Ala	Ile						5195
				-		-	-		gag		-			-	-	5243

gca ttt gtt aat tgg agt tta ttt gct ata cca tca ctt gat ctt gat 529
Ala Phe Val Asn Trp Ser Leu Phe Ala Ile Pro Ser Leu Asp Leu Asp
1615 1620 1625

gat ata gaa ata cca att aga act att atc aac gac gaa tgc ttc act 5339
Asp Ile Glu Ile Pro Ile Arg Thr Ile Ile Asn Asp Glu Cys Phe Thr
1630 1635

- aaa aac act ctt gat gag atg att gag caa gca aga aat aat tta gac 5387 Lys Lys Thr Leu Asp Glu Met Ile Glu Gln Ala Arg Asn Asn Leu Asp 1645 1650 1655
- tot tta toa cac aaa ata toa aaa toa aaa gta toa caa ata aat aca 5435 Ser Leu Ser His Lys Ile Ser Lys Ser Lys Val Ser Gln Ile Asn Thr 1660 1665 1670
- caa tta tca tct ttt gaa ttt gat cct att cta tgg gaa aaa aaa tta 5483 Gln Leu Ser Phe Glu Phe Asp Pro Ile Leu Trp Glu Lys Lys Leu 1675 1680 1685 1685
- ggt ggg cta aga cta tct gga gat ggg cat gga act cac ttc ata ata 5531 Gly Gly Leu Arg Leu Ser Gly Asp Gly His Gly Thr His Phe Ile 11e 1695 1700 1705
- atg cct acc gaa gaa ata tta ata gat gac att tcc acg agc gat agc 5579 Met Pro Thr Glu Glu Ile Leu Ile Asp Asp Ile Ser Thr Ser Asp Ser 1710 1715 1720
- aat aaa aca tca gag cag tct tct cgc tta gaa aaa gct tta tta ggt 5627 Asn Lys Thr Ser Glu Gln Ser Ser Arg Leu Glu Lys Ala Leu Leu Gly 1725 1730
- ttt aca aac aca atg tac agt gat tca aac cct cct att ata gct cgt 5675

  Phe Thr Asn Thr Met Tyr Ser Asp Ser Asn Pro Pro Ile Ile Ala Arg

  1740 1745 1750
- ttt aga gac tat ctg gaa gat ggt gag tgc att gac aga att agc gaa 5723 Phe Arg Asp Tyr Leu Glu Asp Gly Glu Cys Ile Asp Arg Ile Ser Glu 1755 1760 1765
- tca att ttt ttt aca ccg caa gaa ttc aat ctt gca gat cac cac att 5771 Ser Ile Phe Phe Thr Pro Gln Glu Phe Asn Leu Ala Asp His His Ile 1775 1780 1785
- gaa gga tgg ttc aat gaa ttt ggt caa ttc agt gga act gtt tct gtt 5819 Glu Gly Trp Phe Asn Glu Phe Gly Gln Phe Ser Gly Thr Val Ser Val 1790 • 1795
- tat ggt gaa gag cca att cat cat gtc gtg act tgg aaa aat aat 586°.
  Tyr Gly Glu Glu Pro Ile His His Val Val Thr Trp Lys Asn Asn Asn
  1805 1810 1815

""	00/20	050												r	CI/G	B99/03/2
caa	tta	acc	caa	tgc	ggt	cca	ttt	aaa	ata	aaa	tta	gcg	tat	att	cat	5915
Gln	Leu	Thr	Gln	Cys	Gly	Pro	Phe	Lys	Ile	Lys	Leu	Ala	Tvr	Ile	His	
	1820					1825				-	1830		•			
ggt	cgg	ctt	cgt	gat	tca	cgc	tta	ccc	atg	gag	ttg	tgg	qcc	cct	cta	5963
			Arg													
1835	5				1840					1845		_			1850	
aag	gag	aaa	aca	gat	aga	tat	ggt	ggt	tta	tat	atc	tat	cga	gat	qqa	6011
			Thr													
			:	1855				:	1860	_		_	- :	1865	-	
tta	aga	att	ttg	ccc	tat	gga	gat	tca	gat	acg	gat	ttt	cta	aaa	ata	6059
Leu	Arg	Ile	Leu	Pro	Tyr	Gly	Asp	Ser	Asp	Thr	Asp	Phe	Leu	Lys	Ile	
			1870					1875				:	1880	-		
gaa	aag	aga	aga	acg	tta	tcc	gct	tct	gaa	tat	ttt	ttc	tca	tat	cga	6107
Glu	Lys	Arg	Arg	Thr	Leu	Ser	Ala	Ser	Glu	Tyr	Phe	Phe	Ser	Tyr	Arg	
	1	1885				:	1890					1895		_	-	
cgt	ttg	ttt	gga	gca	ata	gaa	tta	aca	aaa	gaa	aac	aat	gct	tca	tta	6155
Arg	Leu	Phe	Gly	Ala	Ile	Glu	Leu	Thr	Lys	Glu	Asn	Asn	Ala	ser	Leu	
1	1900				:	19 <b>05</b>					1910					
gtt	gaa	aaa	gct	ggg	cga	gaa	gga	ttc	att	gaa	aat	aag	cca	tat	aaa	6203
Val	Glu	Lys	Ala	Gly	Arg	Glu	Gly	Phe	Ile	Glu	Asn	Lys	Pro	Tyr	Lys	
191	5			:	1920				:	1925					1930	
cag	ttt	aaa	gaa	atg	ctt	gaa	aat	ttc	ttc	atc	gaa	atc	gca	aga	gat	6251
Gln	Phe	Lys	Glu	Met	Leu	Glu	Asn	Phe	Phe	Ile	Glu	Ile	Ala	Arg	Asp	
				1935					1940					1945		
ttc	ttt	aag	gac	gat	ggc	gat	atg	tct	gaa	tta	ttt	gtt	gag	aca	aag	6299
Phe	Phe	Lys	Asp	Asp	Gly	Asp	Met	Ser	Glu	Leu	Phe	Val	Glu	Thr	Lys	
			1950				:	1955				:	1960			
caa	cgt	aga	aat	gaa	gaa	cat	gat	ttg	tta	tct	aaa	aga	tct	aaa	caa	6347
Gln	Arg	Arg	Asn	Glu	Glu	His	Asp	Leu	Leu	Ser	Lys	Arg	Ser	Lys	Gln	
		1965				:	1970				:	1975				
			aaa													6395
Thr	Lys	Ala	Lys	Lys	Asp	Ara	Leu	Lvs	Lvs	Asp	Leu	Tur	Asp	Phe	Phe	

gat aag tta gat aat gat tac tgg aat att gaa ata aat aag cta atc 6443 Asp Lys Leu Asp Asn Asp Tyr Trp Asn Ile Glu Ile Asn Lys Leu Ile 1995 2000 2005 2010

1990

1985

														•	CII	
aat	aaa	aac	gag	gaa	tat	ttc	tcc	agt	aca	gaa	ata	aca	gac	acc	aat	6491
Asn	Lys	Asn	Glu	Glu	Tyr	Phe	Ser	Ser	Thr	Glu	Ile	Thr	Asp	Thr	Asn	
			2	2015				2	2020				:	2025		
ata	gat	tat	gta	tac	aat	aaa	att	aaa	gaa	caa	aat	gat	qct	atc	att	6539
	-		-						-			-	-	Ile		
	•	_	2030	-		•		2035				-	2040			
												•				
	+	a+ >	aa+	+	++	~+ ~	~~+	-+-						qtt		6587
			-				-		-					Val		0307
гуя			Arg	ASII	ser		-	TTE	гуу	гÀг			GIY	val	GLY	
		2045				•	2050				•	2055				
									-	_				gaa	-	6635
Leu	Thr	Lys	Glu	Leu	Ser	Asn	Leu	Trp	Asp	Arg	Tyr	Gln	Ile	Glu	Arg	
	2060				:	2065					2070					
caa	aaa	ata	ctg	tta	tca	cta	aat	gag	cta	aaa	gat	aac	gtt	gat	aga	6683
Gln	Lvs	Ile	Leu	Leu	Ser	Leu	Asn	Glu	Leu	Lvs	Asp	Asn	Val	Asp	Ara	
207					2080					2085				-	2090	
									_					•		
220	ctt	a+=	<b>~==</b>	cta	at	a a +	222	+	+	~a+	+++	ata	220	tta		6731
										-				Leu		0731
nys	Leu	116		2095	Asp	Maii	ьуъ			Asp	Pile	Leu			Arg	
			•	2095				•	2100					2105		
											-			gaa		6779
Lys	Arg			Asp	Ser	Leu			Gln	Gln	Ser	-	-	Glu	Lys	
			2110					2115					2120			
gaa	cta	aca	aag	tta	tat	aat	gac	gct	aaa	aat	gct	ttg	aaa	gat	gtg	6827
Glu	Leu	Thr	Lys	Leu	Tyr	Asn	Asp	Ala	Lys	Asn	Ala	Leu	Lys	Asp	Val	
		2125					2130					2135				
caa	tct	aaa	qca	aat	agg	tta	att	tct	gat	aat	aaσ	aaa	aaa	cat	aag	6875
									-		-			His		
	2140	Lys	ALU	7.511		2145	116	Der	лор		2150	Буз	Буз	urs	Буз	
	2140					2145					2130					
-	-													ctc		6923
		Leu	Lys			Ser	Tyr	Glu			Ser	Thr	Asn	Leu		
215	5				2160					2165					2170	
ggc	aaa	gat	act	gcg	tat	ata	ttg	gat	gta	aaa	aga	aat	cta	gaa	agt	6971
Gly	Lys	Asp	Thr	Ala	Tyr	Ile	Leu	Asp	Val	Lys	Arg	Asn	Leu	Glu	Ser	
				2175					2180					2105		

aaa att gag aat act tca aac gaa gtg att aat gaa ata aga aaa cta 7019 Lys Ile Glu Asn Thr Ser Asn Glu Val Ile Asn Glu Ile Arg Lys Leu 2190 2195 2200 WO 00/28038 PCT/GB99/03721

acc gac cag att gca ata att agt gat agt acc act tct gaa aat tta 7067

Thr Asp Gln Ile Ala Ile Ile Ser Asp Ser Thr Thr Ser Glu Asn Leu 2205 2210 2215

tca tcg gct caa gta act gaa gca atc gaa ctt gaa cat tta 711 Ser Ser Ala Gln Val Thr Glu Ala Ile Glu Thr Glu Leu Glu His Leu 2220 2225 2230

cga gac caa caa gca aat aac gca gag tta ata cta ctt ggc atg gct 716
Arg Asp Gln Gln Ala Asn Asn Ala Glu Leu Ile Leu Leu Gly Met Ala
2235 2240 2245 2250

ctt tot gta gta cat cat gaa ttt aat ggt aat att agg gca att aga 7211 Leu Ser Val Val His His Glu Phe Asn Gly Asn Ile Arg Ala Ile Arg 2255 2260 2265

agt gcg cta agg gaa tta aaa gca tgg gct gac aga aat cct aag ctt 7259 Ser Ala Leu Arg Glu Leu Lys Ala Trp Ala Asp Arg Asn Pro Lys Leu 2270 2275 2280

gat att ata tac caa aaa atc aga act agt ttt gat cac tta gat ggt 7307 Asp Ile Ile Tyr Gln Lys Ile Arg Thr Ser Phe Asp His Leu Asp Gly 2285 2290 2295

tat tta aaa acc ttt aca cca ttg aca aga cgt tta agt cgc tct aaa 7355 Tyr Leu Lys Thr Phe Thr Pro Leu Thr Arg Arg Leu Ser Arg Ser Lys 2300 2305 2310

acc aat ata act gga act gcc att tta gaa ttt atc aga gat gta ttc 7403 Thr Asn Ile Thr Gly Thr Ala Ile Leu Glu Phe Ile Arg Asp Val Phe 2315 2320 2325 2330

gat gat cgt ctt gag aaa gaa gga att gaa tta ttc act acc tca aag 7451 Asp Asp Arg Leu Glu Lys Glu Gly Ile Glu Leu Phe Thr Thr Ser Lys 2335 2340 2345

ttt gtt aat caa gaa att gta act tac aca tca acc att tac cct gtc 7499
Phe Val Asn Gln Glu Ile Val Thr Tyr Thr Ser Thr Ile Tyr Pro Val
2350 2355 2360

ttt ata aat cta att gat aac gca ata tac tgg ctt ggg aaa aca act 7547 Phe Ile Asn Leu Ile Asp Asn Ala Ile Tyr Trp Leu Gly Lys Thr Thr 2365 2370 2375

gga gaa aaa aga ctt ata ctt gat gct act gaa aca gga ttt gtt att 7599 Gly Glu Lys Arg Leu Ile Leu Asp Ala Thr Glu Thr Gly Phe Val Ile 2380 2385 2390

WO 00/28038 PCT/GB99/03721 ggt gat act ggt ccc ggt gtt tca act aga gat ega gat ata ata ttt Gly Asp Thr Gly Pro Gly Val Ser Thr Arg Asp Arg Asp Ile Ile Phe 2395 gat atg gga ttt aca cga aaa aca gga ggg cgt gga atg gga tta ttc Asp Met Gly Phe Thr Arg Lys Thr Gly Gly Arg Gly Met Gly Leu Phe 2415 2425 att tcc aaa gag tqt tta tct cqa qat gga ttt act ata aga ttg gat Ile Ser Lys Glu Cys Leu Ser Arg Asp Gly Phe Thr Ile Arg Leu Asp 2430 2435 gat tac act cct gaa cag ggt gct ttc ttt att att gag cca tca gaa 7787 Asp Tyr Thr Pro Glu Gln Gly Ala Phe Phe Ile Ile Glu Pro Ser Glu 2445 2450 gaa aca agt gaa tag cggatataaa taa atg aca agc tct act gat ttt 7836 Glu Thr Ser Glu Met Thr Ser Ser Thr Asp Phe 2460 2465 2470 cat aaa ctt tct gaa gac tgc gtt cgc cgt ttt tta cat tct gta gtt His Lys Leu Ser Glu Asp Cys Val Arg Arg Phe Leu His Ser Val Val 2475 2480 gct gta gat gac aat atg tct ttt gga gct ggt agt gat act ttc cct Ala Val Asp Asp Asn Met Ser Phe Gly Ala Gly Ser Asp Thr Phe Pro 2490 2495 2500 aca gac gaa gat att aat get tta gtt gat eec gac gat gat eet aca Thr Asp Glu Asp Ile Asn Ala Leu Val Asp Pro Asp Asp Pro Thr 2505 2510 2515 cca ata ata aca gca tca gca tcc cca agg ata gaa tca act aaa tca 8028 Pro Ile Ile Thr Ala Ser Ala Ser Pro Arg Ile Glu Ser Thr Lys Ser 2520 2525 aaa qca aaq qta aaa aac cat cct ttt qat tac caa qct cta qca qaa

aaa gca aag gta aaa aac cat cct ttt gat tac caa gct cta gca gaa 807 Lys Ala Lys Val Lys Asn His Pro Phe Asp Tyr Gln Ala Leu Ala Glu 2535 2540 2550

gct ttc gcc aaa gat ggt att gct tgt tgc gga tta tta gct aag agt 8124 Ala Phe Ala Lys Asp Gly Ile Ala Cys Cys Gly Leu Leu Ala Lys Ser 2555 . 2560 2565

ttt aat gtt gaa gaa aga gat ata att aca gca tca tcc cac aag gca 8172 Phe Asn Val Glu Glu Arg Asp Ile Ile Thr Ala Ser Ser His Lys Ala 2570 2580

gat ata aca at					8220
Asp Ile Thr Il 2585	e Leu Asp II	-	•	GIY GIN Phe	
2585		2590	2595		
gct att gaa at	a ata aaa tc	g ata atc gtt	tca gat ata	aat tot gga	8268
Ala Ile Glu Il					0208
2600	260		2610	ber ory	
gga cgt tta cg	t ctt ctt tc	t att tat act	ggt gaa cat	gtt act gct	8316
Gly Arg Leu Ar	g Leu Leu Se	r Ile Tyr Thr	Gly Glu His	Val Thr Ala	
2615	2620		2625	2630	
gtt ata act aa					8364
Val Ile Thr Ly		n Glu Leu Lys	Lys Thr Tyr	Arg Ser Val	
	2635	2640		2645	
ata aaa aat «a	t ast sat st				
ata aaa aat ga Ile Lys Asn As					8412
265		2655		Ala Leu Glu 2660	
		2033	•	2000	
caa tgg tgt at	a gtt gtt at	t agt aaa gac	gtt tat gaa	aaa gat ctt	8460
Gln Trp Cys Il					
2665		2670	2675		
cca aat gtg tt					8508
Pro Asn Val Le	u Ile Lys Ly	s Phe Thr Asn	Leu Thr Ala	Gly Leu Leu	
2680	268	5	2690		
taa					
tcc aac gcc gc Ser Asn Ala Al					8556
2695	2700		-	-	
2033	2700		2705	2710	
ggg ata tta ac	a aaa tat aa	t aat aaa tta	gac act gca	tat gtt tcc	8604
Gly Ile Leu Th					
	2715	2720	•	2725	
cac atc tta aa	t tta ata aa	a tcc aag gag	tca agg gca	tat gct tat	8652
His Ile Leu As	n Leu Ile Ly	s Ser Lys Glu	Ser Arg Ala	Tyr Ala Tyr	
273	0	2735	:	2740	
gaa aat gct ca					8700
Glu Asn Ala Hi	s Asp Tyr Al			Glu Ile Arg	
2745		2750	2755		
tca ata ttg ca	a ata agt ga	a aac tta aac	222 tot oto	300 333 5	0740
Ser Ile Leu Gl					8748

tcc tta tcc cat tgg cct att ttt cac tat gca aaa aat ggt tgt aag Ser Leu Ser His Trp Pro Ile Phe His Tyr Ala Lys Asn Gly Cys Lys aat ttt cta tta act gga aaa aaa caa aaa gac tta tca gta gaa cat Asn Phe Leu Leu Thr Gly Lys Lys Gln Lys Asp Leu Ser Val Glu His cta agg aat ata ctc tct gct gat tct tta gaa gaa att caa cac gct Leu Arg Asn Ile Leu Ser Ala Asp Ser Leu Glu Glu Ile Gln His Ala att gaa cac gca tct tta ggt aaa aag gaa tac tta agc caa gat ggt Ile Glu His Ala Ser Leu Gly Lys Lys Glu Tyr Leu Ser Gln Asp Gly gaa gaa gat aaa aag tta atg caa tta tgc tct ctg gaa atc acg cgc Glu Glu Asp Lys Lys Leu Met Gln Leu Cys Ser Leu Glu Ile Thr Arg agg agt tta aga tat cat tct cat ata gat aat gtg tcc tta aaa caa Arg Ser Leu Arg Tyr His Ser His Ile Asp Asn Val Ser Leu Lvs Gln gga act tta ctt tta gat gca tat aat ttt gtc tat cta tgc ata caa Gly Thr Leu Leu Asp Ala Tyr Asn Phe Val Tyr Leu Cys Ile Gln cca tta tgt gat agc gtc aga ttg cat gaa aaa gcc gat ttt tta ttc Pro Leu Cys Asp Ser Val Arg Leu His Glu Lvs Ala Asp Phe Leu Phe ctc agg gga aca ctg gac gat aat aat tac aat ttg tta atc gaa gat Leu Arg Gly Thr Leu Asp Asp Asn Asn Tyr Asn Leu Leu Ile Glu Asp gaa tat ggc ggt ttt tat aaa att aaa atg ccg gca aaa gct tct aat Glu Tyr Gly Gly Phe Tyr Lys Ile Lys Met Pro Ala Lys Ala Ser Asn 2925 -att att tca ttt tca ttt gga gtc gaa aat gga aac ggt gtc atc ata Ile Ile Ser Phe Ser Phe Gly Val Glu Asn Gly Asn Gly Val Ile Ile 

ggg aaa aag aac aat cta gtt aat act gac tat atc tca ttc gtt cct Gly Lys Lys Asn Asn Leu Val Asn Thr Asp Tyr Ile Ser Phe Val Pro

WO 00/28038 PCT/GB9	9/03721
tta ctc gtt gaa aaa ata tct act cca aaa gta ttg aaa tgg atc ggg Leu Leu Val Glu Lys Ile Ser Thr Pro Lys Val Leu Lys Trp Ile Gly	9372
2970 2975 2980	
gaa ata aaa aca acg tac gcg caa aaa ata aca act gat att gtt gct	9420
Glu Ile Lys Thr Thr Tyr Ala Gln Lys Ile Thr Thr Asp Ile Val Ala 2985 2990 2995	
aat ctg tca aga ata ggt tta gat caa cat gag tgg tta cga ata aaa	9468
Asn Leu Ser Arg Ile Gly Leu Asp Gln His Glu Trp Leu Arg Ile Lys 3000 3005 3010	
tca aaa gat ata taaatgatta tatatgccgt cgttttataa aaactggcgg	9520
Ser Lys Asp Tle 3015	
catgtatate tagttagtcc atcatagaag tcaagaaatt tagtttgccc tatatettat	9580
agaaaatata ttttatatgc ttaaaaaaca ccatctttct aagatggcat ttatgtgctt	9640
tgtttcgatc aattacaact gatatattac catattgatt aattttatgt tatttaccaa	9700
agtaacggca tottaatata togtoataat atagtgcgcg ttotgactot aatactgaaa	9760
aatttatttg ttotatttta cacttactgc aaatagcatc cagtttatca tatagtgtcg	9820
catcaattgg cgcag atg tca tca cgc caa atc ctt gag cat tat aat gct Met Ser Ser Arg Gln Ile Leu Glu His Tyr Asn Ala 3020 3025 3030	9871
cta aca tat ccc cta cat caa tca atc ttg ttg cag ata atg act tcg	9919
Leu Thr Tyr Pro Leu His Gln Ser Ile Leu Leu Gln Ile Met Thr Ser 3035 3040 3045	
aat ttg tta tca gtt tgc act gga aaa tcc att tac gag gat atc tcc	9 <b>967</b>
Asn Leu Leu Ser Val Cys Thr Gly Lys Ser Ile Tyr Glu Asp Ile Ser 3050 3055 3060	
ggc agt tot tgg aat atc ata cac ttc aat atc cot ctc ccc atc tct	10015
Gly Ser Ser Trp Asn Ile Ile His Phe Asn Ile Pro Leu Pro Ile Ser 3065 3070 3075	
aga gcg aga ctt tcc ata ttt tct tat tgt gtc aga att aaa cct tgg	10063
Arg Ala Arg Leu Ser Ile Phe Ser Tyr Cys Val Arg Ile Lys Pro Trp 3080 3090	
atg agt atg gat tac atg taaccggctc atttaaaccg tetggtetgt	10111

Met Ser Met Asp Tyr Met

3095	3100				
ttcctccggt t		-		gga cac tat cgt Gly His Tyr Arg 3110	10163
		le Thr Glu		ctt cac ttt gaa Leu His Phe Glu 3125	10211
Glu His Leu				ggc gta cca aaa Gly Val Pro Lys 3140	10259
			Phe Arg Lys	gct ggc ttt tca Ala Gly Phe Ser 155	10307
	Pro Ala Gly M			gat ggc cgt ctt Asp Gly Arg Leu	10355
				agt gga tcg gta Ser Gly Ser Val 3190	10403
	acc tcg aaa t Thr Ser Lys s 3195		tgttaaa acagt	gaaaa tgaggtgatg	10457
				c ccg gag ttc aag r Pro Glu Phe Lys .0	
				cgt gat gtc aga Arg Asp Val Arg 3230	10554
		Glu Leu Asn		ttg cgt aaa tgg Leu Arg Lys Trp 3245	10602
Ile Arg Leu				cca gct ggt aat Pro Ala Gly Asn 3260	10650
gct att acc	cct gaa caa d	cgc gaa att	cag cag ctt	aaa gcg cag ata	10698

Ala Ile Thr Pro Glu Gln Arg Glu Ile Gln Gln Leu Lys Ala Gln Ile

3270

3275

aag ogc gtt gag atg gaa aaa gaa ata cta aag cag got goc gtg ctg 1074: Lys Arg Val Glu Met Glu Lys Glu Ile Leu Lys Gln Ala Ala Val Leu 3280 3285

atg agc gaa atc ccc ggg aag ctg tcg cgc taatcacaca gctgaaagca 10796 Met Ser Glu Ile Pro Gly Lys Leu Ser Arg 3295 3300

aagtggccag tgtgggttat ttgtcattta ttcggtatta accgtagcgt ttattacgcg 10856
caggtgaagc gtcctgttaa tgtgcaaaga attgaattac gaagccgggt gagggctttc 10916
catgctctca gtcgtggcgc agccgggtag ccgggcaatc agtcagatgt tgcgccagag 10976
tggcgttgat gcaggccggt ggctggcatg acgactgatg cgggaatgag ggctgacaag 11036
tcgacagccg gttaaacatc acaaccgggt aaacgaagac aaaagtccgc cattgccaaa 11096
tttactgaac cggcaatttc accccgccgc accaaactgc gtctggtgcg gcgacatcag 11156
ttttattcg

<210> 35

0

E HOOD

. 57153

<211> 366

<212> PRT

<213> Escherichia coli

<400> 35

Ser Asp Met Gln Arg Gly Ile Gln Ala Ala Thr Ala Ala Leu Gln Gly 1 5 10 15

Leu Val Gly Gly Asn Met Ala Gly Ala Leu Ala Gly Ala Ser Ala Pro  $20 \hspace{1.5cm} 25 \hspace{1.5cm} 30$ 

Glu Leu Ala Asn Ile Ile Gly His His Ala Gly Ile Asp Asn Thr  $35 \hspace{1cm} 40 \hspace{1cm} 45$ 

Ala Ala Lys Ala Ile Ala His Ala Ile Leu Gly Gly Val Thr Ala Ala 50 55 60

Leu Gln Gly Asn Ser Ala Ala Gly Ala Ile Gly Ala Gly Thr Gly 65 70 75 80

Glu Val Ile Ala Ser Ala Ile Ala Lys Ser Leu Tyr Pro Gly Val Asp 85 90 95

Pro Ser Lys Leu Thr Glu Asp Gln Lys Gln Thr Val Ser Thr Leu Ala

- Thr Leu Ser Ala Gly Met Ala Gly Gly Ile Ala Ser Gly Asp Val Ala 115 120 125
- Gly Ala Ala Ala Gly Ala Gly Ala Gly Lys Asn Val Val Glu Asn Asn 130 \$135\$ 140
- Thr Lys Val Ala Glu Gln Leu Leu Glu Ile Gly Ala Lys Ala Gly Met 165 170 175
- Ala Gly Leu Ala Gly Ala Ala Val Lys Asp Met Ala Asp Arg Met Thr  $180 \hspace{1cm} 185 \hspace{1cm} 190$
- Ser Asp Glu Leu Glu His Leu Ile Thr Leu Gln Met Met Gly Asn Asp 195 200 205
- Glu Ile Thr Thr Lys Tyr Leu Ser Ser Leu His Asp Lys Tyr Gly Ser 210 215 220
- Gly Ala Ala Ser Asn Pro Asn Ile Gly Lys Asp Leu Thr Asp Ala Glu 225 230 235 240
- Lys Val Glu Leu Gly Gly Ser Gly Ser Gly Thr Gly Thr Pro Pro Pro 245 \$250\$
- Ser Glu Asn Asp Pro Lys Gln Gln Asn Glu Lys Thr Val Asp Lys Leu 260 265 270
- Asn Gln Lys Gln Glu Ser Ala Ile Lys Lys Ile Asp Asn Thr Ile Lys 275 280 285
- Asn Ala Leu Lys Asp His Asp Ile Ile Gly Thr Leu Lys Asp Met Asp 290 295 300
- Gly Lys Pro Val Pro Lys Glu Asn Gly Gly Tyr Trp Asp His Met Gln 305 310 315 320
- Glu Met Gln Asn Thr Leu Arg Gly Leu Arg Asn His Ala Asp Thr Leu 325 330 335
- Lys Asn Val Asn Asn Pro Glu Ala Gln Ala Ala Tyr Gly Arg Ala Thr \$340\$ \$345\$ \$350

Asp Ala Ile Asn Lys Ile Glu Ser Ala Leu Lys Gly Tyr Gly
355 360 365

<210> 36

<211> 128

<212> PRT

<213> Escherichia coli

<400> 36

Met Ile Thr Leu Arg Lys Leu Ile Gly Asn Ile Asn Met Thr Lys Glu  $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$ 

Pro Glu Gln Gln Ser Pro Leu Glu Leu Trp Phe Glu Arg Ile Ile Asp  $20 \hspace{1.5cm} 25 \hspace{1.5cm} 30$ 

Val Pro Leu Glu Lys Leu Thr Val Glu Asp Leu Cys Arg Ala Ile Arg 35 40 45

Gln Asn Leu Cys Ile Asp Gln Leu Met Pro Arg Val Leu Glu Val Leu
50 55 60

Thr Lys Glu Pro Leu Ala Gly Glu Tyr Tyr Asp Gly Glu Leu Ile Ala 65 70 75 80

Ala Leu Ser Thr Ile Lys Gly Glu Asp Leu Lys Asp Gln Lys Ser Thr 85 90 95

Phe Thr Gln Ile Arg Gln Leu Ile Asn Gln Leu Glu Pro Ser Asp Ile 100 105 110

Asn Asp Asp Leu Arg Lys Asp Ile Leu Lys Ile Asn Gln Ile Ile Val 115 120 125

<210> 37

<211> 107

<212> PRT

<213> Escherichia coli

<400× 33

Met Val Ala Lys Ala Phe Ala Tyr Ala Leu Asn Gln Trp Pro Ala Leu  $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$ 

Thr Tyr Tyr Ala Asn Asp Gly Trp Val Glu Ile Asp Asn Asn Ile Ala
20 25 30

Glu Asn Ala Leu Arg Ala Val Ser Leu Gly Arg Lys Asn Phe Leu Phe 35 40 45

Phe Gly Ser Asp His Gly Gly Glu Arg Gly Ala Leu Leu Tyr Ser Leu 50 60

Ile Gly Thr Cys Lys Leu Asn Asp Val Asp Pro Glu Ser Tyr Leu Arg 65 70 75 80

His Val Leu Ala Val Ile Ala Asp Trp Pro Val Asn Arg Val Ser Glu 85 90 95

Leu Leu Pro Trp Arg Ile Ala Leu Pro Ala Glu

<210> 38

<211> 86

<212> PRT

<213> Escherichia coli

<400> 38

Met Leu Met Ser Val Gln Lys Glu Lys Asn Val Ala Glu Ser Val Val
1 5 10 15

Ser Glu Thr His Thr Gly Asp Ser Val Tyr Ala Ser Leu Phe Glu Lys 20 25 30

Ile Asn Leu Asn Pro Val Ser Ala Leu Ser Ala Leu Asp Asn Pro Phe 35 40 45

Arg Ser Ala Asp Asn Ala Thr Gly Arg Ile Thr Ser Ser Ile Gln Pro 50 55 60

Ala Val Gln Cys Ala Ala Ala Ala Ala Thr Glu Gly Ser Cys Pro Arg 65 70 75 80

Gln Ser Pro Cys Ser Gly

<210> 39

<211> 111

<212> PRT

<213> Escherichia coli

<400> 39

Met Val Asp Asn Trp Gln Lys Ser Val Arg Ser Arg Ala Leu Pro Glu

15

Glu Ala Met Thr Gly Trp Asn Glu Gly Met Ile Arg Leu Gln Gln Leu 20 25 30

Ala Glu Arg Leu Asn Arg Gln Asp Glu Gln Arg Gly Lys Tyr Met Thr  $35 \hspace{1cm} 40 \hspace{1cm} 45 \hspace{1cm}$ 

Val Ser Glu Leu Lys Thr Glu Val Phe Gly Ile Met Gln Ala Phe Asn 50 60

Arg His Ile Pro Ala Glu Glu Gln Leu Arg Arg Tyr Gly Glu Val Arg 65 70 75 80

As Gln As Gly Ser Glu Gln Gln Gln Lys Gln Ala Glu Met Ala Leu 85 90 95

As nGln Leu Ile As Arg Tyr Gln Met Ile Arg Ala Gly Lys Gln 100 105 110

<210> 40

STRUKT

No. of Sun Sun

n

1

<211> 143

<212> PRT

<213> Escherichia coli

<400> 40

Met Val Gly Cys Ala Trp Leu Ala Glu Gln Ala Phe Ser Asp His Ala 1 5 10 15

Leu Ser Pro His Ser Ala Trp Pro Tyr Ser Ala Ser Arg Asp Ala Gly
20 25 30

Leu Ala Asp Thr Gly Ala Gly Gly Tyr Pro Thr Cys Lys Gln Arg Trp 35 40 45

Ala Asp Asp Thr Val Gly Leu Lys Ala Arg Leu Leu Gln Leu Pro Ala 50 60

Leu Asp Ile Trp Thr Ala Phe Lys Lys Ile Asp Gln Ser Gln Val Val 65 70 75 80

Tyr Glu Glu Ala Val Leu Arg Ser Arg Val Ser Glu Arg Asn Met Gln

Val Ser Gln Asn Gly Arg Val Tyr Pro Ser Tyr Gly Gly Asn Val Asp 100 105 110

Gly Thr Val Ala Asn Ala Ala Thr Arg Leu Ala Ser Gly Ala Arg Asn 115 120 125

Ile Leu Gly Ser Ile Ala Ala Cys Thr Ala Phe Asp Ser Val Arg 130 135 140

<210> 41

<211> 118

<212> PRT

<213> Escherichia coli

<400> 41

Met Val Gln Ala Gln Leu Gln Ile Ala Leu Val Ile Cys Ile Pro Leu

1 5 10 15

Ile Thr Leu Cys Ser Ala Trp Asp Val Lys Val Val Met Thr Leu Thr
20 25 30

Phe Val Gln Phe Ala Leu Phe Phe Leu Thr Phe Trp Trp Glu Leu Ala 35 40 45

Arg Trp Leu Asp Ser Trp Leu Leu Asp Val Leu Tyr Asn Ser Asp Thr 50 55 60

His Ser Ser Trp Asn Leu Ala Gly Ile Gln Asn Thr Gln Asp Asp Val 65 70 75 80

Ile Ile Asn Leu Val Met Arg Leu Met Phe Leu Val Leu Pro Thr Phe 85 90 95

Trp Leu Gly Ala Met Thr Trp Ala Gly Val Arg Val Gly Val Ala Leu 100 105 110

Asn Gly Ala Leu Ala Gly 115

<210> 42

<211> 81

<212> PRT

<213> Escherichia coli

<400> 42

Met Lys Tyr Leu Phe Phe Glu Asn Ile His Ser Ile Phe Leu Thr Phe  $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ 

Ser Leu Phe Arg Thr Ser Val Ser Pro Asp Phe Pro Met Ile Phe Ala

140

20 25 30

Leu Pro Ser Ile Ile Leu Gly Gln Phe Thr Thr Asn Gln Leu Thr Asn 35 40 45

Phe Val Ile Cys Met Gly Asn Thr Val Glu Arg Arg Leu Gly Val Val 50 55 60

His Asn Pro Phe Lys Arg Ser Gly Asp Gly His Asp Leu Arg Ala Val 65 70 75 80

Ala

<210> 43

<211> 348

<212> PRT

<213> Escherichia coli

<400> 43

Leu Ile Val Ile Asp Phe Phe Cys Gly Cys Gly Gly Ala Ser Glu Gly

1 5 10 15

Leu Arg Gln Ala Gly Phe Asp Ile Glu Leu Gly Leu Asp Ile Asp Gln
20 25 30

Gln Ala Ser Glu Thr Phe Lys Ala Asn Phe Pro Asp Ala Lys Phe Ile 35 40 45

Gln Asp Asp Ile Arg Lys Ile Glu Pro Gln Asp Ile Ser Asp Ile Ile 50 60

Asp Ile Lys Ala Lys Arg Pro Leu Leu Ser Ala Cys Ala Pro Cys 65 70 75 80

Gln Pro Phe Ser Gln Gln Asn Lys Asn Lys Thr Ser Asp Asp Ser Arg 85 90 95

Arg Asn Leu Leu Asn Glu Thr His Arg Phe Ile Arg Glu Leu Leu Pro

Glu Tyr Ile Met Leu Glu Asn Val Pro Gly Met Gln Lys Ile Asp Glu 115 120 125

Glu Lys Glu Gly Pro Phe Gln Glu Phe Ile Lys Leu Leu Lys Glu Leu 130 135 140

Glu Tyr Asn Tyr Ile Ser Phe Ile Ala Asn Ala Glu Asn Tyr Gly Ile

Fro Gln Arg Arg Lys Arg Leu Val Leu Leu Ala Ser Arg Val Gly Lys 165 \$170\$

Val Thr Leu Pro Glu Ile Thr His Gly Lys Asn Lys Ile Pro Phe Lys 180 185 190

Thr Val Arg Asp Tyr Ile Gln Asp Phe Thr Lys Leu Cys Ser Gly Glu 195 200 205

Thr Asp Pro Lys Asp Pro Leu His Arg Ala Gly Thr Leu Ser Pro Leu 210 215 220

Asn Leu Lys Arg Ile Met His Thr Pro Glu Gly Gly Asp Arg Arg Asn 225 230 235

Trp Pro Glu Glu Leu Val Asn Lys Cys His Lys Asn Tyr Asp Gly His 245 250 255

Thr Asp Thr Tyr Gly Arg Met Ser Trp Asp Lys Pro Ala Pro Thr Leu 260 265 270

Thr Thr Lys Cys Asn Ser Tyr Ser Asn Gly Arg Phe Gly His Pro Asp 275 280 285

Pro Thr Gln His Arg Ala Ile Ser Ile Arg Glu Ala Ser Arg Leu Gln 290 295 300

Thr Phe Pro Leu Ser Tyr Val Phe Lys Gly Ser Leu Asn Ser Met Ala 305 310 315 320

Lys Gln Ile Gly Asn Ala Val Pro Cys Glu Leu Ala Arg Leu Phe Gly 325 330 335

Leu His Leu Ile Glu Asn Cys Thr Asn Lys Asp Ser 340 345

<210> 44

DOSTORDA

Į.di

<211> 974

<212> PRT

<213> Escherichia coli

<400> 44

Met Leu Gly Arg Gln Gln Ile Ala Gly Ile Pro Thr Ala Leu Ser Glu

1 5 10 15

Leu Phe Lys Asn Ala His Asp Ala Tyr Ala Asp Asn Val Glu Val Asp
20 25 30

- Phe Phe Arg Lys Glu Asn Leu Leu Ile Leu Arg Asp Asp Gly Leu Gly 35 40 45
- Met Thr Thr Asp Glu Phe Glu Glu Arg Trp Leu Thr Ile Gly Thr Ser  $50 \hspace{1cm} 55$
- Ser Lys Leu Ile Asp Asp Asp Ala Ile Asn Lys Pro Ala Val Asp Ser 65 70 75 80
- Asn Lys Ala Phe Arg Pro Ile Met Gly Glu Lys Gly Ile Gly Arg Leu  $85 \hspace{1.5cm} 90 \hspace{1.5cm} 95$
- Ser Ile Ala Ala Ile Gly Pro Gln Val Leu Val Leu Thr Arg Ala Lys  $100 \hspace{1.5cm} 105 \hspace{1.5cm} 110$
- Arg Asp Asn Glu Leu Lys Pro Leu Val Ala Ala Phe Val Asn Trp Ser 115 120 125
- Leu Phe Ala Ile Pro Ser Leu Asp Leu Asp Asp Ile Glu Ile Pro Ile 130 135 140
- Arg Thr Ile Ile Asn Asp Glu Cys Phe Thr Lys Lys Thr Leu Asp Glu
  145 150 155 160
- Met Ile Glu Gln Ala Arg Asn Asn Leu Asp Ser Leu Ser His Lys Ile 165 170 175
- Ser Lys Ser Lys Val Ser Gln Ile Asn Thr Gln Leu Ser Ser Phe Glu 180 185 190
- Phe Asp Pro Ile Leu Trp Glu Lys Lys Leu Gly Gly Leu Arg Leu Ser 195 200 205
- Gly Asp Gly His Gly Thr His Phe Ile Ile Met Pro Thr Glu Glu Ile 210 215 220
- Leu Ile Asp Asp Ile Ser Thr Ser Asp Ser Asn Lys Thr Ser Glu Gln 225 230 235 240
- Ser Ser Arg Leu Glu Lys Ala Leu Leu Gly Phe Thr Asn Thr Met Tyr 245 250 255
- Ser Asp Ser Asn Pro Pro Ile Ile Ala Arg Phe Arg Asp Tyr Leu Glu 260 265 270

Asp Gly Glu Cys Ile Asp Arg Ile Ser Glu Ser Ile Phe Phe Thr Pro 275 280 285

- Gln Glu Phe Asn Leu Ala Asp His His Ile Glu Gly Trp Phe Asn Glu 290 295 300
- Phe Gly Gln Phe Ser Gly Thr Val Ser Val Tyr Gly Glu Glu Pro Ile 305 310 315 320
- His His Val Val Thr Trp Lys Asn Asn Gln Leu Thr Gln Cys Gly 325 330 335
- Pro Phe Lys Ile Lys Leu Ala Tyr Ile His Gly Arg Leu Arg Asp ser  $340 \hspace{1.5cm} 345 \hspace{1.5cm} 350$
- Arg Leu Pro Met Glu Leu Trp Ala Pro Leu Lys Glu Lys Thr Asp Arg 355 360 365
- Tyr Gly Gly Leu Tyr Ile Tyr Arg Asp Gly Leu Arg Ile Leu Pro Tyr 370 380
- Gly Asp Ser Asp Thr Asp Phe Leu Lys Ile Glu Lys Arg Arg Thr Leu 385 390 395 400
- Ser Ala Ser Glu Tyr Phe Phe Ser Tyr Arg Arg Leu Phe Gly Ala Ile 405 410 415
- Glu Leu Thr Lys Glu Asn Asn Ala Ser Leu Val Glu Lys Ala Gly Arg
  420 425 430
- Glu Gly Phe Ile Glu Asn Lys Pro Tyr Lys Gln Phe Lys Glu Met Leu 435 440 445
- Asp Met Ser Glu Leu Phe Val Glu Thr Lys Gln Arg Arg Asn Glu Glu 465 470 475 480
- His Asp Leu Leu Ser Lys Arg Ser Lys Gln Thr Lys Ala Lys Lys Asp 485 490 495
- Arg Leu Lys Lys Asp Leu Tyr Asp Phe Phe Asp Lys Leu Asp Asn Asp 500 505
- Tyr Trp Asn Ile Glu Ile Asn Lys Leu Ile Asn Lys Asn Glu Glu Tyr 515 520 525

Phe Ser Ser Thr Glu Ile Thr Asp Thr Asn Ile Asp Tyr Val Tyr Asn 530 535 540

- Lys Ile Lys Glu Gln Asn Asp Ala Ile Ile Lys Asn Leu Arg Asn ser 545 550 555 560
- Val Asp Ile Lys Lys Pro Ser Gly Val Gly Leu Thr Lys Glu Leu Ser 565 570 575
- Asn Leu Trp Asp Arg Tyr Gln Ile Glu Arg Gln Lys Ile Leu Leu Ser 580 585 590
- Leu Asn Glu Leu Lys Asp Asn Val Asp Arg Lys Leu Ile Glu Leu Asp 595 600 605
- Asn Lys Asn Asn Asp Phe Leu Asn Leu Arg Lys Arg Leu Glu Asp Ser 610 615 620
- Leu Asn Leu Gln Gln Ser Tyr Tyr Glu Lys Glu Leu Thr Lys Leu Tyr 625 630 635 640
- Asn Asp Ala Lys Asn Ala Leu Lys Asp Val Gln Ser Lys Ala Asn Arg 645 650 655
- Leu Ile Ser Asp Asn Lys Lys Lys His Lys Ser Glu Leu Lys Asn Ile 660 665 670
- Ser Tyr Glu Phe Gln Ser Thr Asn Leu Asn Gly Lys Asp Thr Ala Tyr 675 680 685
- Ile Leu Asp Val Lys Arg Asn Leu Glu Ser Lys Ile Glu Asn Thr Ser 690 695 700
- Asn Glu Val Ile Asn Glu Ile Arg Lys Leu Thr Asp Gln Ile Ala Ile 705 710 715 720
- Ile Ser Asp Ser Thr Thr Ser Glu Asn Leu Ser Ser Ala Gln Val Thr 725  $\phantom{\bigg|}730\phantom{\bigg|}730\phantom{\bigg|}735\phantom{\bigg|}$
- Glu Ala Ile Glu Thr Glu Leu Glu His Leu Arg Asp Gln Gln Ala Asn 740 745 750
- Asn Ala Glu Leu Ile Leu Leu Gly Met Ala Leu Ser Val Val His His 755 760 765
- Glu Phe Asn Gly Asn Ile Arg Ala Ile Arg Ser Ala Leu Arg Glu Leu 770 780

Lys Ala Trp Ala Asp Arg Asn Pro Lys Leu Asp Ile Ile Tyr Gln Lys 785 790 795 800

Ile Arg Thr Ser Phe Asp His Leu Asp Gly Tyr Leu Lys Thr Phe Thr 805 810 815

Pro Leu Thr Arg Arg Leu Ser Arg Ser Lys Thr Asn Ile Thr Gly Thr 820 825 830

Ala Ile Leu Glu Phe Ile Arg Asp Val Phe Asp Asp Arg Leu Glu Lys 835 840 845

Glu Gly Ile Glu Leu Phe Thr Thr Ser Lys Phe Val Asn Gln Glu Ile 850 \$850\$

Val Thr Tyr Thr Ser Thr Ile Tyr Pro Val Phe Ile Asn Leu Ile Asp 865 870 875 880

Asn Ala Ile Tyr Trp Leu Gly Lys Thr Thr Gly Glu Lys Arg Leu Ile 885 890 895

Leu Asp Ala Thr Glu Thr Gly Phe Val Ile Gly Asp Thr Gly Pro Gly 900 905 910

Val Ser Thr Arg Asp Arg Asp Ile Ile Phe Asp Met Gly Phe Thr Arg 915 920 925

Lys Thr Gly Gly Arg Gly Met Gly Leu Phe Ile Ser Lys Glu Cys Leu 930 935

 Ser Arg Asp Gly Phe Thr Ile Arg Leu Asp Asp Tyr Thr Pro Glu Gln

 945
 950
 955
 960

Gly Ala Phe Phe Ile Ile Glu Pro Ser Glu Glu Thr Ser Glu 965 970

<210> 45 <211> 555

<212> PRT

<213> Escherichia coli

<400> 45

Met Thr Ser Ser Thr Asp Phe His Lys Leu Ser Glu Asp Cys Val Arg  $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ 

Arg Phe Leu His Ser Val Val Ala Val Asp Asp Asn Met Ser Phe Gly 20 25 30

- Ala Gly Ser Asp Thr Phe Pro Thr Asp Glu Asp Ile Asn Ala Leu Val  $35 \hspace{1cm} 40 \hspace{1cm} 45 \hspace{1cm}$
- Asp Pro Asp Asp Pro Thr Pro Ile Ile Thr Ala Ser Ala Ser Pro  $50 \hspace{1cm} 55 \hspace{1cm} 60 \hspace{1cm}$
- Arg Ile Glu Ser Thr Lys Ser Lys Ala Lys Val Lys Asn His Pro Phe 65 70 75 80
- Asp Tyr Gln Ala Leu Ala Glu Ala Phe Ala Lys Asp Gly Ile Ala Cys  $85 \hspace{1cm} 90 \hspace{1cm} 95$
- Cys Gly Leu Leu Ala Lys Ser Phe Asn Val Glu Glu Arg Asp Ile Ile 100 105 110
- Thr Ala Ser Ser His Lys Ala Asp Ile Thr Ile Leu Asp Trp Asp Met
- Gln Ser Asp Ser Gly Gln Phe Ala Ile Glu Ile Ile Lys Ser Ile Ile 130 135 140
- Val Ser Asp Ile Asn Ser Gly Gly Arg Leu Arg Leu Leu Ser Ile Tyr 145 150 155 160
- Thr Gly Glu His Val Thr Ala Val Ile Thr Lys Leu Asn Asn Glu Leu 165 170 175
- Lys Lys Thr Tyr Arg Ser Val Ile Lys Asn Asp Asp Ser Ile Phe Ile 180 \$180\$
- Glu Asp Asn Tyr Ala Leu Glu Gln Trp Cys Ile Val Val Ile Ser Lys 195 200 205
- Asp Val Tyr Glu Lys Asp Leu Pro Asn Val Leu Ile Lys Lys Phe Thr 210 215 220
- Asn Leu Thr Ala Gly Leu Leu Ser Asn Ala Ala Leu Ser Cys Ile Ser 225 230 235 240
- Glu Ile Arg Glu Lys Thr His Gly Ile Leu Thr Lys Tyr Asn Asn Lys
  245 250 255
- Leu Asp Thr Ala Tyr Val Ser His Ile Leu Asn Leu Ile Lys Ser Lys 260 265 270
- Glu Ser Arg Ala Tyr Ala Tyr Glu Asn Ala His Asp Tyr Ala Val Asp \$275\$ \$280\$ \$285\$

14

WO 00/28038 PCT/GB99/03721

Leu Ile Ser Glu Glu Ile Arg Ser Ile Leu Gln Ile Ser Glu Asn Leu 290 295 300

Lys Lys Ser Leu Ser Lys Asn Ser Leu Ser His Trp Pro Ile Phe His 305 310 315 320

Tyr Ala Lys Asn Gly Cys Lys Asn Phe Leu Leu Thr Gly Lys Lys Gln 325

Lys Asp Leu Ser Val Glu His Leu Arg Asn Ile Leu Ser Ala Asp Ser 340 345 350

Leu Glu Glu Ile Gln His Ala Ile Glu His Ala Ser Leu Gly Lys Lys 355 360 365

Glu Tyr Leu Ser Gln Asp Gly Glu Glu Asp Lys Lys Leu Met Gln Leu 370 375 380

Cys Ser Leu Glu Ile Thr Arg Arg Ser Leu Arg Tyr His Ser His Ile 385 390 395 400

Asp Asn Val Ser Leu Lys Gln Gly Thr Leu Leu Leu Asp Ala Tyr Asn 405 410 415

Phe Val Tyr Leu Cys Ile Gln Pro Leu Cys Asp Ser Val Arg Leu His 420 \$425\$

Glu Lys Ala Asp Phe Leu Phe Leu Arg Gly Thr Leu Asp Asp Asn Asn 435 \$440\$

Tyr Asn Leu Leu Ile Glu Asp Glu Tyr Gly Gly Phe Tyr Lys Ile Lys 450 455 460

Met Pro Ala Lys Ala Ser Asn Ile Ile Ser Phe Ser Phe Gly Val Glu 465 470 475 480

Asn Gly Asn Gly Val Ile Ile Gly Lys Lys Asn Asn Leu Val Asn Thr 485 490 495

Asp Tyr Ile Ser Phe Val Pro Leu Leu Val Glu Lys Ile Ser Thr Pro  $500 \hspace{1.5cm} 505 \hspace{1.5cm} 510 \hspace{1.5cm}$ 

Lys Val Leu Lys Trp Ile Gly Glu Ile Lys Thr Thr Tyr Ala Gln Lys \$515\$ \$520\$

Ile Thr Thr Asp Ile Val Ala Asn Leu Ser Arg Ile Gly Leu Asp Gln 530 540

His Glu Trp Leu Arg Ile Lys Ser Lys Asp Ile 545 550 555

<210> 46

<211> 82

<212> PRT

<213> Escherichia coli

<400> 4

Met Ser Ser Arg Gln Ile Leu Glu His Tyr Asn Ala Leu Thr Tyr Pro  $1 \hspace{1.5cm} 5 \hspace{1.5cm} 10 \hspace{1.5cm} 15$ 

Leu His Gln Ser Ile Leu Leu Gln Ile Met Thr Ser Asn Leu Leu Ser  $20 \hspace{1cm} 25 \hspace{1cm} 30$ 

Val Cys Thr Gly Lys Ser Ile Tyr Glu Asp Ile Ser Gly Ser Ser Trp  $35 \hspace{1cm} 40 \hspace{1cm} 45$ 

As Ille Ille His Phe As Ille Pro Leu Pro Ille Ser Arg Ala Arg Leu 50 55 60

Ser Ile Phe Ser Tyr Cys Val Arg Ile Lys Pro Trp Met Ser Met Asp  $^{\circ}65$  70 75 80

Tyr Met

<210> 47

<211> 98 <212> PRT

<213> Escherichia coli

<400> 47

Met Ser Ile Ile Phe Asn Gly His Tyr Arg Met Lys His Arg Thr Trp

1 5 10 15

Ile Thr Glu Ala Leu Arg Leu His Phe Glu Glu His Leu Pro Gln Val

Val Val Gly Arg Arg Leu Gly Val Pro Lys Ser Thr Ala Cys Gly Met 35 40 45

Phe Val Arg Phe Arg Lys Ala Gly Phe Ser Trp Pro Leu Pro Ala Gly 50 55 60

Met Ser Glu Arg Glu Leu Asp Gly Arg Leu Tyr Gly Ser Thr Ser Thr

i dis

WO 00/28038 PCT/GB99/03721

65 70 75 80

Val Pro Val Val Leu Cys Ser Gly Ser Val Ile Gln Asp Thr Ser Lys  $85 \hspace{1cm} 90 \hspace{1cm} 95$ 

Ser Cys

<210> 48

<211> 106

<212> PRT

<213> Escherichia coli

<400> 48

Met Ile Lys Thr Arg Arg Thr Lys Arg Thr Phe Ser Pro Glu Phe Lys  $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ 

Leu Glu Ala Phe Glu Gln Val Val Val Lys Tyr Gln Arg Asp Val Arg  $20 \hspace{1.5cm} 25 \hspace{1.5cm} 30$ 

Glu Val Ala Gln Ala Leu Glu Leu Asn Pro Asp His Leu Arg Lys Trp 35 40 45

Ile Arg Leu Tyr Lys Gln Glu Leu Gln Gly Ile Glu Pro Ala Gly Asn
50 55 60

Ala Ile Thr Pro Glu Gln Arg Glu Ile Gln Gln Leu Lys Ala Gln Ile 65 70 75 80

Lys Arg Val Glu Met Glu Lys Glu Ile Leu Lys Gln Ala Ala Val Leu  $85 \hspace{1cm} 90 \hspace{1cm} 95$ 

Met Ser Glu Ile Pro Gly Lys Leu Ser Arg

<210> 49

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide

<400> 49

tgctctagag ccattactca gaatggg

<210> 50 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Oligonucleotide <400> 50 cgcgagctcg acgactgaat gatccc 26 <210> 51 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Oligonucleotide <400> 51 teeceegggt actgeageac teaace 26 <210> 52 <211> 26 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence:Oligonucleotide <400> 52 gatcccggga ccactgaaat gcgtgc 26 <210> 53

<210> 53
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence;Oligonucleotide

<400> 53

togtotagag atgatggtga tggagcg

<210> 54 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Oligonucleotide <400> 54 qaactqcaqc caaatactqa taccaccc 28 <210> 55 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Oligonucleotide <400> 55 gaactgcagg ctaaaacaga agacgcg 27 <210> 56 <211> 27 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence:Oligonucleotide <400> 56 catgcatgca ctccatatga caaccgc 27 <210> 57

<210> 57
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Oligonucleotide

<400> 57

tcgtctagaa tgaagctgcg catgagg

WO 00/28038

<210> 58	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 58	
caactgcagt cgcaaattgc gaactgg	27
<210> 59	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 59	
caactgcaga ccgcaacttt tcgacgc	27
<210> 60	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 60	
catgcatgcc agtgagccat tgttccc	27
<210> 61	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 61	
tgctctagat acgactctga caggagg	27

PCT/GB99/03721

(3)
Ø.
(III
D
4
č
J
1
=50
7
1
de la

<210> 62	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 62	
tcagatatca actaccagca gtttgg	26
<210> 63	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
1	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 63	
tcagatatcc ataaagagtg acgtggc	27
<210> 64 <211> 27	
<211> 27 <212> DNA	
<213> Artificial Sequence	
V2107 ALCITICIAL Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 64	
tgctctagaa aacgtggcaa cagagcg	27
<210> 65	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 65	
\100/ OJ	

101

26

tgctctagaa ggcgttgtcg atcctg

<210> 66	
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 66	
gaactgcagg aaaaggccga gcagactg	28
<210> 67	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
4000	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 67	
gaactgcagt acagccatgt ttacggt	
gadeegeage acageoacge clacgge	27
<210> 68	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
•	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
•	
<400> 68	
catgcatgcg gtgtacgaca gtttgcg	27
<210> 69	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
4400- 60	

26

tgctctagac acatcatggg cacacc

<400> 72

catgcatgca taagcgtcga acaggcg

WO 00/28038 PCT/GB99/03721

<210> 70	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 70	
gaactgcaga accgtccaca tcaggcg	27
<210> 71	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
•	
<220>	
<223> Description of Artificial Sequence:Oligonucleotide	
<400> 71	
gaactgcaga ccctgcttgc cattccg	27
<210> 72	
<211> 72 <211> 27	
<211> 27 <212> DNA	
<213> Artificial Sequence	
/510\ VICITIOISI podeceso	
<220>	
<pre></pre> <pre>C223&gt; Description of Artificial Sequence:Oligopycleotide</pre>	